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ABSTRACT 
Nocturia (waking from sleep at night to void) is one of the most burdensome lower 
urinary tract symptoms (LUTS) among middle-aged and older people. The 
prevalence of nocturia tends to increase with age, due to age-related functional 
changes of the kidneys and bladder, and due to changes in sleep pattern. Nocturia 
can also be brought on by various illnesses and lifestyle factors. People with nocturia 
may be predisposed to further health complications and even mortality. Especially 
among frail elderly subjects with an increased baseline risk for falls and fall-related 
injuries, the presence of nocturia may further increase these risks.  
Treatment of nocturia is often unsuccessful. For more successful care, treatment 
decisions and health promotion, a better understanding of the prognosis of nocturia 
and its associated risks for further morbidity is needed. However, summarising data 
from previous longitudinal studies is challenging due to variation between study 
samples, assessment tools, case definitions and analytic strategies. Systematic reviews 
would clarify the issue, but systematic reviews and meta-analyses of the natural 
history and prognosis of symptoms are challenging and require methodological 
knowledge and innovations.  
The primary aim of the thesis was to ascertain the natural course of nocturia and 
associated risks of falls, fractures and mortality. The secondary aim was to further 
develop methods for systematic reviews and meta-analyses assessing the natural 
history, prognosis and impact of symptoms, including effect sizes and quality of 
evidence (certainty in evidence).  
The thesis comprises three systematic reviews with accompanying meta-analyses 
and one population-based cohort study. The systematic reviews were based on a 
comprehensive search of both published and unpublished reports without language 
restrictions, and subsequent screening of abstracts and full texts according to 
predefined eligibility criteria to detect all available observational cohort studies. The 
quantitative syntheses included random effects meta-analyses addressing the 
incidence/remission rates of nocturia, and relative risks (RR) of all-cause mortality, 
falls and fractures. The Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) approach was used to rate the quality of evidence for 
nocturia as a prognostic and causal factor of mortality, falls and fractures.  
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The longitudinal analysis of Tampere Ageing Male Urologic Study (TAMUS) 
included a population-based sample of men from Pirkanmaa Region (Finland) 
initially aged 50, 60, and 70 years. The cohort was followed-up with mail surveys 
including the assessments of LUTS and comorbidities repeatedly in 1994, 1999, 
2004, and 2009, and for mortality through the population registry until the end of 
2014. LUTS-associated hazard ratios (HR) were analysed with time-dependent Cox 
regression adjusted for year of birth and comorbidities using variable values updated 
every five years.  
The pooled estimates of 12 studies demonstrated a strong association of annual 
incidence of nocturia with age: 0.4% (95% confidence interval 0-0.8%) for adults 
aged < 40 years; 2.8% (1.9-3.7%) for adults aged 40-59 years; and 11.5% (9.1-14.0%) 
for adults aged 60 years. Of those with nocturia, each year 12.1% (9.5-14.7%) 
experienced remission with no significant differences in estimates between age 
groups. 
For association between nocturia and mortality, the pooled estimates of 11 
studies demonstrated an RR of 1.27 (95% CI 1.16-1.40, absolute 5-year mortality 
difference 1.6% in people aged 60 and 4.0% in those aged 75 years). For association 
between nocturia and falls, five studies demonstrated a pooled RR of 1.20 (95% CI 
1.05-1.37, annual risk difference 7.5% among the elderly) and five studies, a pooled 
RR of fractures of 1.32 (95% CI 0.99-1.76, annual risk difference 1.2%). The quality 
of evidence was rated moderate for nocturia as a prognostic factor for mortality and 
very low for nocturia as a cause of mortality. The quality of evidence was rated 
moderate for nocturia as a prognostic factor for falls, low for fractures and very low 
for nocturia as a cause of falls or fractures.  
An association between nocturia and mortality was also observed in the 21-year 
follow-up of the TAMUS cohort of 1,332 men: adjusted HR was 1.38 (1.07-1.79).  
The available evidence suggests that the onset of nocturia is strongly associated 
with age, with much higher rates in those over 60 years; remission occurs in 
approximately 12% each year. Moderate-quality evidence suggests that nocturia is 
associated with a 1.2-fold risk for falls and low-quality evidence suggests that 
nocturia is associated with a 1.3-fold risk for fractures. Furthermore, moderate- 
quality evidence suggests that nocturia is associated with a 1.3-fold risk of death.  
The findings of the thesis suggest that greater attention needs to be paid to 
underlying health conditions in patients with nocturia. Future research should 
address the impact of treatment for nocturia on falls and fractures with adequately 
long follow-up to detect further morbidity and mortality.  
  
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TIIVISTELMÄ  
Yövirtsaaminen (nokturia) on yksi yleisimmistä elämänlaatua heikentävistä 
virtsaamisoireista. Nokturian esiintyvyys kasvaa iän myötä johtuen ikääntymisen 
aiheuttamista muutoksista munuaisten ja virtsateiden toiminnassa. Nokturiaa 
aiheuttavat myös monet sairaudet ja elintavat. Nokturiaan saattaakin liittyä 
lisääntynyttä sairastavuutta ja jopa kuolleisuutta. Varsinkin hauraiden ikäihmisten 
kaatumis- ja murtumariskit saattavat kasvaa entisestään nokturian yhteydessä.  
Nokturian hoito ei aina ole tehokasta. Parempien hoitotulosten ja hoitopäätösten 
tueksi tarvitaan lisää tietoa nokturian luonnollisesta kulusta ja oireeseen liittyvien 
terveyshaittojen riskeistä. Nokturian ennusteen ja terveysvaikutusten selventämiseksi 
tarvitaankin systemaattisia katsauksia ja näihin pohjautuvia meta-analyysejä. 
Aiempien tutkimustulosten yhteenveto on kuitenkin haastavaa johtuen 
tutkimusväestöjen, oirekartoitusmenetelmien, nokturian määritelmien ja 
analyysimenetelmien vaihtelevaisuudesta ja niinpä luonnollista kulkua ja ennustetta 
käsittelevien systemaattisten katsausten ja meta-analyysien tekeminen edellyttävät 
metodologista erikoisosaamista ja innovaatioita.  
Väitöstutkimuksen tavoitteena oli selvittää nokturian ilmaantuvuutta ja remissiota 
väestötasolla, sekä nokturian vaikutusta kaatumisten, murtumien ja ennenaikaisen 
kuoleman riskiin. Lisäksi tavoitteena oli kehittää oireiden ennustetta tutkivien 
systemaattisten katsausten ja meta-analyysien menetelmiä.  
Väitöskirjakokonaisuus koostui kolmesta meta-analyysin sisältävästä 
systemaattisesta katsauksesta ja yhdestä väestöpohjaisesta kohorttitutkimuksesta. 
Systemaattisten katsausten perustana oli laaja-alainen kirjallisuushaku täydennettynä 
julkaisemattomien konferenssiabstraktien erillisellä haulla. Päävastemuuttujina 
kvantitatiivisissa analyyseissä olivat nokturian ilmaantuvuus- ja remissioluvut, sekä 
nokturiaan liittyvät suhteelliset riskit mortaliteetille, kaatumisille ja murtumille. 
Tutkimusnäytön laatu koskien nokturiaa kaatumisten, murtumien ja mortaliteetin 
ennusteellisena ja kausaalisena riskitekijänä arvioitiin GRADE-menetelmällä 
(Grading of Recommendations Assessment, Development and Evaluation).  
Nokturian ja mortaliteetin välistä yhteyttä kotimaisessa väestössä selvitettiin 
pirkanmaalaismiehistä koostuvan TAMUS-kohortin (Tampere Ageing Male 
Urologic Study) avulla. Käytettävissä oli viiden vuoden välein toistetut haastattelut 
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50-, 60- ja 70-vuotiaille miehille vuodesta 1994 alkaen ja tiedot kuolemista vuoden 
2014 loppuun saakka. Haastattelukierrokset sisälsivät tietoja virtsaamisoireista, 
sairauksista, lääkityksistä ja elintavoista. Virtsaamisoireiden ja ennenaikaisen 
kuoleman riskin väliset vaarasuhteet määritettiin aikariippuvaisten Coxin 
regressioanalyysien avulla vakioituna selittävien muuttujien viiden vuoden välein 
päivitetyillä arvoilla. 
Systemaattisen katsauksen avulla identifioidun kahdentoista tutkimuksen 
yhdistetyt estimaatit (meta-analyysi) osoittivat nokturian ilmaantuvuuden kasvavan 
ikääntymisen myötä: nokturian keskimääräinen vuosittainen ilmaantuvuus oli alle 40-
vuotiailla aikuisilla 0.4 % (95% luottamusväli 0–0.8%), 40–59-vuotiailla 2.8% (1.9–
3.7%) ja yli 60-vuotiailla 11.5 % (9.1–14.0%). Vuosittainen remissio oli 12.1 % (9.5–
14.7%). Remissiossa ei ollut merkittäviä eroja ikäryhmien välillä. 
Meta-analyysit osoittivat yhteyden nokturian ja ennenaikaisen kuoleman, sekä 
kaatumisten ja murtumien riskien välillä. Yhdentoista tutkimuksen yhdistetty 
suhteellinen ennenaikaisen kuoleman riski oli 1.27 (95% LV 1.16-1.40) vastaten 1.6 
%:n absoluuttisen riskin kasvua 60-vuotiailla ja 4.0 %:n kasvua 75-vuotiailla viidessä 
vuodessa. Viiden tutkimuksen yhdistetty suhteellinen kaatumisten riski oli 1.20 (1.05-
1.37) ja murtumien riski 1.32 (0.99-1.76), vastaten 7.5% kaatumisten ja 1.2% 
murtumien absoluuttisen riskin kasvua vanhuksilla vuosittain. Tutkimusnäytön laatu 
arvioitiin kohtalaiseksi nokturialle mortaliteetin ennusteellisena riskitekijänä ja hyvin 
heikoksi mortaliteetin kausaalisena riskitekijänä. Tutkimusnäytön laatu arvioitiin 
kohtalaiseksi nokturialle kaatumisten ennusteellisena riskitekijänä ja heikoksi 
murtumien ennusteellisena riskitekijänä. Näytön laatu arvioitiin hyvin heikoksi 
nokturialle kaatumisten ja murtumien kausaalisena riskitekijänä.  
Nokturian ja ennenaikaisen kuoleman välinen yhteys havaittiin myös TAMUS-
kohortin 1332 miehen 21 vuoden seurannassa: vakioitu HR oli 1.38 (1.07–1.79).  
Saatavilla olevan tutkimusnäytön perusteella nokturian ilmaantuvuus liittyy 
voimakkaasti ikääntymiseen ja kiihtyy erityisesti 60 ikävuoden jälkeen. Oireen 
spontaania lievenemistä tavataan vuosittain 12 %:lla niistä, joilla on nokturiaa. 
Kohtalaisen tutkimusnäytön perusteella nokturiaan liittyy 1.2-kertainen kaatumisten 
ja 1.3-kertainen ennenaikaisen kuoleman riski. Heikon tutkimusnäytön perusteella 
nokturiaan liittyy lisäksi 1.3-kertainen murtumien riski.  
Väitöskirjan havaintojen perusteella nokturiaa selvitellessä on suositeltavaa 
huomioida potilaan yleisen terveydentilan kartoitus. Tulevaisuudessa tutkimusten 
odotetaan selvittävän nokturian hoidon vaikutusta kaatumisten ja murtumien riskiin 
ja pitkällä aikavälillä hoidon vaikutusta sairastavuuteen ja kuolleisuuteen
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1 INTRODUCTION 
Nocturia (waking from sleep at night to void) (Hashim et al. 2019) is one of the most 
common and bothersome lower urinary tract symptoms (LUTS) (Abrams et al. 2002, 
Agarwal et al. 2014). The prevalence of nocturia increases markedly with age in both 
genders (Bosch & Weiss 2010), with normal age-related changes in the bladder and 
kidneys, and changes in sleep pattern, each contributing to the increase in nocturia. 
Besides being a major cause of sleep disruption and associated impaired quality of 
life (QoL), nocturia is often associated with illnesses such as diabetes, hypertension, 
cardiovascular diseases, chronic respiratory diseases, neurological diseases and 
malignancies (Tikkinen et al. 2009, Yoshimura 2012, Oelke et al. 2017). The wide 
range of conditions associated with nocturia suggests a multifactorial aetiology and, 
importantly, nocturia may also increase the risk of these conditions (Marshall et al. 
2015).  
Both the multifactorial aetiology and the wide range of associated comorbidities 
make the treatment of nocturia challenging. Furthermore, the elderly are especially 
susceptible to adverse effects of medical treatments (Chrischilles et al. 2001, 
Vaughan et al. 2016). Accurate estimates of progression and remission of nocturia 
over time would facilitate shared decision-making about the initiation and 
continuation of therapeutic options between patients and healthcare providers 
(Blanker et al. 2014). However, the majority of data on age-related changes of 
nocturia comes from cross-sectional studies (Bosch & Weiss 2010), whereas only 
few longitudinal studies have assessed the natural course of nocturia, and with highly 
heterogeneous study settings in terms of assessment tools, case definitions and 
analytic strategies (Marshall et al. 2015). A systematic review would clarify the issue 
but, unlike the case with conventional systematic reviews comparing one treatment 
against another or against a non-treatment control with well-established methods 
(Higgins & Green 2011), systematic reviews and meta-analyses addressing natural 
history or prognosis of symptoms are rare, and therefore require methodological 
innovations.  
Due to its close association with several illnesses, nocturia has been proposed to 
have prognostic importance in predicting further morbidity or even mortality 
 16 
(Yoshimura 2012). However, as people with nocturia tend to be older and are more 
likely to have comorbid conditions, the relevance of using nocturia as a risk factor 
for morbidity and mortality must be considered in light of the effects of various 
confounding factors. Furthermore, heterogeneity in estimates of previous studies 
exploring the longitudinal association between various LUTS and comorbidity, such 
as those exploring male LUTS as an exposure and cardiovascular disease (CVD) as 
an outcome (Bouwman et al. 2015, Gacci et al. 2016), may be due in part to variation 
in follow-up times and age distributions as the natural course of LUTS may vary 
considerably among different populations (Lee et al. 1998, Malmsten et al. 2010). 
Thus, repeated assessments of LUTS and other time-varying factors are required to 
establish robust estimates for associations between various symptoms and long-term 
health-related outcomes in order to differentiate short-term fluctuating symptoms 
from longer-term patient-important symptoms. 
Regarding the links between nocturia, morbidity and mortality, falls and fractures 
comprise an important entity, especially among elderly population. Although 
retrospective and cross-sectional studies have shown associations of nocturia with 
both falls and fractures (Stewart et al. 1992, Kim et al. 2017), there are fewer 
prospective studies, which are more capable in controlling for confounding when 
compared to cross-sectional studies. When considering including nocturia as a 
potentially modifiable risk factor in the health promotion of older adults, accurate 
estimates of nocturia-related fall, fracture and mortality risks in general population 
would be highly relevant. Therefore, to guide future research and clinical practice, a 
critical appraisal of the existing evidence of the consequences of nocturia is 
warranted. 
  
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2 REVIEW OF THE LITERATURE 
2.1 Terms and definitions 
2.1.1 Evidence-based medicine 
Historically and perhaps even in the present day, medical decision-making has been 
based predominantly on physicians’ beliefs and so-called “expert opinion”. Only 
recently has it been acknowledged that determination of the best practice requires 
supplementing the potentially biased subjective decisions with all available 
knowledge from the scientific literature. The first considerations based on systematic 
analyses of evidence took place in the early 1980s, when the American Cancer 
Society launched the first guidelines for cancer screening (American Cancer Society 
1980). This guideline was based on the pioneering work of David Eddy, a physician 
and mathematician, who introduced the term “evidence-based”. The physicians 
Alvin Feinstein and David Sackett and others subsequently published textbooks 
incorporating epidemiological methods into clinical decision-making (Feinstein 
1985, Sackett et al. 1985). These were the initial steps of clinical epidemiology, the 
basic science of “evidence-based medicine” (EBM) – the term introduced slightly 
later, in the early 1990s in medical education at McMaster University by Gordon 
Guyatt. The evidence-based approach came to broader awareness via a 25-piece 
series of “Users’ Guides to the Medical Literature" published in JAMA: The Journal 
of the American Medical Association by the Evidence-based Medicine Working 
Group at McMaster University between 1993 and 2000. The articles taught health 
care professionals how to interpret clinical and epidemiological research studies to 
guide their practice following the principles of evidence-based medicine; i.e. to 
integrate clinical judgment and patient's values with the recommendations from the 
best available evidence (Guyatt 1992, Sackett et al. 1996). 
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2.1.2 Summarising and rating the evidence 
For a today’s health care professional, the rapidly increasing rate of new medical 
publications makes staying up to date with relevant research a challenging task. 
Individual studies tend to be heterogeneous in their settings and samples and the 
results may vary substantially. To bypass the information overload and the challenges 
in interpreting the findings of individual studies, clinicians often turn to review 
articles incorporating the topic of interest. Most available review articles represent a 
narrative approach describing single studies and their results but typically do not 
apply defined methods to synthesise the data. In contrast, reviews utilising an 
evidence-based approach – systematic reviews – are conducted using rigorous 
methods to summarise the data. A systematic review is defined by the Cochrane 
Handbook, as follows: 
“A review of a clearly formulated question that uses systematic and explicit methods to identify, 
select and critically appraise relevant research, and to collect and analyze data from the studies that 
are included in the review.” (Higgins & Green 2011) 
Besides providing a pooled qualitative summary of the analysed data, systematic 
reviews may include a statistical summary of the results of primary studies, typically 
a meta-analysis (Table 1). Systematic reviews are therefore able to provide valid, 
precise and widely applicable answers to clinical questions (Oxman et al. 2005). 
Furthermore, by summarising large amounts of data, systematic reviews are more 
likely than any individual trial to describe the true clinical effect of an intervention. 
Thus, systematic reviews have a crucial role in informing clinical decisions, guidelines 
and future research. 
One of the chief principles of EBM is the hierarchical system of classifying 
evidence. EBM categorises different types of evidence and rates them according to 
the probability of bias across studies. Accordingly, when exploring cause-and-effect 
associations and the effects of treatments, randomised controlled trials (RCT) 
typically provide the highest quality of evidence, whereas case series or expert 
opinions typically provide the lowest quality. RCTs have less risk of systematic errors 
through their approach of randomly allocating subjects to different treatments, and 
thereby also randomising potential known and unknown confounding factors that 
may bias results. On the other hand, case series or expert opinions are often biased 
by the authors’ opinions and have no control for confounding factors (Schultz & 
Grimes 2002, Bhandari et al. 2004, Guyatt et al. 2008c).  
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Table 1. Differences between narrative reviews and systematic reviews (modified from Cook et al. 
1997 and Guyatt et al. 2008a). 
In 2000, the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) working group developed a system taking into account more 
dimensions than just the quality of research. In addition, within the GRADE 
framework, evaluators are required to consider the impact of different factors on 
their confidence in the results. The approach grades the quality of evidence 
(synonymously confidence or certainty in estimates) into four levels (high, moderate, 
low or very low quality confidence/certainty), according to their confidence in the 
observed effect (a numerical value) being close to the true effect. The confidence is 
based on judgements assigned in different domains. 
In the GRADE approach to causality, the evidence from RCTs begins as high 
quality, whereas that from observational studies begins as low quality. 
Contradictorily, with respect to prognosis – the likelihood of future health outcomes 
in people with a given disease or health condition or with particular characteristics 
i.e. not involving comparison of treatments (Iorio et al. 2015), GRADE stipulates 
that observational studies can often provide trustworthy inferences. Therefore, in 
the GRADE approach to prognosis, the evidence from observational studies begins 
as high-quality but may be downgraded in five different domains (Schünemann et al. 
2013):  
  
Characteristic Narrative review Systematic review 
Clinical question Seldom reported, or addresses 
several general questions 
Focused question specifying population, 
intervention or exposure, and outcome 
Search for primary 
articles 
Seldom reported; if reported, not 
comprehensive 
Comprehensive search of several evidence 
sources 
Selection of primary 
studies 
Seldom reported; if reported, often 
biased sample of studies 
Explicit inclusion and exclusion criteria for 
primary studies 
Evaluation of quality of 
primary articles 
Seldom reported; if reported, not 
usually systematic 
Methodologic quality of primary articles is 
assessed 
Summary of results of 
primary studies 
Usually qualitative nonsystematic 
summary 
Synthesis is systematic (qualitative or 
quantitative; if quantitative, this is often 
referred as meta-analysis) 
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• Risk of bias. Is a judgement made on the basis of the chance that bias in the 
studies included has influenced the estimate of effect? 
• Imprecision. Is a judgement made on the basis of the chance that the observed 
estimate of effect could change completely? Occurs when studies have wide 
confidence intervals, typically because of relatively few patients or events. 
• Indirectness. Is a judgement made on the basis of the differences in 
characteristics of how the study was conducted and how the results are 
actually going to be applied? Indirectness may arise from differences in the 
population or outcome of interest between the studies included and the 
studies addressed in the review question. In cases of little evidence with 
questionable applicability, quality of evidence is rated down for indirectness. 
• Inconsistency. Is a judgement made on the basis of the variability of results 
across the studies included? Refers to widely differing estimates 
(heterogeneity or variability in results) across studies. Variability may arise 
from differences in populations or methodology. If estimates vary 
substantially across studies, or if confidence intervals show little or no 
overlap, quality of evidence is likely to be rated down for inconsistency. 
• Publication bias. Is a judgement made on the basis of the question whether all 
the research evidence has been taken to account? Should be suspected when 
available evidence comes from a number of small studies, most of which 
have been commercially funded.  
Respectively, the quality of evidence can be upgraded in three domains (Schünemann 
et al. 2013):  
• Large effect. Observed effect is so large that the probability of it changing 
completely is less likely. 
• Confounding. In the presence of a possible confounding factor, expected to 
reduce the observed effect, the effect estimate still shows significant effect. 
• Dose-response gradient. Increasing levels of exposure are associated with either 
an increasing or a decreasing risk of the outcome.  
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Interpretation of the levels of evidence according to GRADE:  
• High quality evidence. The authors are very confident that the true effect lies 
close to the estimate of the effect: there is very low probability of further 
research completely changing the conclusions presented.  
• Moderate quality evidence. The authors are moderately confident that the true 
effect is likely to be close to the estimate of the effect, but there is a 
possibility that it is substantially different: further research may completely 
change the conclusions presented.  
• Low quality evidence. The authors’ confidence in the effect estimate is limited 
and the true value may be substantially different from the estimate of the 
effect: further research is likely to completely change the conclusions 
presented. 
• Very low quality evidence. The authors do not have any confidence in the 
estimate and it is likely that the true value is substantially different from it: 
new research will most probably completely change the conclusions 
presented.  
The GRADE working group defines “quality of evidence” and “strength of 
recommendations” based on the quality as two different concepts which are 
commonly confused with each other (Atkins et al. 2004, Balshem et al. 2011). The 
strength of recommendation for an intervention can be determined with GRADE 
approach by evaluating the confidence in the benefits of treatment outweighing the 
undesirable effects, quality of evidence, variability in values and preferences, and 
resource use. The recommendations are appraised to be either strong or weak in 
favour or against treatment (Guyatt et al. 2008b, Andrews et al. 2013). 
  
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2.1.3 Lower urinary tract symptoms and nocturia 
For fluent communication between healthcare providers and researchers, adequate 
terminology is essential. In cases of various forms of lower urinary tract dysfunction 
in which treatment decisions are heavily dependent on patients’ subjective 
perceptions, relevant terminology is especially important. One of the most essential 
remarks for improved communication between clinicians and patients is the 
differentiation between “symptoms” and “signs”. A symptom refers to a subjective 
indicator of a disease or change in condition as perceived by the patient, potentially 
leading him/her to seek care, whereas a sign refers to an observation – typically by 
a physician – with an instrument such as a frequency volume chart (FVC), pad test 
or a validated symptom questionnaire, aiming to quantify the intensity of 
dysfunction. Symptoms may either be volunteered or described during the patient 
interview. In general, symptoms are usually qualitative and cannot provide a 
definitive diagnosis. Accordingly, lower urinary tract symptoms (LUTS) refers to a 
group of symptoms involving the urinary bladder, sphincter, urethra, and, in men, 
the prostate. Symptoms may also indicate pathologies such as urinary tract infection. 
Various LUTS can result from dysfunction during bladder filling (storage), emptying 
(voiding) or post-voiding phase, and often occur in combination (Abrams et al. 2002, 
Drake 2018). 
To facilitate the utilisation of congruent definitions of various LUTS in clinical 
practice and in research, the standardisation sub-committee of the International 
Continence Society (ICS) has provided recommendations for terminology beginning 
from 1988 (Abrams et al. 1988). According to the current ICS definitions, LUTS are 
broadly divided into three major groups: (1) storage, (2) voiding and (3) post-voiding 
symptoms (Abrams et al. 2002, Drake 2018). Although the recommendations of ICS 
are applicable to all patients regardless of gender, increased specificity and 
complexity of diagnoses has led to a need to update the terminology for lower urinary 
tract and pelvic floor symptoms and dysfunction using gender-specific approaches 
(Haylen et al. 2010, D’Ancona et al. 2019).  
The symptom discussed in more detail in this thesis, nocturia (waking from sleep 
at night to void) (Hashim et al. 2019), has recently been recognised as a separate 
clinical entity, and gained a context-specific terminology report from the ICS 
(Hashim et al. 2019). Currently, nocturia is defined as follows: 
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“The number of times urine is passed during the main sleep period. Having woken to pass urine for 
the first time, each urination must be followed by sleep or the intention to sleep. This should be 
quantified using a bladder diary.” (Hashim et al. 2019) 
The new terminology emphasises the importance of clear nocturia case definitions 
with no attempt to differentiate between the bother and multifactorial causes of 
nocturia i.e. whether a compelling desire to void at night results from any underlying 
pathology or whether waking up due to external stimuli leads to subsequent voiding 
for convenience (Bing et al. 2007, Weiss et al. 2008, Tikkinen et al. 2009). The new 
definition also takes into account the previous findings that one nocturia episode is 
a common and usually well-tolerated phenomenon, i.e. not necessarily a “complaint” 
(Irwin et al. 2006, Tikkinen et al. 2010, Kupelian et al. 2012). Furthermore, the 
definition also underlines the importance of documenting sleep fragmentation with 
a bladder diary as sleep disorders are one of the most common reasons for care-
seeking among people with nocturia; and sleep disruption is one of the potential 
mediators between nocturia and further morbidity (Ancoli-Israel et al. 2011). 
The assessment of a patient with nocturia should begin from a more detailed 
characterisation of nocturnal symptoms based on the findings of the bladder diary 
or alternatively an FVC – providing data on the time of each micturition and the 
volume voided for at least 24 h. As a distinction to FVC, a bladder diary comprises 
of a set of more explicit recordings also including fluid intake, pad usage, 
incontinence episodes and the degree of incontinence and, if necessary, episodes of 
sensations such as urgency as well as the activities associated with urinary leakage 
can also be recorded. If supplemented with two or three days of recording, a bladder 
diary is currently considered the standard tool most likely to provide clinically useful 
data to guide nocturia treatment (Haylen et al. 2010, Cornu et al. 2012, Oelke et al. 
2014, Hashim et al. 2019). 
Notably, if a patient with nocturnal symptoms presents with urinary incontinence, 
it is crucial to differentiate between nocturia and nocturnal enuresis, which refers to 
a complaint of intermittent incontinence occurring during the main sleep period 
(Hashim et al. 2019). This distinction is crucial as episodes of incontinence (enuresis) 
occurring during sleep periods are always an abnormal phenomenon in adults and 
should prompt investigations for comorbidities (Sakamoto & Blaivas 2001, Wadie 
2004, Lee et al. 2018). On the other hand, a more common phenomenon, especially 
among the frail elderly, is an urgency type of urinary incontinence occurring after 
waking up and not reaching the toilet before passing urine (Gibson & Wagg 2014). 
 24 
The cornerstone in the differential diagnostics of nocturia is the consideration of 
functional bladder capacity and whether any excess fluid intake or urine production 
(diuresis) is present. Whereas nocturia indicates the number of voids recorded at 
night, omitting the first morning void not followed by intention to sleep, nocturnal 
urine volume (NUV) describes the amount of urine produced during the night, also 
including the first morning void because this urine has been produced during the 
night. Respectively, 24-hour urine volume refers to the total volume of urine passed 
during a 24-h period excluding the first morning void of the period (Hashim et al. 
2019). 
The estimate nocturia index (Ni) indicates the ratio between NUV and maximal 
voided volume (MVV). If Ni > 1, nocturia occurs because MVV is exceeded by 
NUV. Respectively, the estimate nocturnal bladder capacity index (NBCi) indicates 
whether the bladder can store the amount of urine produced at night, corresponding 
to the actual number of nocturnal voids (Nvoids) minus the predicted number of 
voids. The predicted number of voids is obtained by subtracting 1 from Ni (NBCi 
= Nvoids - Ni - 1). Accordingly, NBCi > 0 indicates nocturia at volumes less than 
MVV, implying bladder storage problems at night (Cornu et al. 2012, Weiss 2012, 
Oelke et al. 2014, Hashim et al. 2019). The term nocturnal polyuria (NP) refers to 
an abnormally large urine volume produced during the nighttime. It has been 
suggested that, for example, Ni > 1.5 and NUV > 10 ml/kg (based on body weight) 
are indicators of nocturia secondary to NP (Burton et al. 2011, Homma et al. 2000). 
According to the most commonly used definitions of ICS, the criteria for NP are 
met if the ratio of NUV and 24-hour urine volume i.e. nocturnal polyuria index (NPi) 
exceeds >33% in the elderly (aged > 65 years) and 20% in younger individuals 
(Hofmeester et al. 2015, Hashim et al. 2019). The criteria for 24-h (global) polyuria 
are considered to be met when overall urine volume is >40 ml/kg per 24 hours 
(Hashim et al. 2019). 
Whereas the term nocturia indicates sleep fragmentation caused by awakenings 
before voiding and attempts to continue sleeping after voiding, nighttime frequency 
is the term to be used to describe solely the number of nocturnal voids (Hashim et 
al. 2019). Accordingly, the vast majority of studies of nocturia have actually assessed 
nighttime frequency while sleep before or after nighttime voids has been 
documented only rarely (Oelke et al. 2014). Nocturia has been included in several 
questionnaires designed to assess the presence of LUTS. In most of these 
questionnaires, nocturia is included as one of several items, usually summed together 
to form a total score (Barry et al. 1992, Hansen et al. 1995). After acknowledgment 
of the multidimensional complexity and distinct characteristics of nocturia, 
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questionnaires measuring severity of nocturia have been supplemented with 
assessment tools for QoL and quality of sleep (Abraham et al. 2004, Chartier-Kastler 
et al. 2007, Kim et al. 2009 & 2011). 
The new nocturia definition emphasises the term “main sleep period” instead of 
“night” because the period from the time of falling asleep to the time of intending 
to rise may, depending on individual's sleep cycle, take place between sunset and 
sunrise or during the daylight hours. Therefore, among shift workers, the main sleep 
period during the daylight hours is considered as “nighttime” and any void during 
this main sleep period is considered to be nocturia (Hashim et al. 2019).  
2.2 Pathophysiology 
Due to a highly multifactorial aetiology, the treatment of nocturia can be challenging. 
The pathophysiologic mechanisms of nocturia have been divided into five main 
categories: reduced bladder capacity, nocturnal polyuria, global polyuria, sleep 
disorders and circadian clock disorders. Furthermore, multiple pathophysiologic 
mechanisms are often concomitantly present (Chang et al. 2006, Tikkinen et al. 2009, 
Cornu et al. 2012, van Kerrebroeck & Andersson 2014, Oelke et al. 2014).  
Besides the evaluation of present nocturnal symptoms and associated bother, the 
approach to a patient with nocturia should include a detailed assessment of symptom 
history to differentiate between fluctuating and persistent symptoms. Diuresis, lower 
urinary tract function and sleep quality, as well as perceived bother may vary 
periodically due to environmental and physiological factors (Yoshimura et al. 2005, 
Vaughan et al. 2014, Breyer et al. 2013). Nocturnal symptoms may be persistent due 
to underlying comorbidities as numerous health-impairing conditions can present as 
nocturia by affecting the urinary system or sleep. Therefore, the approach should 
include an assessment of the previously diagnosed medical conditions, lifestyle 
factors, and also risk factors for developing illnesses relevant for each individual 
(Oelke et al. 2014, Everaert et al. 2019). An overview of some of the common 
pathophysiologic mechanisms is presented in Fig. 1. 
The treatment of nocturia requires understanding of the common age-related 
functional, anatomical and hormonal changes potentially causing mismatch between 
nocturnal diuresis and the bladder’s capacity to store urine overnight (Boongird et 
al. 2010). It has been shown that nocturnal bladder capacity and detrusor contractility 
diminish with age, one reason being an increased collagen to smooth muscle ratio 
(Kawauchi et al. 2000, Susset et al. 1978). Although both overactive bladder (OAB) 
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symptoms and urodynamically verified detrusor overactivity (DO) become more 
common with age in both genders (Drake 2018), the number of muscarinic receptors 
in the bladder has been demonstrated to decline, also suggesting an increasing 
tendency for underactive bladder (UAB) symptoms with age (Birder & Andersson 
2013, Mansfield et al. 2005, Suskind 2017, Chapple et al. 2018). Besides causing 
changes in the mucosal (urothelial) and muscle layers of the lower urinary tract and 
the level of neurotransmitters/receptors, ageing induces inflammation and oxidative 
stress, potentially further provoking LUTS (Suskind 2017). 
 
Figure 1.  Exemplary causes of nocturia, often present in combination (reproduced from Cornu et al. 
2012). 
 
The anatomical capacity of the bladder may decrease due to fibrosis and scarring 
caused by radiotherapy for a malignancy of the lower urinary tract or other pelvic 
organs, after endoscopic surgery, such as transurethral resection of bladder tumour 
(TURBT) or after any abdominal surgery involving resection of the bladder. 
ANF = atrial natriuretic factor, AVP = arginine vasopressin, BOO = benign outlet obstruction, CNS = central nervous system, 
FVC = frequency volume chart, MS = multiple sclerosis, NBCi = nocturnal bladder capacity index, NPI = nocturnal polyuria 
index, OAB = overactive bladder, SCI = spinal cord injury  
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Impairment of functional bladder capacity and progression of male LUTS are often 
associated with benign prostatic hyperplasia (BPH), affecting over 50% of men after 
the age of 50 (Berry et al. 1984, Bosch et al. 2008). Although nocturia in older men 
is frequently associated with BPH, there are several other urologic conditions that 
may cause reduction in functional bladder capacity. For example, in cases of a 
tendency for post-void residual urine, particularly common among older men with 
BPH, the development of bladder stones may further cause irritative LUTS, 
including nocturia (Oelke et al. 2017). LUTS may likewise occur in association with 
a malignant tumour affecting the lower urinary tract. A malignancy particularly often 
perceived to be related to male LUTS is prostate cancer (pCa) – the most prevalent 
cancer in men in Western countries. The results of autopsy studies have shown that 
almost 30% of men over the age of 50 have histological evidence of pCa (Scardino 
1989). However, there is no evidence supporting LUTS as risk factors for advanced 
prostate cancer (Østerø et al. 2018). 
Other causes of reduced functional bladder capacity include neurogenic 
dysfunction related to neurologic illnesses and conditions such as Parkinson’s 
disease, multiple sclerosis (MS), spinal cord injury (SCI), or stroke. Bladder irritation 
may be caused by chronic inflammatory conditions such as interstitial cystitis or 
recurrent urinary tract infections (UTI), the latter especially common in older women 
due to urogenital atrophy associated with estrogen deficiency. Bladder problems may 
also stem from age-related weakening of the structures supporting the pelvic floor 
leading to pelvic organ prolapse (Oelke et al. 2017). Furthermore, women with a 
history of spontaneous vaginal deliveries are at an increased for LUTS among other 
pelvic floor disorders (Blomquist et al. 2018, Tähtinen et al. 2016, Tikkinen et al. 
2008). 
Besides age-related physiological changes and illnesses, various lifestyle and 
environmental factors may affect functional bladder capacity (Coyne et al. 2009, 
Smith et al. 2014). Theoretically physical activity may protect against LUTS in both 
genders by decreasing resting sympathetic muscle tone, reducing systemic 
inflammation and changing certain hormonal factors, particularly those relevant to 
the metabolic syndrome (Platz et al. 1998, Sea et al. 2009, Parsons et al. 2011, 
Maserejian et al. 2012, Kim et al. 2017a). Given that body mass index (BMI) and 
waist circumference are associated with nocturia in both genders, weight 
maintenance may partly explain the beneficial associations with physical activity 
(Tikkinen et al. 2006, Kupelian et al. 2009, Shiri et al. 2008, Wolin et al. 2015, 
Asplund et al. 2004, Wen et al. 2015, Milsom et al. 2017). 
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Although the nocturia-provoking side effects of various medications are often 
mediated via nocturnal polyuria, some drugs may directly affect functional bladder 
capacity. For example, widely used antidepressants, the selective serotonin reuptake 
inhibitors (SSRIs), have been shown to be associated with a two-fold increased risk 
for developing urinary incontinence and nocturia. The mechanism accounting for 
storage LUTS associated with SSRI use is plausibly activation of neuronal 5-HT4 
receptors located in the detrusor muscle, thereby potentiating cholinergic 
neuromuscular transmission and detrusor activation (Cardozo & Robinson 2002, 
Movig et al. 2002, Asplund et al. 2005, Boongird et al. 2010). 
In older people, the pathogenesis of nocturnal polyuria typically comprises altered 
sodium handling and water conserving mechanisms of the renal system, as well as 
altered circadian rhythm of glomerular filtration rate (GFR). The concentrating 
ability of the kidney has been shown to decline with increasing age owing to impaired 
responsiveness to arginine vasopressin (AVP) i.e. antidiuretic hormone (ADH) 
(Ouslander et al. 1998, Tian et al. 2004). Among younger healthy individuals, AVP 
secretion normally has a circadian pattern in which its blood concentration peaks 
during the night, resulting in a reduction of nocturnal diuresis (Kirkland et al. 1983, 
Duffy et al. 2016). However, in older people, while the AVP response to volume and 
osmotic stimuli often remains intact, circadian nocturnal AVP secretion has a 
tendency to become disrupted, potentially resulting to nocturnal polyuria (Kirkland 
et al. 1983, Koopman et al. 1989, Ouslander et al. 1998). However, dysregulation of 
AVP secretion is only one of the factors potentially contributing to nocturnal 
polyuria among older people as it has been observed that altered circadian rhythm 
of GFR may also contribute to increased nocturnal urine production and urinary 
sodium excretion rates with increasing age (Asplund & Aberg 1991, Kikuchi 1995, 
Tian et al. 2004, Boongird et al. 2010). 
Besides taking into account the common age-related changes in the lower urinary 
tract and renal function, one must consider the different mechanisms of diuresis 
related to various comorbidities. Water diuresis may result from excess intake of 
fluids (primary polydipsia). It may also result from a defect in the secretion or action 
of AVP caused by a hypothalamic or pituitary lesion (central diabetes insipidus), or 
when the renal capacity to concentrate urine is impaired (nephrogenic diabetes 
insipidus) caused by conditions such as hypercalcaemia or medications such as 
lithium – a drug used to treat the manic episodes of bipolar disorder (Goldfarb & 
Agus 1984,  Kishore & Ecelbarger 2013). Osmolarity and volume status are the two 
greatest factors that affect ADH secretion. However, a variety of other factors 
promote ADH secretion as well, including pain, nausea, hypoglycaemia, nicotine, 
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opiates, and certain medications, and a syndrome characterised by an excessive 
unsuppressible release of AVP – syndrome of inappropriate antidiuretic hormone 
secretion (SIADH) – can result from conditions that dysregulate ADH secretion in 
CNS, tumours that secrete ADH, drugs that increase ADH secretion and many 
others.  Respectively, several factors may inhibit the release of AVP, such as caffeine 
and alcohol (Antunes-Rodrigues et al. 2004, Ellison & Berl 2007). 
Osmotic (solute) diuresis may result, for example, from poorly controlled 
diabetes mellitus (DM) or intentionally after administration of mannitol – a strong 
diuretic used, for example, to lower increased intracranial pressure. However, the 
most common type of osmotic diuresis typically occurs in the presence an excess 
sodium excretion (natriuresis), which is the main mechanism of nocturia in chronic 
kidney disease (CKD) (Feinfeld & Danovitch 1987, Fukuda et al. 2006, Boongird et 
al. 2010). Due to a long-established association of CKD with nocturnal polyuria, 
studies on renal physiology and the regulation of homeostasis in CKD patients have 
contributed substantially to the identification of the various pathophysiological 
mechanisms of nocturia (Boongird et al. 2010). Furthermore, due to ageing of 
populations and also to increasingly common lifestyle-associated comorbidities such 
as hypertension, diabetes and obesity, the global burden of CKD is increasing from 
its current prevalence of over 10% (Hill et al. 2016).  
Enhanced natriuresis has been found to be associated with a lack of nocturnal 
blood pressure (BP) fall, a common phenomenon in CKD patients known as 
nondipping (Agarwal et al. 2009, Fukuda et al. 2006, Boongird et al. 2010). In CKD 
patients, nocturia-related increased nighttime physical activity has been suggested to 
contribute to nondipping BP patterns (Agarwal et al. 2009). Furthermore, a potential 
contributor to increased BP in individuals with CKD is endothelial dysfunction, 
mediated by elevated serum levels of asymmetric dimethylarginine (ADMA) 
(Vallance et al. 1992), also hypothetically associated with nocturia via nitric oxide 
(NO) pathway: it has been suggested that LUTS, secondary to BOO, could be caused 
by the lack of NO bioactivity at the bladder outlet (Andersson & Persson 1994, 
Mumtaz et al. 2000, Aizawa et al. 2011). ADMA is a major endogenous competitive 
inhibitor of NO synthase (Valtonen et al. 2008). The cells of the inner layer of blood 
vessels (endothelial cells) are responsible for the continuous basal production of 
nitric oxide (NO), which serves to counteract the neural vasoconstrictor tone and to 
regulate blood flow and BP (Stamler et al. 1994). Accordingly, elevated ADMA levels 
have been observed in association with DM, arterial hypertension (HTN), pre-
eclampsia, dyslipidemia and CVD (Chan & Chan 2002), as well as in patients with 
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exaggerated blood pressure response to exercise (EBPR), a suggested predictor of 
future HTN and CVD (Kayrak et al. 2010, Singh et al. 1999, Kurl et al. 2001).  
Previous observations suggest an independent association between nocturnal 
polyuria and nondipping BP among community-dwelling older people after 
adjustments for various factors including physical activity, serum levels of ADMA 
and suspected sleep-disordered breathing (SDB) (Obayashi et al. 2015). Although 
the association between nondipping BP and nocturnal polyuria seems robust, the 
mechanisms between nocturia and hypertension have not been fully explained. The 
relationship between the rate of blood flowing to the renal system (perfusion) and 
sodium excretion, i.e. the pressure natriuresis (PN) response, has long been regarded 
as the core mechanism to determine BP homeostasis. In hypertension, higher levels 
of BP are required to excrete the same amount of sodium and accordingly, PN 
response is abnormal in most, if not all, models of hypertension (Feldstein 2013, 
Goessaert et al. 2014, Ivy & Bailey 2014). It has been hypothesised that nocturia-
associated defects in the NO pathway may lead to the resetting of the PN 
relationship in the kidney, leading to sodium retention and compensatory nocturnal 
natriuresis. This suggestion is consistent with evidence that ageing and hypertension 
are both associated with defects in the NO pathway (McKeigue & Reynard 2000, 
Boongird et al. 2010).  
Besides age-related changes in the kidney, there are multiple alterations in the 
hormonal systems governing water and sodium regulation that may occur with 
ageing. The renin-angiotensin-aldosterone (RAA) system is of major importance in 
maintaining blood pressure and fluid volume. It exerts this function through 
regulation of renal blood flow and solute reabsorption, thereby affecting urine 
production (Carey & Siragy 2003). Atrial natriuretic peptide (ANP) i.e. atrial 
natriuretic factor (ANF) is a natriuretic peptide hormone secreted from the cardiac 
atrial myocytes in response to atrial distension and sympathetic stimulation. The 
main function of ANP is to cause a reduction in expanded extracellular fluid volume 
by increasing renal sodium excretion through its direct natriuretic effect and 
suppression of renal renin and aldosterone secretion. Furthermore, ANP inhibits 
AVP secretion, in part by inhibiting angiotensin II-induced stimulation of AVP 
secretion (Matsukawa & Miyamoto 2011). With advanced age, the baseline ANP 
level has been shown to be 3- to 5-fold higher than in younger adults (Ouslander et 
al. 1998, Asplund & Aberg 1991). Moreover, plasma renin and aldosterone activities 
also tend to decrease with age. As a consequence, the aforementioned hormonal 
changes promote diuresis via natriuresis (Boongird et al. 2010, Goessaert et al. 2014).  
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In cases of non-dipping BP and associated nocturnal polyuria, the diminished 
renal sodium excretory capability is related to low plasma renin activity and normal 
aldosterone levels. The relative aldosterone excess with sodium retention during 
daytime leads to enhanced natriuresis during nighttime (Satoh et al. 2011, Goessaert 
et al. 2014). Sleep deprivation is known to further induce diuresis and natriuresis by 
altering the circadian rhythm of the RAA system as well as attenuating nocturnal BP 
dipping (Kamperis et al. 2010). The non-dipping pattern of BP is also found in 
subjects with sodium sensitive hypertension, in whom a significant rise in BP occurs 
as a response to sodium intake. While the pathophysiology of this type of 
hypertension remains unclear, older age, female sex, as well as several genetic and 
environmental factors have been suggested as potential aetiologic factors. Lower 
renin and aldosterone levels are found in these subjects, together with a decreased 
number of beta2 receptors – one binding site of catecholamines in the activation of 
the sympathetic nervous system (SNS) (Goessaert et al. 2014, Giner et al. 2000). 
In patients with oedema-forming conditions, such as congestive heart failure 
(CHF), CKD, hypoalbuminaemia, or use of certain medications such as 
nonsteroidal anti-inflammatory drugs (NSAID) or calcium channel blockers, fluid 
accumulated in the lower extremities while standing during the day may become 
mobilised into the circulatory systems at night, inducing ANP release. Enhanced 
ANP secretion because of medical conditions can also cause nocturnal polyuria. 
ANP is released by atrial myocytes in response to atrial distension and sympathetic 
stimulation. It affects the kidneys by increasing GFR and filtration fraction, which 
in turn produces natriuresis and diuresis. Similarly, respiratory diseases associated 
with increased airway resistance, typically different types of sleep-disordered 
breathing and particularly obstructive sleep apnea (OSA), stimulate ANP secretion 
through hypoxic-induced vasoconstriction causing increased right atrial pressure 
(Boongird et al. 2010, Yalkut et al. 1996). 
Besides AVP, ANP and other natriuretic peptides, studies have also addressed 
other hormones related to nocturia. Previous findings have suggested that the brain 
renin-angiotensin system may modulate the synthesis of melatonin – a hormone with 
a well-established role in regulating circadian rhythms (Campos et al. 2013). In post-
menopausal women, oestrogen has been shown to have a stimulatory effect on AVP 
while progesterone antagonises this effect, also reducing the nocturnal rise in AVP 
(Bossmar et al. 1995, Graugaard-Jensen et al. 2008).  
In addition to OSA, primary sleep disorders such as insomnia, restless leg 
syndrome, narcolepsy and arousal disorders, such as sleepwalking and nightmares, 
can cause nocturia. Various conditions such as CHF, chronic obstructive pulmonary 
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disease (COPD), endocrine disorders, as well as several neurologic conditions may 
cause sleep disorders and subsequent nocturia. Other factors that may result in sleep 
disturbances and associated nocturia are psychiatric conditions such as depression 
and anxiety, chronic pain, alcoholism or drug use, and medications such as 
corticosteroids, beta-blockers, thyroid hormones and various drugs acting on a CNS 
(Cornu et al. 2012, van Kerrebroeck & Andersson 2014). Furthermore, although 
there is an evident cause-and-effect association between wakefulness and nocturia, 
acute sleep deprivation is also a potential inducer of natriuresis and nocturnal 
polyuria (Ancoli-Israel et al. 2011, Kamperis et al. 2010). Sleep deprivation can also 
cause nocturnal polyuria and reduced bladder capacity by altering the endogenous 
circadian rhythm i.e. leading to circadian clock disorders (Negoro et al. 2013, Kim 
2016). 
2.3 Assessment 
According to the European Association of Urology Guideline on Management of 
Non-neurogenic Male LUTS, in addition to the bladder diary, the basic assessment 
of a patient with bothersome nocturia should include a detailed symptom history 
with a validated symptom questionnaire, documentation of previously diagnosed 
medical conditions and a physical investigation (Gravas et al. 2019). Basic 
investigations also include urinalysis, measurement of post-void residual volume and 
uroflowmetry. Additional tests on an individual basis may include urodynamic 
studies, cystoscopy and blood analyses for comorbidities (Oelke et al. 2017, Everaert 
et al. 2019, Gravas et al. 2019) (Fig. 2). In case of suspicion of underlying 
comorbidities, referral to another specialist such as a pulmonologist, nephrologist, 
or cardiologist may also be necessary. Recognition of the complex aetiology of 
nocturia has led to the development of specific tools to screen for potential 
contributing factors in addition to other LUTS, including cardiovascular and 
metabolic risk factors, sleep variables, mental health and wellbeing (Bower et al. 
2017). 
 
 
  
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Figure 2.  Evaluation of Nocturia in non-neurogenic Male LUTS (reproduced from Gravas et al. 
2019). 
 
  
FVC = frequency volume chart, DRE = digital rectal examination, NP = nocturnal polyuria, MoA = mechanism 
of action, PVR = post-void residual, PSA = prostate-specific antigen, US = ultrasound 
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2.4 Treatment 
Before deciding on interventions, it is necessary to define the treatment goals. For 
patients with bothersome nocturia, besides aiming at any decrease in nocturnal 
voiding frequency, regression of nocturia to less than two episodes per night, 
prolongation of undisturbed sleep for up to at least four hours, feeling rested after 
awakening and the improvement of QoL are likely to be patient-important outcomes 
(Abraham et al. 2004, Chartier-Kastler et al. 2007, Cornu et al. 2012, Oelke et al. 
2014). Although there are specific treatments available targeted at several 
hypothesised pathophysiologic mechanisms of nocturia, behavioural treatments and 
lifestyle modifications should nonetheless be included in every treatment strategy, as 
they appear to be beneficial in the majority of cases despite differences in the 
underlying pathophysiology (Oelke et al. 2014). Furthermore, behavioural 
treatments and lifestyle modifications likely have very few or no side effects, may 
also benefit the treatment of other conditions and are often very inexpensive or free. 
Interventional studies have shown that walking exercises, fluid restriction in the 
evening, reduction of salt intake and a combination of lifestyle changes, including 
refraining from excess hours in bed and keeping warm in bed, may alleviate nocturia 
in the majority of cases (Sugaya et al. 2007, Tani et al. 2014, Matsuo et al. 2019, Soda 
et al. 2010). Furthermore, restriction of caffeinated or alcoholic beverages, emptying 
the bladder before sleep and elevating legs in the presence of lower limb oedema, 
can be suggested as potential behavioural treatments if considered appropriate to the 
individual (Oelke et al. 2014, Everaert et al. 2019). Especially in cases of frail elderly 
individuals and those with multiple illnesses, lifestyle changes may even be the only 
possible treatment for nocturia due to lowered tolerability to medications, i.e. 
treatments manipulating diuresis, sleep or lower urinary tract function, and other 
interventions (Chrischilles et al. 2001, Vaughan et al. 2016). 
Earlier studies have indicated nocturnal polyuria as a major contributing factor in 
nocturia among men and women of all ages, and particularly in the elderly in up to 
85% of nocturia cases (Weiss et al. 2011, Rembratt et al. 2003). Although the 
association between nocturnal polyuria and nocturia is clear, according to a recent 
meta-analysis, many people with nocturnal polyuria do not, however, have nocturia, 
and therefore, the clinical importance of this association appears to be less obvious 
than previously suggested (Hofmeester et al. 2014). Accordingly, some patients with 
nocturnal polyuria may have a bladder capable of storing large volumes of urine 
without presenting as nocturia, whereas patients with a low bladder storage capacity 
may report nocturia in the absence of nocturnal polyuria. Therefore, in the 
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assessment of a patient with nocturia, it is advisable to explore whether concomitant 
LUTS are present and set as the primary goal in treatment the alleviation of the most 
bothersome symptom (Agarwal et al. 2014). For example, among adult male patients 
presenting with nocturia and nocturnal polyuria, diurnal symptoms of decreased 
functional bladder capacity, such as those suggestive of BPH, are often also present 
(Chang et al. 2006, Oelke et al. 2014). 
Pharmacological therapies are indicated after failure of lifestyle modifications and 
behavioural treatments which, however, should be continued together with the drugs 
(Oelke et al. 2017). Currently, the only drug approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of nocturia due to nocturnal polyuria is 
desmopressin – a synthetic analogue of AVP (FDA 2017 & 2018). Compared to 
endogenous AVP, desmopressin has a pronounced antidiuretic effect, with no blood 
pressure-enhancing (vasopressor) effect (Cvetković & Plosker 2005). Desmopressin 
has been shown to decrease nocturnal diuresis and to prolong the first uninterrupted 
sleep period (Chang et al. 2007, Juul et al. 2013). The risk of a potential adverse 
effect, hyponatremia, has to be taken into account, especially among older patients 
and in women, who seem to be more prone to this effect (Rembratt et al. 2006, Juul 
et al. 2011, Goessaert et al. 2014). The first formulation of desmopressin approved 
by FDA for the treatment of nocturia, was a low-dose intranasal formulation with 
recommended doses of 0.83 ug for patients over 65 years and 1.66 ug for those under 
65 years (FDA 2017). Subsequently, a sublingual low-dose formulation was approved 
with recommended doses of 25 μg for women and 50 μg for men (FDA 2018). The 
benefits of both low dose formulations include a rapid absorption, a high 
bioavailability and a limited duration of action (4-6 hours for intranasal and 3-5 hours 
for sublingual formulation) with reduced risk of hyponatremia (Kaminetsky et al. 
2018, Sand et al. 2013, Weiss et al. 2013). However, the results of available RCTs 
have shown only modest benefits for desmopressin over placebo (Han et al. 2017). 
For example, in 3-month RCTs, treatment of a mixed-gender population with 
intranasal formulation led to a reduction of 1.4 nocturia episodes with a dosage of 
0.83 ug and of 1.5 episodes with dosage of 1.66 ug vs 1.2 episodes with placebo 
(Kaminetsky et al. 2018). Similarly, in 3-month RCTs, treatment of women with 
sublingual formulation with a dosage of 25 ug led to a reduction of 1.5 episodes vs. 
1.2 episodes with placebo (Sand et al. 2013), whereas treatment of men with a dosage 
of 50 ug led to a reduction of 1.3 episodes vs. 0.9 episodes with placebo (Weiss et al. 
2013). Overall, the current quality of evidence of the outcomes of treatment of 
nocturia with various formulations and doses of desmopressin has been rated low 
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due to the limitations of the previous studies providing data only for small samples 
with short-term follow-up of three months or less (Han et al. 2017).  
Medical treatment of male LUTS with α1-adrenergic antagonists, 5α-reductase 
inhibitors, phosphodiesterase type 5 inhibitors, antimuscarinics, β3-agonist 
mirabegrone, and phytotherapy have generally not proven superior to placebo for 
nocturia-related outcomes in previous RCTs (Sakalis et al. 2017). The reduction of 
nocturia episodes with LUTS/BPH drugs is only modest compared to placebo or 
active comparator with a difference of approximately 0.2 voids per night, regardless 
of the drug class (Oelke et al. 2014). Combination therapies have not proven 
consistently superior to monotherapy with desmopressin in men affected by 
nocturnal polyuria and LUTS (Sakalis et al. 2017, Han et al. 2017). Similarly, in 
mixed-gender samples of patients affected by OAB, previous RCTs on the impact 
onabotulinumtoxinA injections have shown only modest improvements in nocturia 
over placebo with a mean reduction of 0.5 nocturia episodes vs. 0.2-0.3 episodes at 
three months (Chapple et al. 2013, Nitti et al. 2017). Similarly, regarding the targeted 
treatments for BOO in men in whom medical therapy is unsuccessful, surgical 
procedures, such as transurethral resection of the prostate (TURP) may alleviate 
nocturia among other LUTS, although surgery should not be considered in men 
whose isolated complaint is nocturia, i.e. in the absence of other bothersome LUTS 
(Marshall et al. 2015). In a single-centre study randomising 66 men with LUTS to 
receive TURP or tamsulosin 0.4 mg, a significant mean difference of approximately 
0.8 voids/night was observed in favour of TURP over Tamsulosin at one year. 
Duration of undisturbed sleep period was also prolonged in both groups without 
any statistically significant difference between the two groups (Simaioforidis et al. 
2011).  
Taking into account the complex etiology of nocturia, efficient treatment of 
underlying comorbidities is generally considered to be one of the most important 
aspects (Bower et al. 2017, Evereaert et al. 2019, Gravas et al. 2019). For example, 
treatment of hypertension may have a substantial effect on nocturia. Diuretic use is 
associated with an up to twofold increase in nocturia and the risk of nocturia is 
increased especially if diuretics are administered in the evening (Hall et al. 2012, Park 
et al. 2013, Oelke et al. 2017). However, changing the timing of the diuretic to late 
afternoon may help to resolve nocturnal polyuria and nocturia (Asplund 2007, Oelke 
et al. 2017, Everaert et al. 2019). Calcium channel blockers, which lower blood 
pressure by increasing natriuresis, may cause leg oedema during daytime and 
potentially nocturia when the oedema fluid is resorbed during the night (Everaert et 
al. 2019). In these cases, changing to a different type of antihypertensive medication 
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may be helpful. Angiotensin II type 1 receptor blockers administered in the morning 
seem to restore the circadian rhythms of blood pressure and natriuresis from 
nocturnal non-dipping to dipping patterns in patients with CKD. This, however, is 
not only due to inhibition of the renin-andiotensin-aldosterone system itself, but 
mainly to enhanced renal sodium excretion during daytime (Fukuda et al. 2011). This 
is similar to the effect of diuretics on nocturnal polyuria (Reynard et al. 1998, 
Goessaert et al. 2014). It has been suggested that treatment of nondipping blood 
pressure may improve nocturnal polyuria (Takayama et al. 2019). 
In patients with OSA and treated with continuous positive airway pressure 
(CPAP) or surgery (uvulopalatopharyngoplasty), nocturia has been shown to 
improve (Wang et al. 2015, Park et al. 2016). The treatment of OSA may be beneficial 
in reducing nocturia in several ways. First, after the reduction of apneic episodes via 
treatments, the awakenings and subsequent bathroom trips in order to void may 
resolve. In addition, other biochemical mechanisms may also be involved. For 
example, OSA is known to be associated with decreased nocturnal plasma renin and 
aldosterone secretion, and treatment with CPAP reverses these effects, potentially 
leading to decreased nocturnal natriuresis. Furthermore, as nocturnal diuresis seems 
to be also partially mediated through enhanced release of ANP and elevated 
sympathetic tone, the reversing effect of CPAP on these pathways may also play a 
central role in reducing nocturnal polyuria (Ancoli-Israel et al. 2011). In patients with 
OSA, observational studies have consistently indicated a reduction in the number of 
nocturia episodes to be associated with treatment with CPAP, albeit with substantial 
variation in their estimates (Wang et al. 2015). A recent systematic review and meta-
analysis of five studies (of which four were observational) showed an average 
reduction of 2.3 nocturia episodes and a mean decrease of 180 ml in nocturnal urine 
to be associated with treatment with CPAP (Wang et al. 2015). The single RCT 
included in the review – a multi-centre trial including 278 patients aged over 65 years 
with recently diagnosed OSA randomised to receive either CPAP and best 
supportive care (BSB) in combination or BSB alone – showed a mean reduction of 
0.3 nocturia episodes at one year but no differences between the two groups 
(McMillan et al. 2014). In a single-centre study including 66 patients undergoing 
surgery for OSA, successful treatment showed a decrease of nocturia episodes from 
1.9 to 0.7 (Park et al. 2016). 
While the evidence supports the treatment of OSA in sleep disorders and 
nocturia, there is only little evidence supporting other sleep-promoting therapies, 
such as pharmacological or behavioural sleep aids, in the treatment of nocturia 
(Denys et al. 2018, Everaert et al. 2019). There is some evidence that taking 2 mg of 
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melatonin at bedtime may improve nocturia in men with BPH: in an RCT of 20 men 
with bladder outflow obstruction and nocturia (mean 3.1 episodes/night), a 
reduction of approximately 0.3 nocturia episodes was observed in the melatonin 
group and 0.1 episodes in the placebo group (Drake et al. 2004). In an RCT of 26 
patients with nocturia secondary to multiple sclerosis, no significant difference in the 
reduction of nocturia episodes was observed between the melatonin and placebo 
groups (Drake et al. 2018). As an advisable behavioural treatment, patients with 
insomnia symptoms should avoid spending excess hours in bed, which may make 
their sleep shallower, leading to a worsening of their nocturia: the longer patients 
stay in bed, the more likely they are to need to urinate (Spielman et al. 1987, 
Yoshimura & Terai 2005). Furthermore, patients should be advised to try to go to 
bed at the same time each day in order to prevent the development of irregular sleep-
wake rhythm type circadian rhythm sleep disorders (Zee & Vitiello 2009). 
2.5 Natural course 
Knowledge about the patterns of progression, remission and fluctuation of nocturia 
over time would facilitate shared decision-making about the initiation and 
continuation of therapeutic options between patients and healthcare providers 
(Blanker et al. 2014). To date, only a little is known about the natural history of 
nocturia as the majority of the data on the epidemiology of nocturia is based on 
cross-sectional studies, whereas only few longitudinal studies are available (Marshall 
et al. 2015, Milsom et al. 2017). 
The prevalence of nocturia varies depending on the nocturia case definition (≥1, 
≥2, ≥3 voids per night etc.) (Tikkinen et al. 2006, Bosch & Weiss 2010, Milsom et 
al. 2017).  Estimates of the prevalence of nocturia, stratified by different nocturia 
case definitions, have shown substantial variation, suggesting that several factors in 
the study characteristics, including the comparability of the sample to general 
population, recruitment methods, participation rate and symptom assessment tools 
are likely to affect the estimates. Accordingly, for men aged 20-40 years studies have 
indicated a prevalence range of 11-35% for nocturia defined as ≥1 episodes and 2-
17% for nocturia defined as ≥2 episodes/night, and for women in the same age 
group, a range of 20-44% for ≥1 episode and 4-18% for ≥2 episodes/night. For 
men aged over 70 years studies have indicated a prevalence range of 69-93% for ≥1 
episodes and 29-59% for ≥2 episodes/night, and for women in the same age group 
a range of 74-77% for ≥1 episodes and 28-62% for ≥2 episodes/night (Bosch & 
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Weiss 2010). Overall, there is no great difference between genders in the prevalence 
of nocturia. Nocturia may be more common among women at a younger age but the 
differences disappear by middle age, while in the elderly nocturia may be more 
frequent among men (Tikkinen et al. 2006, Milsom et al. 2017). 
For accurate estimates of the prognosis of nocturia, a summary of observational 
cohort studies would shed light on the issue. However, taking into account the 
substantial variation between symptom assessment tools, nocturia case definitions 
and analytic strategies, summarising the data is expected to be challenging. 
Furthermore, while a number of studies have explored the epidemiology of nocturia, 
only few have critically discussed the potential sources of bias (Marshall et al. 2015). 
A systematic review would elucidate the issue but, unlike the case with conventional 
systematic reviews comparing one treatment against another or against a non-
treatment control with well-established methods (Higgins & Green 2011), systematic 
reviews and meta-analyses addressing natural history or prognosis require 
methodological innovations, and are therefore rare (Milsom et al. 2017).  
2.6 Health consequences of nocturia 
Whereas the estimates on the natural course of symptoms are important for shared 
decision-making between clinicians and patients, it should also be clear that it is 
equally important to estimate the risks of nocturia if the symptom is left untreated. 
While we earlier discussed the impact of comorbidities on nocturia, such as diabetes, 
cardiovascular diseases, chronic respiratory diseases, neurological diseases and 
malignancies (Mitropoulos et al. 2002, Tikkinen et al. 2009, Johnson et al. 2005, 
Marshall et al. 2015), in many cases the association may stem from bidirectional 
causality. Even if nocturia is not a direct cause of other diseases, it may be an 
important prognostic marker of disease, as in the suggested case of CKD and 
progressing kidney injury (Hsu et al. 2009, Krol et al. 2009, Boongird et al. 2010). 
Furthermore, especially among frail elderly subjects with increased baseline risk for 
falls and fall-related injuries, nocturia has been suggested to further increase these 
risks (Stewart et al. 1992, Kim et al. 2007b). Suggesting a number of possible causal 
pathways, some authors have postulated that nocturia may increase the risk of death 
(Yoshimura et al. 2012).  
One of the major contributing factors to the health consequences of nocturia is 
believed to be sleep fragmentation. Besides the impairing effects of sleep disruption 
on the patient’s vitality, concentration and mood, nocturia may also increase the 
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patient’s risk of accidents at work, on the road, and at home (Chartier-Kastler et al. 
2007). Observational studies have shown a clear association between sleep 
deprivation and metabolic disorders, including obesity, type 2 DM and hypertension, 
each of these is also linked to nocturia (Oelke et al. 2017). In men, an indication of 
the beneficial effect of nocturia treatment on hypogonadism has been observed – an 
effect possibly mediated by prolongation of the first period of uninterrupted sleep 
(Schmid et al. 2012, Luboshitzky et al. 2001, Kim et al. 2014, Shigehara et al. 2017). 
In a single-centre observational study of 62 men with late-onset hypogonadism, 
treatment with desmopressin had no significant effect on baseline testosterone levels 
in the whole cohort although the treatment was associated with a mean reduction of 
1.2 nocturia episodes at three months. However, in the subgroup of 27 men with 
particularly low testosterone levels (<3.5 ng/mL), treatment resulted in a mean 
increase of approximately 2.9 ng/ml in testosterone levels in the presence of a 
decrease of approximately one nocturia episode per night at three months (Kim et 
al. 2014). Furthermore, sleep deprivation has also been associated with reduced 
natural immune responses and cytokine levels in the blood, resulting in an increased 
risk of infections (Irwin et al. 1996, Chartier-Kastler et al. 2007).  
In addition to the health-impairing effects of nocturia-related sleep 
fragmentation, another hypothesised factor mediating nocturia-related morbidity 
and even mortality, is the potentially increased risk of falls and fractures. These 
comprise an important entity, especially among elderly population as older adults are 
at increased risk of falling due to age-related deterioration in balance and gait, which 
is exacerbated by illness and medications (Kannus et al. 2005, Deandrea et al. 2010). 
Over 30% of people aged over 65 years and living at home fall at least once per year 
(Deandrea et al. 2010, Morrison et al. 2013). Although only a minority of falls leads 
to fractures (Morrison et al. 2013), injuries due to falls are common and, among older 
adults, are associated with substantial healthcare costs, long-term functional 
impairment and a high risk of institutionalisation (Burns et al. 2016, Tinetti et al. 
1997). Furthermore, falls account for the largest percentage of deaths related to 
unintentional injuries among older people (Burns et al. 2018). Therefore, developing 
multifactorial fall prevention programmes is a major focus in geriatric research 
(Gillespie et al. 2012).  
The relationship between nocturia and falls and fractures is complex as they are 
all associated with multiple comorbidities that could confound or mediate 
associations. Common factors associated with both nocturia and falls include older 
age, diabetes, cardiovascular diseases, depression and physical inactivity (Fitzgerald 
et al. 2007, Tikkinen et al. 2009, Gibson et al. 2018). Some risk factors, such as 
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obesity, however, may increase nocturia but decrease fractures (Tikkinen et al. 2006a, 
De Laet et al. 2005). Furthermore, the postulations regarding the relationship 
between nocturia and falls and fractures are based mainly on cross-sectional studies 
which in spite of finding a consistent association of nocturia with falls (Stewart et al. 
1992, Kim et al. 2007b) have less consistently supported the association with 
fractures (Stewart et al. 1992, Asplund 2006). Hence, given that in cross-sectional 
studies one can never be sure of the temporal relation between exposure and 
outcome, longitudinal studies are required to ascertain the association between 
nocturia and falls/fractures. 
2.7 Mortality 
Premature deaths occur before the average age of death in a certain population and 
are of interest since these are often deemed to be preventable through reduced 
exposure to behavioural risk factors and timely and effective treatment. According 
to recent European statistics from 2017, CVD and cancer remain the most common 
causes of premature death. Annually, CVD contributes to 35% of deaths in people 
under 75 years and 29% of deaths in those under 65 years. For cancer, the 
corresponding proportions are 29% and 27% (Timmis et al. 2018). Among working 
age adults, excessive alcohol consumption remains a leading cause of premature 
death, being responsible for one in ten deaths among working age adults (Stahre et 
al. 2014, Timmis et al. 2018).  
As people with nocturia tend to be older and are more likely to have comorbid 
conditions, the relevance of using nocturia as a mortality risk factor must take note 
of the effect of various confounders on the association between nocturia and 
mortality (Fig. 3). To optimally assess the impact of nocturia on mortality, one must 
also take into account fluctuation of nocturia, as well as follow-up time (time interval 
after initial assessment) (Vaughan et al. 2013). Furthermore, investigators should use 
a validated nocturia assessment method, and, to further minimise the risk of bias, 
reliably register all deaths during follow-up.  
When interpreting the findings of population-level studies of associations and 
prognosis, one must consider the validity of the estimates and their applicability to 
real-world practice. Summarising the data of observational studies on nocturia seems 
a challenging task due to substantial variation in study methods and populations. 
Therefore, to guide future research and clinical practice for people with nocturia, 
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there is an increasing need for systematic reviews and meta-analyses supplemented 
with assessments of the quality of evidence. 
Figure 3.  Directed acyclic graph of potential confounders and mediators between nocturia and 
associated mortality. 
 
 
  
NOTE: The ovals represent the potential confounders (ageing, diseases and lifestyle factors) on the association 
between nocturia and mortality. The arrows demonstrate the directions of the mediators (sleep disorders and 
falls/injuries) on the causal pathway between nocturia and mortality.  
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3 AIMS OF THE STUDY 
The aims of this thesis are broadly divided in two major topics. First, the work aims 
to describe the natural course of nocturia and its associated risks of falls, fractures 
and mortality. Second, the work aims to further develop methods for systematic 
reviews and meta-analyses assessing natural history and prognosis of symptoms. The 
detailed objectives are the following: 
1. To explore and compare, using different analytical methods and definitions, 
the average annual cumulative incidence and remission of nocturia, and 
separately, the progression of nocturia. 
2. To establish the risk of bias criteria for systematic reviews assessing 
prognosis by developing a tool to assess the risk of bias in longitudinal 
symptom research studies aimed at the general population.  
3. To contribute to the methodology of meta-analyses of the natural course of 
symptoms by comprehensively extracting data from individual studies and 
converting the measures to the same effect size metric to pool incidence and 
remission rates of nocturia. 
4. To evaluate the association of nocturia with mortality, both as a prognostic 
and causal risk factor, by performing a systematic review and meta-analysis, 
including assessment of the quality of evidence (certainty in estimates). 
5. To evaluate the association of nocturia with falls and fractures, both as a 
prognostic and causal risk factor, by conducting a systematic review and 
meta-analysis, including assessment of the quality of evidence (certainty in 
estimates). 
6. To estimate the association of nocturia, daytime urinary frequency, and urinary 
urgency with mortality in a population-based cohort of middle-aged and 
elderly Finnish men.   
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4 MATERIALS AND METHODS 
4.1 Systematic reviews and meta-analyses 
4.1.1 Data sources and searches 
The three systematic reviews included in the thesis (Studies I, II and III) were based 
on the same, comprehensive literature search, updated regularly in order to provide 
up-to-date estimates. Accordingly, for Study I, the literature search was performed 
up to 31 August 2015 and for Studies II and III, up to 31 December 2018. 
An experienced research librarian (M.A.) collaborated in planning the search 
strategy, in PubMed (from 1946 to present), Scopus (1995 to present), and 
Cumulative Index of Nursing and Allied Health Literature (CINAHL, 1960 to 
present) without search limits or language restrictions. As increasing evidence 
suggests the benefits of including “grey” literature in the systematic reviews (Montori 
et al. 2008), we also searched abstracts published in the annual meetings of the 
American Urological Association (AUA), the European Association of Urology 
(EAU), the International Continence Society (ICS), and the International 
Urogynecological Association (IUGA)  from 2005 until 2015 for Study I and until 
2018 for Studies II and III for ongoing and unpublished studies. Appendix 1 
provides the search strategy. We also manually searched reference lists of all included 
articles.  
4.1.2 Study selection and data extraction 
We screened the studies identified by the literature search according to their titles 
and abstracts and further included them in the full-text article screening phase if they 
complied with each of the following criteria: (1) a longitudinal study with a follow-
up of at least three months, (2) a study assessing urinary symptoms at baseline, (3) a 
study sample consisting of 95% adults, and (4) a study examining the effect of any 
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intervention, including those with untreated control arms. We retrieved full text 
articles if the reviewers answered “yes” or “unclear” to all selection criteria.  
As an additional selection criterion in Study I, taking into account the interaction 
between nocturia and several comorbidities, and therefore, to avoid potential 
selection bias, we excluded studies assessing lower urinary tract symptoms (LUTS) 
in patients with any specific health disorder, such as obstructive sleep apnea, diabetes 
or post stroke. Furthermore, to rule out the potentially biasing effect of recent 
delivery to LUTS, we excluded studies assessing the impact of pregnancy or delivery 
on LUTS if the baseline LUTS assessment was carried out either during pregnancy 
or in the first post-partum year. 
The screening of full text articles was accomplished with more specific eligibility 
criteria based on the research question of each review. Accordingly, for the 
systematic review of incidence and remission of nocturia (Study I), we included 
observational cohort studies providing data on either incident or remittent cases of 
nocturia or periodic prevalences of nocturia in a sample of community-dwelling 
individuals not primarily seeking treatment for LUTS or sleep problems. For the 
systematic reviews of the impact of nocturia on mortality and falls/fractures (Studies 
II and III), we included observational cohort studies providing relative measures of 
association of nocturia as an exposure and mortality or falls/fractures as an outcome.  
We developed standardised, pilot-tested forms together with detailed instructions 
for the screening of abstracts and full texts, risk of bias assessments, and data 
extraction. The reviewers conducted pilot screening and data extraction exercises to 
achieve a high level of agreement. Pairs of reviewers, independently and in duplicate, 
screened study reports for eligibility, assessed risk of bias and collected data from 
each eligible study. Reviewers resolved disagreements through discussions; one of 
two adjudicators resolved remaining disagreements.  
When more than one report provided data from the same study, we used the 
most complete report, and additionally combined data from less complete reports 
where possible. We recorded the country/source of the study sample, age and sex 
distribution, exclusion criteria used in individual studies, assessment tools used for 
nocturia, follow-up time, sample size including response rate and the data for desired 
outcomes for each review i.e. incidence and remission of nocturia and relative 
measures of association of nocturia with mortality and falls/fractures as well as 
variables used in adjustments of the reported estimates.  
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4.1.3 Risk of bias and quality of evidence assessment 
One challenge for a systematic review assessing prognosis (Study I) is that risk of 
bias criteria, as well as criteria for overall certainty in estimates, although well 
established for reviews of therapeutic trials, are controversial in observational studies 
(Guyatt et al. 2011). Through iterative discussion and consensus building, and 
informed by the existing literature (Hayden et al. 2013, Kim et al. 2013), we 
developed a novel instrument to categorise studies as carrying either low or high risk 
of bias, evaluating the representativeness of the source populations, accuracy of the 
outcome assessment and the proportion of missing data (Appendix 2) (Tikkinen et 
al. 2012). In Study I we categorised the overall risk of bias as low if the study met 
criteria for low risk of bias in each of the three domains of the assessment (Appendix 
2). 
Furthermore, not only the methods of studies assessing prognosis, but generally 
the methods of all observational cohort studies require development regarding their 
risk of bias evaluation (Guyatt et al. 2011). Motivated by the shortcomings of the 
methodology available and taking the existing literature into account (Tähtinen et al. 
2016, Hayden et al. 2013, Kim et al. 2013), we developed instruments for 
observational cohort studies examining nocturia as exposure and mortality (Study II) 
and falls/fractures (Study III) as outcome. This includes the features of the studies 
included that could potentially bias the estimates: the comparability of source 
populations, confidence in the assessments of both exposure (nocturia) and  
outcome (separately for mortality, falls and fractures), proportion of missing data 
and adjustments for important potential confounders/risk factors for each outcome. 
In Studies II and III we categorised the overall risk of bias as low if the study met 
the criteria for low risk of bias in each of the five domains of the assessment 
(Appendices 3 and 4).  
According to the GRADE framework, for assessments of prognosis, a body of 
observational studies begins as high-quality evidence. Several categories of 
limitations may, however, impair evidence quality, including risk of bias, imprecision, 
inconsistency and indirectness (Iorio et al. 2015). In contrast, in the GRADE 
approach for studies of interventions, a body of observational studies begins as low-
quality evidence, and may be rated down to “very low” by the same limitations as in 
intervention studies, but may also be rated up by factors such as a large effect size 
or  dose-response gradient (Guyatt et al. 2008c). Therefore, in this thesis, which 
includes only observational studies, the evidence can provide trustworthy inferences 
about prognosis (i.e. if nocturia is associated with mortality, falls or fractures) but 
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not causation (i.e. if nocturia causes mortality, falls or fractures). To formally 
compare the certainty of the pooled estimates for nocturia both as a prognostic 
factor (synonymous with risk factor) and as a cause of mortality, falls and fractures, 
we assessed the quality of evidence with the GRADE framework for both prognostic 
and intervention research (Iorio et al. 2015, Guyatt et al. 2008c).  
4.1.4 Data synthesis and analysis 
For Study I, we used three different analytic definitions to assess the incidence of 
nocturia: (1) any new case of nocturia (≥1 voids/night) at follow-up for individuals 
without nocturia at baseline, (2) any new case of ≥2 voids/night for individuals with 
no or one void per night at baseline, and (3) any new case of ≥3 voids/night for 
individuals with two or less voids per night at baseline. Similarly, we used three 
analytic definitions for nocturia remission: (1) one or more voids per night resolving 
to no nocturia, (2) two or more nocturia episodes resolving to no or one void per 
night, and (3) three or more nocturia episodes resolving to two or fewer voids per 
night. Epidemiological studies have suggested that a difference of at least one void 
per night is often patient-important (Tikkinen et al. 2010, Kupelian et al. 2012).  
For cumulative incidence and remission rates, person-years were calculated by 
multiplying the number of individuals without/with nocturia (for incidence and 
remission respectively) at follow-up by follow-up time (simple cumulative incidence 
methodology). Standard errors and 95% confidence intervals (CI) were calculated 
for natural logarithms of incidence/remission rates per 1000 person- years of follow-
up. In the case of zero events, a correction of 0.5 was added to observed events and 
person-years to enable calculation of confidence intervals.  
We calculated pooled rates of incidence and remission of nocturia using the 
DerSimonian–Laird random effects inverse variance method. Rates were expressed 
as observed events per 1000 person-years of follow-up. If a study provided more 
than one definition for incidence/remission of nocturia, when pooling data, we 
preferred nocturia estimates using a definition of two or more voids/night. Finally, 
we also used actuarial cumulative incidence methodology for sensitivity analyses 
(Appendix 5). 
For the pooled analyses in Studies II and III, we extracted hazard ratios (HR), or 
alternatively relative risks (RR) to be used interchangeably with HRs. From the 
regression models reported, we selected the estimates with the highest level of 
adjustments to minimise the effect of confounding.  
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Although the proportional hazards model utilising time-to-event data is superior 
to the logistic regression model in the analyses of longitudinal data by incorporating 
more information, in cases of relatively short follow-up periods, as is typically the 
case with observational studies of nocturia, where distribution of events and 
therefore, censoring, is concentrated at the end of follow-up, the loss of statistical 
power is known to be weak, even in cases of moderate values of survival function 
(Annesi et al. 1989). Therefore, in cases of outcomes of rare events, estimates for 
proportions at follow-up provided by adjusted regression models, i.e. odds ratios 
(OR) and RRs, are probably close approximates to HRs (Annesi et al. 1989). 
Accordingly, as the baseline risk of deaths and fractures is typically low, we 
considered the interchangeable use of HRs and RRs justified (for easier 
interpretation, we converted ORs to RRs). 
Regarding outcomes of common events (such as falls in the elderly), where the 
majority of events occur within a short time period, the effects of censoring and 
competing risks (such as deaths) are less significant and therefore HRs are seldom 
reported. Taking into account the typically high baseline risk of falls, conversion to 
the same effect size metric is required, hence, if a study reported only an odds ratio 
(OR) instead of RR, we converted the OR into RR using the following formula: 
 RR = OR / (1 – p + (p x OR)) 
in which p represents the baseline risk i.e. the risk of the outcome (death or 
falls/fractures) in people without nocturia at baseline (Sinclair & Bracken 1994). We 
calculated the pooled RRs using the DerSimonian–Laird random effects inverse 
variance method. When raw data were available, to take account of the effect of 
potential confounders including age and comorbidities, we derived adjusted RRs 
from multivariable logistic regression models.  
4.1.5 Additional analyses 
In each meta-analysis, we tested effect modification with subgroup analyses, 
stratified by at least with following covariables: (1) Mean age (2) gender distribution 
(3) length of follow-up, (4) nocturia case definition, and (5) risk of bias. Pre-specified 
hypotheses were employed to examine heterogeneity between the estimates using 
meta-regression analysis weighted by the inverse of the variance in a random effects 
model. We set a threshold of p-value less than 0.05 as a minimum criterion for a 
credible subgroup effect. 
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The subgroup analyses of Study I were stratified into three age groups (18–39, 
40–59 and 60 years and over) as earlier research suggest substantial differences in 
prevalence of nocturia between individuals in young adulthood, middle age and in 
older age (Bosch & Weiss 2010). We moreover stratified the analyses by gender and 
across the three nocturia case definitions (defined as ≥1, ≥2 or ≥3 voids/night). 
Separately for each nocturia case definition (≥1, ≥2 or ≥3 voids/night), we examined 
the following variables as potential sources of heterogeneity: (1) mean age, (2) sex 
distribution, (3) length of follow-up and (4) risk of bias. For incidence, we had pre-
specified hypotheses that effect estimates would be higher for: (1) older age, (2) 
higher proportion of male population, (3) shorter follow-up time and (4) lower risk 
of bias. For remission, we had pre-specified hypotheses that effect estimates would 
be higher for: (1) younger age, (2) higher proportion of female population, (3) shorter 
follow-up time and (4) lower risk of bias. 
The subgroup analyses of Study II were stratified by three age groups (18-49, 50-
69 and ≥70 years) to address the effect of age and the natural history of nocturia on 
the relative measures of association between nocturia and mortality. We moreover 
stratified the analyses by gender, follow-up time (<10 vs. ≥10 years), risk of bias, 
study region and across varying nocturia case definitions in terms of a binary variable 
(≥2 vs. 0-1; and ≥3 vs. 0-2 voids/night) and a three-value categorical variable (2 vs. 
0-1 and ≥3 vs. 0-1 voids/night), using the latter to explore exposure-response 
relationship of nocturia with mortality. In meta-regression we examined the 
following variables as potential sources of heterogeneity: (1) gender, (2) age, (3) 
length of follow-up, (4) nocturia case definition and (5) risk of bias.  We pre-specified 
hypotheses that the effect of nocturia on mortality would be higher for: (1) male vs. 
female or mixed gender, (2) younger age (<70 vs. ≥70 years), (3) shorter follow-up 
time (<10 vs. ≥10 years), (4) higher nocturia case definition (≥3 vs. ≥2 voids/night) 
and (5) high vs. low risk of bias.  
The subgroup analyses of Study III were stratified by age, gender, follow-up time, 
risk of bias and across varying nocturia case definitions in terms of a binary variable 
(≥2 vs. 0-1 and ≥3 vs. 0-2 voids/night) and a three-value categorical variable (2-3 vs. 
0-1 and ≥4 vs. 0-1 voids/night), using the latter to explore the exposure-response 
relationship of nocturia with falls and fractures. Additional subgroup-analyses with 
similar stratifications were conducted for studies reporting recurrent falls as an 
outcome. Due to the paucity of included estimates, conducting a meta-regression 
analysis to detect any interactions between variables was not considered relevant in 
Study III.  
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In Study I, to facilitate the understanding of the natural course of nocturia, we 
visually demonstrated the relationship between annual incidence, remission and 
prevalence of nocturia by the three nocturia case definitions (≥1, ≥2 and ≥3 
episodes/night). For this illustration, we estimated the baseline prevalence of 
nocturia separately for each nocturia case definition using an existing comprehensive 
systematic review (Bosch & Weiss 2010).  
For better communication and knowledge translation regarding the 
consequences of nocturia, considering that optimal decision-making requires 
estimates of both relative and absolute effects, we illustrated the difference in the 
absolute risks of the assessed outcomes between individuals with and without 
nocturia. Accordingly, in Studies II and III we reported the association of nocturia 
with mortality and falls/fractures in terms of both relative and absolute estimates, 
presenting five-year absolute risks of death and annual risks of falls and fall-related 
fractures in people of two exemplary age groups over 60 years – an age group 
commonly affected by nocturia (Bosch & Weiss 2010).  
In Study II, when calculating the baseline risks of death, we first estimated the 
average five-year death rates from the reported annual death rates for people aged 
55-64 and 75-84 years in the USA (Centers for Disease Control and Prevention 
2016). Then, for the average estimates of the prevalence of nocturia of two or more 
voids per night (Tikkinen et al. 2010) in the desired age groups, we extracted the 
reported prevalences from studies included in an earlier comprehensive systematic 
review (Bosch et al. 2010), calculated the 95% confidence intervals (CI) for the 
natural logarithms of prevalences per 100 people and pooled the estimates in a 
random-effects meta-analysis (Appendix 6). Finally, to derive the baseline risks in 
the absence and presence of nocturia, we divided the average death rates into 
proportions based on the prevalence of nocturia and pooled relative risks for the 
desired age groups. 
In Study III, to assess the average risks of falls and fractures in general elderly 
population, the annual number of people with ≥1 falls/year and the proportion of 
those who fell and sustained a fracture were extracted from prospective Western 
population-based studies included in a previous systematic review (Morrison et al. 
2013). After calculating the 95% confidence intervals for the natural logarithms of 
incidence rates of fallers per 100 person-years and the proportions of individuals 
with a fall-related fracture per 100 fallers, the estimates were pooled in random-
effects meta-analyses (Appendices 7 and 8). To stratify the pooled estimates of 
average annual fall and fall-related fracture rates by age, we used coefficients from 
another systematic review assessing various risk factors for falls (Deandrea et al. 
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2010). Finally, to derive the baseline risks in the absence and presence of nocturia, 
we divided the average annual fall and fracture rates in proportions based on 
prevalence of nocturia (Appendix 6) and pooled relative risks for the desired age 
groups. Statistical analyses were performed using metan and metareg in Stata 12.1 
(StataCorp, College Station, TX, USA) (Harris et al. 2008).  
4.2 The Tampere Ageing Male Urologic Study 
A population-based cohort study focusing on urological symptoms and sexual 
functioning among middle-aged and elderly men was launched in Pirkanmaa Region, 
Finland in 1994, with repeat rounds in 1999, 2004, and 2009. Details have been 
published previously (Koskimäki et al. 1998, Häkkinen et al. 2006). Briefly, a sample 
of 3143 men, living in Pirkanmaa Region, was identified from the Finnish Population 
Register in 1994, comprising all men born in 1924, 1934, or 1944 residing in the 
study area at baseline. Self-administered questionnaires were mailed to the men in 
the study population at all rounds. Non-responders were reminded with a second 
mailing after three months. The questionnaire comprised items on frequency and 
bother of LUTS, major health conditions and medications, as well as 
sociodemographic, anthropometric, and lifestyle factors (Appendix 9). 
We assessed the frequencies of LUTS using the Danish Prostatic Symptom Score 
(DAN-PSS-1) (Hansen et al. 1995), consistent with the International Continence 
Society definitions (Abrams et al. 2002). An exception was made in 1994 in the 
assessment of urgency, where a modified question backtranslated from Finnish to 
English was as follows: “Is your need to urinate so urgent that it is difficult to hold 
it back until you reach the toilet?”, which was since modified and used at sub-sequent 
the rounds in 1999, 2004, and 2009 as “Do you experience an imperative (strong) 
urge to urinate?”. The response options were never, rarely, often, always. The 
question concerning daytime frequency was “What is the longest interval between 
each voiding, from when you wake up until you go to bed?” with response options 
of more than 3 h, 2-3 h, 1-2 h, less than 1 h. The question concerning nocturia was 
“How many times do you have to urinate per night?” with response alternatives of 
none, 1 or 2 times, 3 or 4 times, 5 times or more. The preceding 4-week period was 
used as the reference time frame for the questions.  
As only moderate and severe LUTS are typically patient-important, we compared 
these with symptoms of milder intensity, after recoding each symptom into a binary 
variable (O'Leary 2005). Accordingly, we categorised urgency as “often or always” 
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vs. “never or rarely” and daytime frequency as nine or more vs. eight or fewer 
voids/day. Based on the response alternatives for nocturia question in DAN-PSS, 
we considered the case definition of three or more vs. two or less voids per night to 
most adequately detect patient-important cases with best comparability to the 
generally acknowledged case definition for significant nocturia of two or more 
voids/night (Tikkinen et al. 2010, Kupelian et al. 2012). For the analysis, we recoded 
each symptom into a binary variable: no or mild vs. moderate or severe symptoms 
(the first two versus the two latter options). We followed up the men for mortality 
through the population registry until the end of 2014. We obtained information on 
times and causes of death by a deterministic linkage with the unique personal 
identification number as the key.  
For analyses of mortality, we included men who had answered LUTS questions 
at every survey in 1994-2009 (while alive) and for comorbidities at least in the 1994 
survey. To adjust the analyses for confounders, we selected variables with well-
established prognostic importance for regression analyses. These variables, of which 
many are also known to be associated with LUTS, included age, marital status 
(married or cohabiting versus single or widowed), body mass index (BMI, ≤25 versus 
>25 kg/m2), current smoking (yes/no), alcohol consumption (≤150 g/week vs. 
>150g/week), previous diagnosis of diabetes, hypertension, cardiac disease, 
pulmonary disease, cerebrovascular disease, cancer and neurological disease.  
We performed univariate Cox regression analyses for each urinary symptom and 
potential prognostic variable. Independently of their effects in unadjusted analyses, 
we included each potential prognostic variable in multivariable-adjusted regression 
models of the three assessed LUTS. Each characteristic was treated as a time-
dependent categorical variable. We used the “last observation carried forward” 
method (Little & Rubin 2002) for comorbidities with missing values in the following 
rounds. We performed parallel analyses for each three urinary symptoms to provide 
time-varying HRs using variable values updated every five years (time-dependent 
analysis). To further examine the effect of fluctuation of LUTS and associated 
comorbidities, and for easier comparison to earlier studies, we conducted sensitivity 
analyses using values of all variables fixed to the baseline assessment (1994) and used 
Kaplan-Meier curves to graphically represent these associations. We moreover 
evaluated interaction terms in the regression models of the association of each 
urinary symptom with mortality and conducted subgroup analyses for the variables 
with a significant interaction. For all statistical analyses in Study IV, we used the 
Statistical Package for the Social Sciences (SPSS) version 23.  
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4.3 Ethical considerations 
Our studies comply with the Declaration of Helsinki. In accordance with the Finnish 
regulations on questionnaire surveys, we were granted an exemption from ethical 
review by the ethics committee of the Pirkanmaa Hospital District for the Tampere 
Ageing Male Urologic Study (Study IV: tracking number 99050). In the three 
systematic reviews included in the thesis (Studies I-III), we registered the protocols 
in an international prospective register of systematic reviews, PROSPERO 
(CRD42012001985, Pesonen et al. 2014; CRD42016051132, Pesonen et al. 2016a; 
CRD42016051525, Pesonen et al. 2016b) and followed the Preferred Reporting 
Items for Systematic Reviews and Meta-analyses (PRISMA) guidance (Moher et al. 
2009). 
  
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5 RESULTS 
5.1 Incidence and remission of nocturia – a systematic review 
and meta-analysis (Study I) 
We screened 4165 abstracts and retrieved 74 full texts and two eligible conference 
abstracts (Fig. 4). Sixteen studies provided usable data from 15 142 men and 18 726 
women (Table 2). Of these 16 studies, two provided proportional measures of 
progression and remission of nocturia among all persons in follow-up but did not 
report actual numbers of incident or remitting cases (Lee et al. 1998, Temml et al. 
2003). Similarly, one study provided only periodic prevalences of nocturia but not 
data on incident or remitting cases (Malmsten et al. 2010). We were therefore able 
to include 13 studies (114 964 person-years) in the meta-analyses of incidence and 
remission rates of nocturia.  
Table 2 provides a description of the 16 studies. Ten (62%) were conducted in 
Europe, three (19%) in North America, and three (19%) in Asia. The studies varied 
widely, including gender and age distributions, as well as in follow-up times (median 
4.5 years; range, from 6 months to 16 years). Fifteen studies (94%) used symptom 
questionnaires and one (6%) used frequency-volume charts.  
  
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Figure 4.  Flow chart – Study I. 
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Of the 16 studies included, 14 (88%) accurately assessed nocturia both at baseline 
and at follow-up, nine (56%) had a little missing data in the follow-up and eight 
(50%) used representative source populations. Of these studies, 10 (62%) were 
judged to have high and six (38%) low risk of bias (Fig. 5). 
 
Figure 5.  Risk of bias of the included studies – Study I. 
 
 
 
  
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In the meta-analyses of the incidence rates of nocturia (12 studies, five low and seven 
high risk of bias), the pooled average annual cumulative incidence was 4.9% (95% 
confidence interval 4.1-5.8, I2=98.6%; no difference between simple and actuarial 
cumulative incidence methodology) (Fig. 6, Appendix 5). With age stratification, 
annual incidence increased with increasing age: 0.4% (0-0.8%, I2=65.1%) for adults 
aged < 40 years, 2.8% (1.9-3.7%, I2=98.1%) for adults aged 40-59 years, and 11.5% 
(9.1-14.0%, I2=98.8%) for adults aged ≥60 years (Fig. 6). Pooled incidence rates did 
not significantly differ by nocturia case definition (4.1% (3.0-5.2%) for ≥1 episodes 
per night, 4.4% (3.6-5.2%) for ≥2 episodes per night, and 3.7% (2.4-5.1%) for ≥3 
episodes per night (Appendix 10).  
In multivariable meta-regression, (borderline) significant predictor for higher 
incidence was older age (4.7% increase/decade for ≥1 voids/night, -1.4 to 10.8, 
p=0.12, 2.5% increase/decade for ≥2 voids/night, 0.1-4.9, p=0.04; and 2.6% 
increase/decade for ≥3 voids/night, -0.2 to 5.4, p=0.06). Follow-up time, sex 
distribution, or risk of bias were not strongly suggestive of higher or lower incidence 
of nocturia (Appendix 11).  
In the meta-analyses of remission rates of nocturia (12 studies, five low and seven 
high risk of bias), the pooled average annual cumulative remission was 12.1% (9.5–
14.7%, I2=97.8%; no difference between simple and actuarial cumulative remission 
methodology) (Fig. 7, Appendix 5). With age stratification, annual remission rates 
did not differ by age: 11.1% (3.7–18.5%, I2=0.0%) for adults aged <40 years, 9.4% 
(6.2–12.6%, I2=94.1%) for adults aged 40–59 years, and 13.9% (9.0–18.8%, 
I2=98.8%) for adults aged ≥60 years (Fig. 7). Pooled remission rates for nocturia 
increased with higher nocturia case definition: 6.7% (4.5–8.9%) for ≥1 voids/night, 
15.5% (10.4–20.6%) for ≥2 voids/night, and 22.3% (13.2–31.3%) for ≥3 
voids/night (Appendix 10).  
In multivariable meta-regression, age, sex distribution, follow-up time, or risk of 
bias were not consistently suggestive of higher or lower remission of nocturia 
(Appendix 12).  
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Figure 6.  Forest plot of incidence rates of nocturia per 1000 person-years of follow-up – Study I. 
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Figure 7.  Forest plot of remission rates of nocturia per 1000 person-years of follow-up – Study I. 
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Figure 8 illustrates the relation of baseline prevalence (of having or not having 
nocturia) with (average annual) cumulative incidence and remission. For instance, 
baseline prevalence is 5% for ≥3 nocturia episodes. Therefore, 5% of population are 
‘‘at risk’’ of nocturia remission and 95% are ‘‘at risk’’ of nocturia incidence. 
According to our meta-analyses (Appendix 10), cumulative incidence is 3.7% (2.4–
5.1%) and cumulative remission is 22.3% (13.2–31.3%) for ≥3 nocturia episodes. 
However, due to the baseline prevalence, indeed more incident than remittent 
nocturia cases emerge annually and the prevalence therefore increases with age. 
Figure 8.  Relation of annual incidence and remission rates of nocturia to baseline prevalence of at 
least one void per night (30%), at least two voids per night (12%), and at least three voids 
per night (5%) – Study I. 
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Three studies provided proportional measures for progression/remission of 
nocturia (Lee et al. 1998, Temml et al. 2003, Heidler et al. 2011). In a Scottish study 
conducted among middle-aged and elderly men (Lee et al. 1998), progression of 
nocturia occurred in 40% and remission in 10%, whereas in 50% of men nocturia 
remained unchanged after 5-year follow-up. In an Austrian study also conducted 
among middle-aged and elderly men (Temml et al. 2003), progression occurred in 
28%, remission in 27%, while in 45% of men nocturia symptoms were unchanged. 
An Austrian study conducted among women of all adult ages (Heidler et al. 2011), 
reported after 6.5-year follow-up, progression from one void to at least two voids 
per night occurred in 21% of women with one void per night at baseline, and 
remission to one void per night in 23% of women with at least two voids per night 
at baseline.  
5.2 Impact of nocturia on mortality – a systematic review and 
meta-analysis (Study II) 
We screened 5230 abstracts and retrieved 132 potentially eligible full text reports and 
22 conference abstracts (Fig. 9). Ten original full text articles and one conference 
abstract provided data on nocturia-associated death, including 19 590 men and 14 
241 women with a total follow-up of 297 379 person-years (Table 3). Five (45%) of 
the 11 authors confirmed the accuracy of our data extraction; two (18%) corrected 
some errors or provided additional information and four (36%) were unable respond 
to our requests for data checks and clarifications. 
Studies were conducted on three continents, in male and mixed gender 
populations that varied widely in their age distributions and follow-up times (Table 
5). Nocturia was defined as ≥2 episodes per night in six (55%), and as ≥3 episodes 
per night in five (45%) studies. Reflecting the differences in study populations, as 
well as variations in symptom assessment methods, the baseline prevalence of 
nocturia in the study populations varied widely, with ranges of 8-34% based on a 
case definition of ≥2 (vs. 0-1 voids/night) and 2.5-35% with a case definition of ≥3 
(vs. 0-2 voids/night) in adults aged <70 years; in adults aged ≥70 years, the range 
was 35-49% in the broader case definition and 8-38% in the more restrictive 
(Appendix 13). 
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Figure 9.  Flow chart – Study II. 
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To identify eligible individuals, two studies used electoral rolls, two household 
registries, and three civil registries. One study used a combination of hospital and 
primary care registries, one recruited patients from a hospital’s diabetes clinic and 
one used primary care registries for White and zip code lists for Black participants. 
We considered the cohorts of seven studies to adequately represent general 
populations with a satisfactory participation rate (Fig. 10, Table 3). For assessment 
of nocturia at baseline, ten studies used symptom questionnaires and one used 
frequency-volume charts. We considered eight studies (73%) to have assessed 
nocturia accurately (Fig. 10, Table 3). Five studies (45%) collected mortality data 
from a national death registry, and five (45%) used linkage to registries of different 
health care institutions. We considered that ten studies (91%) assessed mortality 
accurately through registry data. Eight studies (73%) had little missing data. Six 
studies (55%) adequately performed adjustments for their estimates (Fig. 10, Table 
3, Appendix 13). The overall risk of bias was judged as high in nine studies (82%), 
and as low in two studies (18%) (Fig. 10). 
Figure 10. Risk of bias of the included studies – Study II. 

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The pooled relative risk of death in 11 studies (2 low and 9 high risk of bias) proved 
higher in people with nocturia compared to those without nocturia (RR 1.27; 95% 
CI 1.16-1.40; heterogeneity: I2=48.3%; moderate quality evidence for prognosis and 
very low quality evidence for causality) (Figure 11, Table 4).  
In subgroup meta-analyses, the pooled estimates for association between nocturia 
and mortality did not differ significantly for samples stratified by age, gender, follow-
up time, nocturia case definition, risk of bias, or study region (Appendices 13-15). 
This was also true for the multivariable-adjusted meta-regression analyses (Appendix 
16).  
Based on the mean death rates in the USA among people aged 60 and 75 years 
with respective age-specific prevalences of nocturia (≥2 episodes per night) of 
approximately 20% and 40% (Appendix 6), the nocturia-associated increase in the 
overall five-year absolute death risk were 1.6% and 4.0% among people aged 60 and 
75 years respectively (Figure 12, Appendix 17). 
We rated down the quality of evidence due to high risk of bias (to which the 
majority of the included studies were susceptible). We therefore rated the quality of 
evidence (synonymously confidence or certainty in estimates) as moderate for 
nocturia as a prognostic risk factor for mortality, and as very low quality for nocturia 
as a causal factor for mortality (Table 4). 
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Figure 11. Forest plot of the relative risks of death in people with nocturia – Study II. 
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Figure 12. Relative and absolute risk of death in five years between people with and without nocturia 
– Study II. 
 
 
5.3 Impact of nocturia on falls and fractures – a systematic 
review and meta-analysis (Study III) 
We screened 5230 abstracts and retrieved 132 potentially eligible full text articles and 
22 conference abstracts (Fig. 13). Five studies provided data on the association 
between nocturia and falls and five on nocturia and fractures (Table 5).  
Of the five studies assessing falls, three were conducted in North America, one 
in Europe and one in Australia. Of the five studies assessing fractures, two were 
conducted in North America, two in Europe and one in Eastern Asia. The studies 
included mainly older people in their seventies and predominantly men, with follow-
up times varying from one to six years for studies of falls and four to nine years for 
studies of fractures (Table 5). Two studies were conducted on the same base 
population of older men with separate reports on falls and non-spine fractures with 
varying follow-up times. We identified one conference abstract (Fitzgerald et al. 
2009), which reported only death as an endpoint (was included in Study II) but access 
to the study raw data provided assessments also for both falls and fractures (Palloni 
et al. 2013) (Appendix 18). We were therefore able to include five studies in the meta-
 72 
analysis of falls with a total follow-up of 23 678 person-years and five studies in the 
meta-analysis of fractures with a total follow-up of 87 973 person-years. 
 
Figure 13. Flow chart – Study III. 
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Of the five studies assessing falls, three used representative source populations, three 
conducted the baseline assessments of nocturia and follow-up assessments of falls 
accurately, three had little missing data at the follow-up, and three adequately 
adjusted their estimates for important prognostic risk factors for falls. We judged 
three studies, of those assessing impact on falls, to be at overall high risk of bias (Fig. 
14, Table 5, Appendix 19).  
Of the five studies assessing fractures, three used representative source 
populations, three assessed nocturia accurately, four assessed fractures accurately, 
three had little missing data at follow-up, and two adequately adjusted their estimates 
for important prognostic risk factors for fractures. We therefore considered four 
studies, of those assessing impact on factures, to be at overall high risk of bias (Fig. 
14, Table 5, Appendix 19). 
Figure 14. Risk of bias of the included studies – Study III. 
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In the meta-analysis of estimates of the association between nocturia and falls, 
adjusted at least for age and gender (5 studies: 2 low and 3 high risk of bias), the 
pooled relative risk of falling at least once in follow-up was higher in people with 
nocturia than in those without nocturia at baseline (RR 1.20; 95% CI 1.05-1.37; 
heterogeneity: I2=52%; moderate-quality evidence for prognosis and very low quality 
for causality) (Fig. 15, Table 6). In the subgroup analyses, the estimates did not differ 
by age, gender, follow-up time, nocturia case definition or risk of bias (Appendix 
20).  
In the additional analysis of studies reporting recurrent falls as an outcome (3 
studies: 1 low and 2 high risk of bias), the pooled, adjusted relative risk was 38% 
higher in people with nocturia at baseline (RR 1.38; 95% CI 1.11-1.71; I2=54.7%). 
The estimates were only available for men and did not differ by age, follow-up time, 
nocturia case definition, or risk of bias (Appendix 21). 
The absolute risk of falling at least once a year was 5.5% higher among people 
aged 65 years with nocturia (defined as ≥2 voids/night) than among people without 
nocturia (defined as 0-1 voids/night), and 7.5% higher in people aged 80 years with 
nocturia than among people without (Fig. 17, Appendix 23). 
In the meta-analysis of estimates on the association between nocturia and 
fractures, adjusted at least for age and gender (5 studies: 1 low and 4 high risk of 
bias), the pooled relative risk of having a fracture at follow-up was 32% higher in 
people with nocturia than in those without nocturia at baseline (RR 1.32; 95% CI 
0.99-1.76; heterogeneity: I2=57.5%; low-quality evidence for prognosis and very low-
quality for causality) (Fig. 16, Table 6). In the subgroup analyses, the estimates did 
not differ significantly by age, gender, follow-up time, nocturia case definition or risk 
of bias (Appendix 22). 
Regarding assessments of the association between nocturia and different types of 
fractures, only one estimate was available for each specific association with RRs of 
1.36 (95% CI 1.03-1.79) for hip fractures in men, 1.00 (95% CI 0.90-1.20) for non-
spine fractures in men, 1.37 (95% CI 0.19-9.86) for osteoporotic fractures in men, 
and 2.20 (95% CI 1.04-4.68) for specifically fall-related fractures in a mixed gender 
population respectively (Appendix 19). 
The absolute annual risk of fractures was 0.9% higher in people with nocturia 
than in people without among those aged 65 years. The absolute difference in annual 
fracture risk among people aged 80 years was 1.2% between people with and without 
nocturia (Fig. 17, Appendix 23). 
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Figure 15. Forest plot of the relative risks of falls in people with nocturia – Study III. 
 
Figure 16. Forest plot of the relative risks of fractures in people with nocturia – Study III. 
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Figure 17. Absolute risk of falls and fall-related fractures between older people with and without 
nocturia – Study III. 
 
Of the five studies assessing falls, three had high and two had low risk of bias (Fig. 
14). We rated down the quality of evidence due to high risk of bias (to which the 
majority of the studies included were susceptible). We therefore rated the quality of 
evidence as moderate for nocturia as a prognostic risk factor and as very low quality 
for nocturia as a causal factor for falls (Table 6). Of the five studies assessing 
fractures, four had high and one low risk of bias. We therefore rated down for risk 
of bias. We also rated down for imprecision (confidence interval crossed no effect). 
We therefore rated the quality of evidence as low for nocturia as a prognostic risk 
factor for fractures, and as very low quality for nocturia as a causal factor of fractures 
(Table 6). 
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5.4 Impact of nocturia, daytime frequency and urinary urgency 
on mortality among middle-aged and elderly Finnish men – 
(Study IV) 
A total of 2198 questionnaires (70 %) were returned in 1994, 2133 (75%) in 1999, 
1905 (76%) in 2004 and 1424 (66%) in 2009, of which 1332 were eligible for the 
study in that they provided sufficient data for the analyses, i.e. they included 
responses to questions regarding LUTS at every survey round (while alive). 
Regarding the age distribution of the men included, the respective proportions were 
41%, 36% and 23% for men aged 50, 60 and 70 at baseline. Men with LUTS were 
generally older than those without LUTS and virtually all medical conditions were 
more frequent among men with LUTS (Table 7, Appendix 24). 
Table 7. Characteristics of men with and without urgency, daytime frequency and nocturia at follow-
up midpoint (2004) – Study IV. 
 Urgency Daytime frequency Nocturia 
 Yes No Yes No Yes No 
 n % n % n % n % n % n % 
Number of men 190  877  82  985  100  967  
Year of birth             
1944 66 34.7 432 49.5 34 41.5 464 47.1 25 25.0 473 48.9 
1934 84 44.2 328 37.4 33 40.2 379 38.5 44 44.0 368 38.1 
1924 40 21.1 117 13.3 15 18.3 142 14.4 31 31.0 126 13.0 
Marital status             
Married/cohabiting 148 77.9 717 81.8 63 76.8 802 81.4 81 81.0 784 81.1 
Single/divorced 33 17.4 111 12.7 15 18.3 129 13.1 15 15.0 129 13.3 
Widowed 9 4.7 49 5.6 4 4.9 54 5.5 4 4.0 54 5.6 
BMI             
≤25 60 31.6 289 33.0 21 25.6 328 33.3 36 36.0 313 32.4 
25-30 89 46.8 431 49.1 39 47.6 481 48.8 51 51.0 469 48.5 
>30 41 21.6 157 17.9 22 26.8 176 17.9 13 13.0 185 19.1 
Current smoking 28 14.7 121 13.8 9 11.0 140 14.2 12 12.0 137 14.2 
Alcohol intake 
>150 g/week 38 20 134 15.3 8 9.8 164 16.6 8 8.0 164 17.0 
Medical 
conditions             
Diabetes 35 18.4 93 10.6 15 18.3 113 11.5 15 15.0 113 11.7 
Hypertension 101 53.2 391 44.6 47 57.3 445 45.2 46 46.0 446 46.1 
Cardiac disease 60 31.6 188 21.4 26 31.7 222 22.5 32 32.0 216 22.3 
Pulmonary disease 27 14.2 99 11.3 8 9.8 118 12.0 19 19.0 107 11.1 
Cerebrovascular 
disease 16 8.4 48 5.5 9 11.0 55 5.6 8 8.0 56 5.8 
Cancer 22 11.6 79 9.0 8 9.8 93 9.4 18 18.0 83 8.6 
Neurological 
disease 13 6.8 27 3.1 5 6.1 35 3.6 6 6.0 34 3.5 
  
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The symptoms showed substantial fluctuation with a decreasing trend for daytime 
frequency with a prevalence of 10.8% at baseline and 7.3% at 15 years and an 
increasing trend for nocturia with a prevalence of 3.8% at baseline and 8.9% at 15 
years. Reflecting the modified question in the assessment of urgency in 1994, its 
prevalence was materially lower at baseline (1.8%) than in subsequent rounds (14.5% 
at five, 17.8% at 10 and 19.1% at 15 years) (Fig. 18). 
Figure 18. Flow chart of mortality rates of men in relation to baseline prevalences and periodic 
incidence and remission rates of urinary urgency, frequency and nocturia – Study IV. 
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During the 21-year follow-up, 514 men died, of whom 139 during the first, 126 
during the second and 112 during the third 5-year period and 137 during the last 
period of six years. The overall mortality was 10.4% at five years, 19.9% at 10 years, 
28.3% at 15 years and 38.6% at 21 years (this means that 61.4% survived the whole 
follow-up). Mortality was higher among men with LUTS at every stage of follow-up 
(Fig. 18). In unadjusted time-dependent analyses, each of the storage symptoms 
studied was strongly associated with an increased risk of death: HR was 1.71 (95% 
CI 1.36-2.14) for urgency, 1.95 (1.52-2.49) for daytime frequency and 2.31 (1.79-
2.98) for nocturia (Table 8). In unadjusted analyses with fixed baseline 
characteristics, daytime frequency and nocturia were significantly associated with 
increased risk of death, while urgency showed no significant association: HR 1.43 
(1.11-1.84) for daytime frequency, 2.56 (1.81-3.63) for nocturia and 1.52 (0.86-2.69) 
for urgency (Figs. 19 & 20, Table 8). 
In multivariable-adjusted time-dependent analyses, daytime frequency and 
nocturia remained significantly associated with an increased risk of death, while 
urgency showed only a suggestive association: the adjusted HR was 1.42 (1.11-1.83) 
for daytime frequency, 1.38 (1.07-1.79) for nocturia and 1.19 (0.94-1.50) for urgency 
(Table 8, Appendix 25). In multivariable-adjusted analyses with fixed baseline 
characteristics, only nocturia was suggestively associated with increased risk of death: 
the adjusted HR was 0.94 (0.52-1.68) for urgency, 1.09 (0.84-1.42) for daytime 
frequency and 1.41 (0.99-2.02) for nocturia (Table 8, Appendix 26). 
Table 8. Unadjusted and adjusted associations of urinary urgency, frequency and nocturia with all-
cause mortality in Cox regression analyses using variable values updated every five years 
(time-dependent analysis) and values fixed to the baseline assessment of 1994 (fixed 
analysis) – Study IV. 
  
  Urgency Frequency Nocturia 
  HR 95% CI HR 95% CI HR 95% CI 
Time-dependent 
analysis 
Unadjusted 1.71 1.36-2.14 1.95 1.52-2.49 2.31 1.79-2.98 
Adjusted a 1.19 0.94-1.50 1.42 1.11-1.83 1.38 1.07-1.79 
Fixed analysis 
Unadjusted 1.52 0.86-2.69 1.43 1.11-1.84 2.56 1.81-3.63 
Adjusted b 0.94 0.52-1.68 1.09 0.84-1.42 1.41 0.99-2.02 
a A regression model including the year of birth and following categorical variables with time-varying values: LUTS, marital status, 
BMI, smoking, alcohol consumption, diabetes, hypertension, cardiac disease, pulmonary disease, cerebrovascular disease, 
neurological disease and cancer. “Last observation carried forward” method (Little & Rubin 2002) used for comorbidities with 
missing values in the follow-up rounds. 
b All above-mentioned variables treated as fixed categorical variables in the regression model i.e. the variable values fixed to the 
baseline assessment of 1994.  
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Figure 19. Kaplan-Meier curves for men with and without daytime frequency at baseline (1994) – 
Study IV. 
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Figure 20. Kaplan-Meier curves for men with and without nocturia at baseline (1994) – Study IV. 
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In the regression analysis, a significant interaction was found between smoking and 
urgency (p=0.02), likewise between previously diagnosed cardiac disease and urgency 
(p=0.04). The effect of urgency was suggestively stronger among non-smokers than 
smokers (HR 1.46, 1.12–1.91 vs. 0.73, 0.45–1.20) and among those without a 
diagnosed cardiac disease compared to those with a diagnosis (HR 1.30, 0.95–1.79 
vs. 1.04, 0.73–1.48) (Table 9). The effects of daytime frequency and nocturia showed 
no significant differences between any subgroups (Appendix 27).  
Table 9. Unadjusted and adjusted association analyses for variables with significant interaction in 
the regression models: association of urinary urgency with mortality among smoking and 
non-smoking men and among men with and without previously diagnosed cardiac disease 
– Study IV. 
 
 
 Unadjusted  Adjusted a 
 HR 95% CI  HR 95% CI 
Current smoking      
Yes 0.95 0.60-1.51  0.73 0.45-1.20 
No 2.09 1.61-2.71  1.46 1.12-1.91 
Cardiac disease      
Yes 1.20 0.86-1.69  1.04 0.73-1.48 
No 2.11 1.55-2.86  1.30 0.95-1.79 
a A regression model including the year of birth and following categorical variables with time-varying values: LUTS, marital status, 
BMI, smoking, alcohol consumption, diabetes, hypertension, cardiac disease, pulmonary disease, cerebrovascular disease, 
neurological disease and cancer. “Last observation carried forward” method (Little & Rubin 2002) used for comorbidities with 
missing values in the follow-up rounds. 
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6 DISCUSSION 
6.1 Summary 
In this thesis, we summarised the incidence and remission of nocturia among 
community-dwelling people using data from five low and eight high risk of bias 
studies. Across all available studies, the pooled incidence of nocturia was 0.4% per 
year among adults aged <40 years, 2.8% among those aged 40–59 years and 11.5% 
among those aged 60 years or more, while the overall pooled remission rate was 
12.1% per year. Estimates, however, varied considerably among studies. While 
incidence did not depend on nocturia case definition, remission was more common 
in cases of more frequent nocturia episodes: 6.7% per year for 1 void/night, 15.5% 
for 2 voids/night, and 22.3% for 3 voids/night. Estimates did not differ between 
genders, length of follow-up or study risk of bias. 
We also summarised the relative death risk associated with nocturia among 
community-dwelling people using data from two low and nine high risk of bias 
studies and found a 27% increase in relative risk of death in adults with nocturia 
(defined as either ≥2 or ≥3 voids/night) compared to those without nocturia after 
adjusting for age, gender and various comorbidities. This corresponds to a nocturia-
associated increase in the overall five-year absolute death risk of 1.6% among those 
aged 60 years and 4.0% among those aged 75 years. The magnitude of the association 
did not differ across a number of predictor variables.  
We further summarised the relative risks of falls and fractures associated with 
nocturia among community-dwelling people using data from two low and three high 
risk of bias studies and found an excess relative risk of 20% for falling at least once, 
and an excess relative risk of 38% for falling recurrently during follow-up in people 
with nocturia compared to those without nocturia at baseline. The 20% relative risk 
increase corresponds to a nocturia-associated increase in the absolute annual risk of 
falling by 5.5% among people aged 65 years and by 7.5% among people aged 80 
years. Similarly, from one low and four high risk of bias studies we found a possible 
increased relative risk of fracture of 32% in people with nocturia compared to people 
without nocturia after adjusting for age, gender and various comorbidities. The 
absolute risk of fractures was 0.9% higher in people with nocturia than in people 
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without nocturia among those aged 65 years, and 1.2% higher among those aged 80 
years.  
Finally, we examined the association of three common urinary storage symptoms 
– daytime frequency, nocturia and urgency – with mortality in a population-based 
cohort of middle-aged and elderly Finnish men. In the course of a follow-up of 21 
years, we observed a 1.4-fold increased risk of death in men with daytime frequency 
and nocturia, even after adjustments for behavioural risk factors and comorbidities. 
However, the associations were established only in analyses where the symptoms 
and comorbidities were updated every five years, whereas the sensitivity analyses 
with fixed baseline characteristics did not show any significant association between 
the symptoms assessed and mortality.  
6.2 Strengths 
The strengths of this thesis include the utilisation of robust methods to provide the 
best available evidence on the natural course of nocturia and associated risks of falls, 
fractures and mortality. Besides that the data are of importance as the world 
population is rapidly ageing, the work provides innovative approaches for future 
systematic reviews and meta-analyses, as well as longitudinal association studies of 
LUTS. 
To the best of our knowledge, the systematic reviews included in the thesis 
(Studies I-III) provide, to date, the most comprehensive estimates of the natural 
course of nocturia and of the associated risks of morbidity and mortality. To facilitate 
communication between patients and healthcare providers as well knowledge 
translation of the information, we provided absolute effects in addition to relative 
estimates of the associations of nocturia with falls, fractures and mortality. For this 
purpose, we also meta-analysed the prevalence of nocturia; this information is likely 
of interest itself to many researchers, clinicians, patients and other stakeholders, see 
Appendix 6. The reviews involved a contemporary and comprehensive search of 
both published and unpublished studies without language restrictions, the duplicate 
assessment of eligibility and data extraction, and the appraisal of risk of bias. We 
used appropriate statistical methods to generate pooled estimates, followed a pre-
specified data analysis plan, and employed a limited number of important and 
plausible hypotheses to explore potential determinants of heterogeneity. We applied 
and further refined novel approaches to risk of bias assessment (Tikkinen et al. 
2012), and successfully contacted many authors for clarifications and additional data. 
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Finally, we appraised the quality of evidence using the GRADE approach for 
inferences regarding nocturia both as a prognostic factor and as a causal factor for 
falls, fractures and mortality.  
The original population-based study included in the thesis, TAMUS (Study IV), 
provides two important improvements on earlier longitudinal association studies 
exploring LUTS and mortality. Firstly, we are not aware of any former study utilising 
repeated assessments and thus taking into account the fluctuation and development 
of symptoms and comorbidities during follow-up. Secondly, our follow-up is longer 
than in any study so far on the topic and covers more than 500 deaths (including 
>70 deaths among men with each of the LUTS examined).  
6.3 Limitations 
Although the estimates presented in the thesis for the course and consequences 
nocturia are among the most accurate to date and well-applicable as a reference for 
clinical interpretation, the work inevitably involves several limitations. The 
weaknesses of the eligible studies account for the majority of the limitations of the 
three systematic reviews (Studies I-III). Although we excluded all studies examining 
the effect of any intervention, all reviews did include some people receiving 
interventions and therefore, are somewhat limited as not entirely representing the 
‘‘natural’’ history. In all systematic reviews, none of the included studies was free of 
risk of bias and limitations related to non-representativeness of source populations, 
inaccuracy in assessments of nocturia, falls, fractures and mortality, missing data and 
inadequately adjusted analyses were common. Furthermore, our appraisals of risk of 
bias should be interpreted cautiously due to limited testing of the instruments. 
In prospective studies of nocturia, it is challenging to determine the most 
appropriate follow-up time for measurements of patient-important incidence and 
remission of nocturia in order to differentiate between short-term fluctuating and 
longer-term patient-important symptoms. Although we chose to include studies with 
a follow-up of three months or more, we found no eligible study with follow-up of 
less than six months. The variation in follow-up times makes comparison of 
estimates challenging because of the fluctuating nature of nocturia (Vaughan et al. 
2013, Yoshimura & Terai 2005). Accordingly, pooling the measures from studies 
with follow-up times varying from six months to 16 years inevitably involves some 
approximation, especially when trying to estimate average annual incidence and 
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remission (Study I) but also in cases of longitudinal association studies if repeated 
assessments in the course of follow-up are unavailable (Studies II and III).  
The paucity of age- and gender-stratified measures limits the comparability of the 
estimates on the incidence and remission of nocturia (Study I). Similarly, the lack of 
age- and gender-specific estimates in the elderly age groups leads to approximation 
when estimating the risks of falls, fractures and mortality in elderly population 
(Studies II and III). To rule out the temporary effects of pregnancy on the lower 
urinary tract, diuresis and sleep, as well as frequent nightly awakenings in the post-
partum period due to various reasons, such as baby care (Lose et al. 2001, Moline et 
al. 2003, Tikkinen et al. 2008), we excluded studies with baseline LUTS assessed 
either during pregnancy or in the first post-partum year. 
Due to an uneven global distribution of studies, we were unable to explore the 
plausible regional differences between the estimates. Respectively, for the meta-
analysis of incidence of nocturia (Study I), we included 12 studies of which seven 
were conducted in Europe, two in East Asia, and three in North America. Similarly, 
for the meta-analysis of remission of nocturia (Study I), we included 12 studies of 
which seven studies were conducted in Europe, three in East Asia and two in North 
America. While none of the European studies on nocturia incidence or remission 
included older women or younger men, and none of the North American studies 
provided age-stratified estimates for younger people, the reliability of comparing the 
estimates by study region was compromised. Similarly, while the majority of the 
studies included in the systematic reviews exploring the associations of nocturia were 
conducted in Western populations (8 out of 10 studies of mortality, 8 out of 9 studies 
of falls/fractures) the pooled estimates were considered valid for application to 
Western populations only, albeit with approximation (Figs. 10 & 14).  
Another limitation is the lack of frequency volume charts (FVC) in most of the 
reports included. According to the guidelines, FVC (or bladder diary) is a mandatory 
tool in clinical practice when evaluating patients with nocturia in order to 
differentiate between the various causes of nocturia, such as nocturnal polyuria 
(Hashim et al. 2019). However, according to a recent meta-analysis, the association 
of nocturnal polyuria with nocturia appears to be less obvious than usually thought 
(Hofmeester et al. 2014). 
Although questionnaires are susceptible to recall bias as they rely on the 
respondent’s memory, in earlier studies, increasing accuracy of questionnaires (in 
relation to FVC or bladder diary) has been found among those with fewer nocturia 
episodes (Jaffe et al. 2002, Yoshimura & Terai 2005). Therefore, our pooled 
estimates with pre-defined case definitions (≥1, ≥2, or ≥3 voids/night) are less likely 
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to suffer from recall bias. FVCs also have limitations. First, if used at population 
level, the studies using FVCs are likely to suffer from low response rates (as FVCs 
are burdensome to record). For instance, in the only study included (van Doorn et 
al. 2011), of the 3398 men invited, 1225 completed FVC and 1122 were included in 
the baseline population. After 2.1 years of follow-up, FVCs were available for 692 
individuals. Secondly, questionnaires assess the typical frequency over a longer time 
period retrospectively, whereas voiding FVCs typically assess one, two, or three 
nights prospectively. Hence, the studies compare two different time periods. The 
nights during FVC may not have been typical. Finally, participating in a prospective 
FVC evaluation may alter voiding habits (bladder training effect) (Tikkinen 2010).  
Although the analyses in the systematic reviews of the associations of nocturia 
(Studies II & III) showed no effect for nocturia case definition, only three studies of 
mortality and two studies of falls and fractures provided estimates for nocturia as a 
discrete variable with multiple values (number of voids), limiting our analyses to test 
for an exposure-response relationship between nocturia and the outcomes. 
Regarding the specific limitations of the systematic review of the association 
between nocturia and mortality (Study II), none of the studies included addressed 
causes of death and none of the studies utilised more sophisticated analytical 
techniques, such as structural equation modelling, to identify potential causal 
pathways between nocturia and mortality (Bielby & Hauser 1977). However, the 
establishment of a relationship between a risk/causal factor and mortality does not 
necessarily require addressing all the specific causes of death as this is a different 
question. Nevertheless, when causation is an issue and one has only observational 
evidence, it is reasonable to attempt such inferences – and indeed investigators do 
so frequently at the risk of making extravagant claims of causal effects (e.g. World 
Health Organization claims about red meat and cancer) (Bouvard et al. 2015). 
There was also a paucity of studies assessing sleep disorders as potential comorbid 
conditions with nocturia and thus, we were unable to differentiate between the roles 
of insomnia symptoms as potential confounders vs. mediators for mortality (nocturia 
caused by primary insomnia vs. insomnia secondary to nocturia) (Ancoli-Israel et al. 
2011). Given that, especially among the older people, nocturia is one of the leading 
causes of sleep disruption, which has further been shown to prognosticate mortality, 
analyses to test effect modification by sleep disorders would be relevant (Cappuccio 
et al. 2010, Da Silva et al. 2016). Accordingly, in the two available studies exploring 
the role of sleep disruption as one of the potential mediators between nocturia and 
mortality, both conducted in Western male populations and one of them excluded 
from our review due to being an interventional study (a randomised trial of 5α-
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reductase inhibitor, dutasteride, for prostate cancer chemoprevention), the 
association between nocturia and mortality turned non-significant after controlling 
the estimates for sleep disorders and other comorbidities (Endeshaw et al. 2016, 
Bliwise et al. 2019).  
One specific limitation of the systematic review of the association between 
nocturia and falls/fractures (Study III) was the small numbers of events, resulting in 
somewhat wide confidence intervals around the estimates. Because the majority of 
studies were at high risk of bias, quality ratings were low for prognosis of fractures 
and very low for causation for both falls and fractures (indeed no data are available 
on whether successful treatment of nocturia prevents falls or fractures, evidence that 
would be required to be confident about a causal relationship). 
Regarding the limitations of TAMUS (Study II), the nocturia question in DAN-
PSS-1 does not distinguish between one void and two voids per night. Of the 
response options of DAN-PSS-1, one or two voids/night was considered unlikely 
to distinguish meaningful nocturia and thus, ≥3 voids/night was considered a more 
robust indicator of important nocturia. Furthermore, although the incidence of 
nocturia is independent of nocturia case definition (≥1, ≥2 or ≥3 voids/night) 
according to our meta-analysis (Study I), remission frequency increases with more 
stringent criteria and accordingly, due to a more stringent case definition in our 
analyses, remission over time is more likely and repeated assessments are therefore 
crucial. 
Due to the relatively small number of deaths related to specific symptoms, our 
study did not have adequate statistical power to analyse the impact of multiple LUTS 
in combination. However, earlier findings suggest that storage symptoms frequently 
overlap and various LUTS often occur in combination (Tikkinen et al. 2007, Sexton 
et al. 2009). Furthermore, we were unable to assess the effect of treatments of LUTS 
on death. However, according to earlier studies, only a minority of men seek 
treatment for their LUTS (Sexton et al. 2009, Chong et al. 2012) and response to 
treatment may be unsatisfactory, particularly for storage symptoms (Taylor et al. 
2007, Han et al. 2014, Michel & De La Rosette 2005). Finally, some residual 
confounding is likely present in spite of extensive adjustments of the estimates with 
various medical conditions and lifestyle factors 
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6.4 Nocturia as a cause vs. as a risk factor 
Although randomised trials provide estimates of treatment effect with the lowest risk 
of bias, the populations enrolled are likely to differ from general populations in a 
variety of ways, making application to general populations limited (van Spall et al. 
2007). Hence, in order to explore the natural course of nocturia and associated risks, 
we chose to provide estimates from observational studies of unselected patients; 
such studies are likely to be the best source of estimates of prognosis (Iorio et al. 
2015).  
While nocturia is arguably more of a symptom than a disease, its applicability to 
the GRADE framework on prognosis can be justified by the synonymous use of the 
terms “risk factor” and “prognostic factor”. Some authors use prognosis as 
predicting outcome in individuals who already have a target condition (for instance, 
the prognosis in people with cancer), and distinguish this from risk as predicting 
outcome in those without a target condition (Guyatt et al. 2008a). Using the language 
in this way we are addressing risk and not prognosis. In this example, nocturia can 
be a marker of having other risk factors for falls, fractures and mortality. To state 
the distinction in terms of the topic of this thesis: if one has already had a fracture, 
one might talk about the prognosis regarding a second fracture. If one has not had 
a fracture, one would not talk about prognosis but rather risk of having a fracture. 
However, in this thesis, we have not made this distinction and use “risk factor” and 
“prognostic factor” synonymously. 
The association between nocturia and mortality likely reflects chronic illness as a 
cause of both nocturia and mortality. For instance, it is not difficult to imagine how 
diabetes could cause both nocturia and premature death. It is less likely, but still 
possible, that nocturia is on the causal pathway leading to premature death. For 
instance, impaired sleep as a result of nocturia could impair physiological nighttime 
blood pressure dipping, increase sympathetic activity (Obayashi et al. 2015), and thus 
increase cardiovascular deaths. In addition, fractures and other injuries may result 
from falls or other accidents related to frequent nighttime toileting and daytime 
fatigue, and complications of these events could result in premature death. These 
causal pathways are, however, speculative as one should be very cautious about 
making causal inferences from observational studies. 
The relationship between nocturia and all-cause mortality is somewhat 
comparable to the association between smoking and all-cause mortality where 
exposure is causal through multiple mechanisms (CVD, COPD, cancer etc.). 
However, whereas a robust causality between smoking and all-cause mortality has 
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been established from observational studies with an indication of large effect and a 
dose-response relationship (Reitsma et al. 2017), the magnitude of the association 
between nocturia and mortality is small, and there is no evidence of a dose-response 
relationship. Therefore, we can only speculate on mediating comorbidities such as 
falls, fractures and cardiovascular outcomes as a result of sleep disturbance. 
An important message of the thesis is that one can address two different 
questions: is there a true association between nocturia and mortality, falls or 
fractures, and does nocturia cause increase in deaths, falls or fractures? Accordingly, 
while the evidence is moderate for the association between nocturia and mortality, 
moderate for the association between nocturia and falls, and low for the association 
between nocturia and fractures, the evidence is only very low for causation (Tables 
4 & 6).  
6.5 Implications of the findings 
The pooled estimates of all available observational cohort studies highlight the 
burden of nocturia among older men and women compared with that in younger 
adults. Those aged over 60 years were nearly four times more likely to develop 
nocturia than were adults aged 40–59 years. Also, while one out of every eight 
persons with nocturia reported remission annually, for clinicians and patients, 
nocturia remains a challenging condition to treat (Marshall et al. 2015, Drake 2015).  
Remission of nocturia was more common in people with more frequent nightly 
episodes, with more than one out of five persons with three or more nightly episodes 
experiencing resolution to two or less episodes at follow-up. The hypothetical 
mechanisms explaining spontaneous resolution of nocturia include fluctuations in 
the functional bladder capacity, diuresis and sleep, possibly reflecting variation in 
individuals’ general health status and lifestyle factors. Therefore, in addition to 
plasticity in the function and morphology of the lower urinary tract with age, a higher 
tendency of spontaneous resolution suggests presence of various modifiable risk 
factors in people with more frequent nocturia episodes. Finally, a portion of the 
fluctuation noted in nocturia in these analyses may represent regression to the mean 
(Bland & Altman 1994). 
Although nocturia is a very common symptom at a population-level, the majority 
of people with nocturia do not report moderate or major bother from it. High 
prevalence estimates attract attention, and can, in theory, lead to increased disease 
awareness, and ultimately to earlier presentation and initiation of effective care. 
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However, maximised prevalence estimates can also be used inappropriately for 
commercial purposes to make the condition seem as widespread as possible to 
maximise the magnitude of a medical problem (Moynihan et al. 2002, Tikkinen 2010) 
and can lead to medical over-use. Risks of overdiagnosis and disease mongering 
should be kept in mind when creating guidelines. Individual healthcare providers 
should focus on patients with bothersome nocturia. 
The findings of the population-based TAMUS study suggest aiming for repeated 
assessments when designing long-term prospective studies of male LUTS-associated 
outcomes, including mortality. Due to the fluctuating nature of symptoms (Vaughan 
et al. 2014), repeated assessments are probably more reliable than fixed baseline 
assessments in the detection of patient-important and persistent symptoms, often 
associated with ill health. We found an indication of a 1.4-fold increased risk of death 
in Finnish men presenting with nocturia.  
Due to challenges related to treatments, nocturia may warrant more attention as 
a separate clinical entity. According to all available observational cohort studies 
conducted predominantly in middle-aged and older people, we found a probable 1.3-
fold increased risk of premature death associated with nocturia. Similarly, according 
to all available cohort studies conducted predominantly in older people, we found a 
probable 1.2-fold increased risk of falls, and a possible 1.3-fold increased risk of 
fractures associated with nocturia. Clinicians and patients should be aware that 
nocturia occurring at least twice per night may be a marker of ill health and lead, via 
a number of potential pathways, to premature death. Especially in the cases of elderly 
patients with early signs of frailty, the increased risks of falls and fractures may 
suggest considering occupational therapy assessment of their home environment if 
the patient also reports two or more episodes of nocturia. 
Although urological treatments have the potential to improve the quality of life 
of patients with nocturia, clinicians should focus not only on treating the symptom, 
but also on exploring patients’ general health taking into account the relevant risk 
factors for each individual (Oelke et al. 2016, Sakalis et al. 2017). Especially when 
managing older adults reporting nocturia, the treatment requires understanding of 
the multifactorial aetiology of nocturia. At its worst, medical treatment of nocturia 
by manipulating diuresis, sleep or lower urinary tract function, may cause more harm 
than good, especially in the case of frail elderly subjects (Vaughan et al. 2016, 
Chrischilles et al. 2001, Welk et al. 2015). Along with the ageing of populations 
worldwide and the well-recognised negative health impact of frequent nocturia 
(Tikkinen et al. 2010, Zhang et al. 2015, Han et al. 2017) development of well-
tolerated novel treatment strategies remains a research priority. 
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Randomised trials on the impact of nocturia treatment have mostly examined 
only a few nocturia-related short-term outcomes such as QoL and sleep, while long-
term data on nocturia-related morbidity is lacking (Cornu et al. 2012, Shigehara et al. 
2017). As evidence of nocturia as a causal factor for mortality seems to be lacking, 
the potential mediators of mortality, such as falls and cardiovascular events, could 
be included as outcomes in randomised trials of nocturia management, with 
sufficiently long follow-up to detect these outcomes and even the mortality related 
to them. 
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7 CONCLUSIONS 
The evidence available suggests that nocturia onset is strongly associated with age, 
with much higher rates in those over 60 years while remission occurs in 
approximately 12% each year. Moderate-quality evidence suggests that nocturia is 
associated with a 1.2-fold risk for falls and low-quality evidence suggests that 
nocturia is associated with a 1.3-fold risk for fractures. Furthermore, moderate 
quality evidence suggests that nocturia is associated with a 1.3-fold risk of death.  
The estimates, presented in the thesis, can aid with management decisions and 
counselling related to nocturia and associated comorbidities. This work provides two 
core messages for clinical practice and future research: first, in patients with nocturia 
the underlying health conditions warrant increased attention. Second, future 
investigations should address the impact of treatment for nocturia on falls and 
fractures with an adequately long follow-up to detect further morbidity and 
mortality.  
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Database: PubMed 
Search strategy: 
 
nocturia OR nycturia OR ((noctur* OR night*) AND (pollakiuria OR void* OR urination OR micturition 
OR polyuria OR "LUTS" OR "lower urinary tract symptoms" OR "BPH" OR "benign prostatic 
hyperplasia")) OR "night* frequency" OR "nocturnal frequency" AND (longitudinal OR "natural history" 
OR cohort OR incidence OR remission OR progression OR prospective OR "community-based" OR 
"population-based" OR epidemiol* OR "follow-up") 
 
Database: Scopus 
Search strategy: 
 
TITLE-ABS-KEY (nocturia OR nycturia OR ((noctur* OR night*) AND (pollakiuria OR void* OR urination 
OR micturition OR polyuria OR "LUTS" OR "lower urinary tract symptoms" OR "BPH" OR "benign 
prostatic hyperplasia")) OR "night* frequency" OR "nocturnal frequency" AND (longitudinal OR "natural 
history" OR cohort OR incidence OR remission OR progression OR prospective OR "community-
based" OR "population-based" OR epidemiol* OR "follow-up")) 
 
Database: Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
Search strategy: 
 
S8 S6 and S7   
S7 S1 or S3 or S5   
S6 ((MH "Prospective Studies+") OR prospective OR longitudinal OR (MH "Incidence") OR 
incidence OR (MH "Disease Remission") OR remission OR (MH "Disease Progression") OR 
progression OR (MH "Epidemiology+") OR epidemiol* OR "natural history" OR "community-based" OR 
"population-based" OR cohort OR "follow-up")   
S5 S2 and S4   
S4 (pollakiuria OR void* OR urination OR micturition OR polyuria OR "LUTS" OR "lower urinary 
tract symptoms" OR (MH "Prostatic Hypertrophy") OR "benign prostatic hyperplasia" OR "BPH")   
S3 ("night* frequency" OR "nocturnal frequency")   
S2 noctur* OR night*   
S1 nocturia OR nycturia 
 
Database: Abstracts published in the annual meetings of the American Urological Association (AUA), 
European Association of Urology (EAU), International Continence Society (ICS) and International 
Urogynecological Association (IUGA) from years 2005-2017 
Search Strategy:  
 
night* OR noctur* OR nycturia 
 
 
  
Appendix 1. Search strategies – Studies I-III. 
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1. Is the source population (sampling frame) representative of the general population? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)                (high risk of bias) 
 
Examples of low risk of bias: Selection of target population from a representative population roster 
such as national population registry with a response proportion more than 50% at baseline and missing 
data in the key characteristics within questionnaires less than 20%. Provincial or single community-
based study with a response proportion more than 75% at baseline and missing data within 
questionnaires less than 10%.  
 
Examples of high risk of bias:  Selection of target population from a representative population roster 
such as national or provincial population registry with a response proportion less than 50% at baseline 
or missing data in the key characteristics within questionnaires more than 20%. All hospital-based 
patient records; studies where the source population cannot be defined (or enumerated), i.e. any 
volunteer studies using self-recruitment (including health screening studies). 
 
2. Is the assessment of the outcome accurate both at baseline and at follow-up? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)       (high risk of bias) 
 
Examples of low risk of bias: Repeated interview or other ascertainment asking about current state 
with validated instrument or method (with demonstrated validity) with a clearly specified time window for 
the assessment (for time-dependent conditions). 
 
Examples of high risk of bias: Unvalidated instrument or method with concern of accuracy of 
responses; Uncertain how information was obtained; Studies with non-standardised clinical interviews 
(including physicians’ unstructured assessment of symptoms); Studies, which assessed primary 
outcome as "physician-diagnosed condition"; Simple assessment of the presence (or absence) of the 
symptom(s) without making an effort to quantify the severity/extent; Use of different instruments at 
different time points with concern of accuracy of responses; Not clearly specified time window for the 
assessment (for time-dependent conditions). 
 
3. Is there little missing data in the follow-up?  
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)       (high risk of bias) 
 
Examples of low risk of bias: High response proportion (rate) at follow-up with little missing data (in 
the key characteristics): response proportion was more than 75% and missing data in the key 
characteristics within questionnaires less than 10%. 
 
Examples of high risk of bias: Low response proportion at follow-up with high level of missing data: 
response proportion was <50% and missing data in the key characteristics within questionnaires more 
than 20%.  
  
Appendix 2. Tool to assess risk of bias in longitudinal symptom research studies 
aimed at the general population – Study I. 
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1. Is the source population (sampling frame) representative of the general population? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)                (high risk of bias) 
 
Examples of low risk of bias: Selection of target population from a representative population roster 
such as a hospital or healthcare registry with a response proportion more than 50% at baseline and 
missing data in the key characteristics within questionnaires less than 20%.  
 
Examples of high risk of bias:  Selection of target population from a representative population roster 
such as a hospital registry with a response proportion less than 50% at baseline or missing data in the 
key characteristics within questionnaires more than 20%.  
 
2. Is the assessment of nocturia at baseline accurate? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)       (high risk of bias) 
 
Examples of low risk of bias: Validated instrument or methods with an assessment of nocturia at 
baseline with a clear quantification and definition of nocturia. 
 
Examples of high risk of bias: Invalidated instrument or method with concern of accuracy of responses; 
Uncertain how information was obtained; Simple assessment of the presence (or absence) of the 
symptom(s) without making an effort to quantify the severity/extent. 
 
3. Is the assessment of mortality accurate during follow-up? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)       (high risk of bias) 
 
Examples of low risk of bias: Data collection has been conducted by a registry or hospital records; 
Data collection relies on a passive method (e.g. not by patient´s peers) and depends on a registry. 
 
Examples of high risk of bias: Data collection depended on the reporting of patient´s relatives or peers.  
 
4. Is there little missing data in the follow-up?  
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)       (high risk of bias) 
 
Examples of low risk of bias: High response proportion (rate) at follow-up with little missing data (in 
the key characteristics): response proportion was more than 95% and missing data in the key 
characteristics within questionnaires less than 10%. 
 
Examples of high risk of bias: Low response proportion at follow-up with high level of missing data: 
response proportion was less than 90% and missing data in the key characteristics within questionnaires 
more than 10%. 
 
Appendix 3. Tool to assess risk of bias in longitudinal research studies with a 
nocturia population aimed at measuring mortality – Study II. 
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5. Did the statistical analysis adjust for all important prognostic variables? 
 Definitely yes              Mostly yes                   Mostly no                    Definitely no 
(low risk of bias)                                                                                  (high risk of bias) 
 
Examples of low risk of bias: adjustment for at least age, gender, smoking and comorbidity. 
 
Examples of high risk of bias: failure of adjustment for one or more of age, gender, smoking and 
comorbidity. 
  
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1. Is the source population (sampling frame) representative of the general population? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)                (high risk of bias) 
 
Examples of low risk of bias: Selection of target population from a representative population roster 
such as a hospital or healthcare registry with a response proportion more than 50% at baseline and 
missing data in the key characteristics within questionnaires less than 20%.  
 
Examples of high risk of bias:  Selection of target population from a representative population roster 
such as a hospital registry with a response proportion less than 50% at baseline or missing data in the 
key characteristics within questionnaires more than 20%.  
 
2. Is the assessment of nocturia at baseline accurate? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)       (high risk of bias) 
 
Examples of low risk of bias: Validated instrument or methods with an assessment of nocturia at 
baseline with a clear quantification and definition of nocturia. 
 
Examples of high risk of bias: Invalidated instrument or method with concern of accuracy of responses; 
Uncertain how information was obtained; Simple assessment of the presence (or absence) of the 
symptom(s) without making an effort to quantify the severity/extent. 
 
3.a) Is the assessment of falls accurate during follow-up? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)       (high risk of bias) 
 
Examples of low risk of bias: prospective falls diary for falls that has been filled in by the patient.  
 
Examples of high risk of bias: depending on the memory of patients (or peers) for retrospective 
evaluation of their falls. 
 
3.b) Is the assessment of fractures accurate during follow-up? 
Definitely yes  Probably yes  Probably no  Definitely no 
(low risk of bias)       (high risk of bias) 
 
Examples of low risk of bias: medical records or national / hospital registries for fractures. 
 
Examples of high risk of bias: depending on the memory of patients (or peers) for retrospective 
evaluation of their fractures. 
 
4. Is there little missing data in the follow-up?  
Definitely yes  Probably yes  Probably no  Definitely no 
Appendix 4. Tool to assess risk of bias in longitudinal research studies with a 
nocturia population aimed at measuring falls/fractures – Study III. 
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(low risk of bias)       (high risk of bias) 
Examples of low risk of bias: High response proportion (rate) at follow-up with little missing data (in 
the key characteristics): response proportion was more than 95% and missing data in the key 
characteristics within questionnaires less than 10%. 
 
Examples of high risk of bias: Low response proportion at follow-up with high level of missing data: 
response proportion was less than 90% and missing data in the key characteristics within questionnaires 
more than 10%. 
 
5.a) Did the statistical analysis adjust for all important prognostic variables for falls? 
Definitely yes              Mostly yes                   Mostly no                    Definitely no 
(low risk of bias)                                                                                  (high risk of bias) 
 
Examples of low risk of bias: adjustment for at least age, gender, history of recent falls and comorbidity. 
 
Examples of high risk of bias: failure of adjustment for one or more of age, gender, history of recent 
falls and comorbidity. 
 
5.b) Did the statistical analysis adjust for all important prognostic variables for fractures? 
Definitely yes              Mostly yes                   Mostly no                    Definitely no 
(low risk of bias)                                                                                  (high risk of bias) 
 
Examples of low risk of bias: adjustment for at least age, gender, history of recent falls and any factor 
indicating osteoporosis based on either diagnostic testing, history of recent fractures or comorbidity with 
a strong association. 
 
Examples of high risk of bias: adjustment for at least age, gender, history of recent falls and any factor 
indicating osteoporosis. 
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In calculating the person-years for incidence and remission rates the simple cumulative method was 
considered to be equally appropriate with the actuarial cumulative method. In the latter, the assumption 
is that the symptom was developed at a half-way point between follow-ups when it is not known exactly 
when a person develops the symptom in question. However, in the case of fluctuating symptom such 
as nocturia where short-term incidence and remission is remarkably high, the cumulative incidence and 
remission at the end of each follow-up is actually the net effect resulting from a symptom becoming 
incident and remittent in turns. There were only slight differences in the pooled estimates calculated 
with both methods: simple vs. actuarial cumulative incidence 49.4 (41.3-57.5) vs. 55.8 (46.6-65.0) per 
1000 person-years, simple vs. actuarial cumulative remission 121.3 (95.2-147.4) vs. 154.5 (122.8-
186.3.0) per 1000 person-years. 
 
  
Appendix 5. Further information on simple versus actuarial cumulative 
incidence/remission methodology – Study I. 
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  
Note: mean age ranges are overlapping due to unavailability of reported mean ages in cases of several studies. Therefore, by relying 
on an assumption of samples complying with normal age distribution, subgroups of studies were placed under age categories by 
selecting the mean age range with a midpoint closest to the estimated mean age of each sample.  
Appendix 6. Forest plot of prevalence of nocturia in population-based samples 
including people aged ≥60 yr and using a nocturia case definition of ≥2 voids/night 
– Studies II &III.  
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  
Appendix 7. Forest plot of incidence rates of fallers per 100 person-years of follow-
up in prospective Western population-based studies – Study III.
Note: The studies presented in the figure, providing data on the annual number of fallers (persons with ≥1 
falls/year) and resulting fractures were extracted from a previous systematic review (Figure 5 of Morrison et al. 
2013). To avoid potential selection bias, a study including only previous fallers was excluded from the analyses 
(Nevitt et al. 1989). 
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  
Appendix 8. Forest plot of proportion of individuals with a fall-related fracture per 
100 fallers in prospective Western population-based studies – Study III.  
Note: The studies presented in the figure, providing data on the annual number of fallers (persons with ≥1 
falls/year) and resulting fractures were extracted from a previous systematic review (Figure 5 of Morrison et 
al. 2013). To avoid potential selection bias, a study including only previous fallers was excluded from the 
analyses (Nevitt et al. 1989). 
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Appendix 9. Questionnaire of the Tampere Ageing Male Urologic Study (TAMUS) 
in 2009 – Study IV. 
MIESTEN UROLOGISET OIREET
KYSELYLOMAKE OSA I Päivämäärä vastaushetkellä: /  2009
Olkaa hyvä ja vastatkaa alla oleviin kysymyksiin rastittamalla sopiva vaihtoehto tai täydentämällä 
kysymykseen liittyvä vastaustila.
1 HENKILÖTIEDOT  
SYNTYMÄAIKA
2 AMMATTI
 Olen työelämässä ja ammattini on (kirjoittakaa ruutuun)  
 Olen eläkkeellä, ammattini oli
 Olen työttömänä, ammattini on
3 KOULUTUS
 Kansakoulu
 Ammattikoulu tai vastaava
 Opistotutkinto
 Yliopisto- tai korkeakoulututkinto
4 SIVIILISÄÄTY
 Naimisissa tai avoliitossa  
 Eronnut Vuonna _________
 Leski Vuodesta _________
 Naimaton
5 TERVEYS
Viimeisen viiden vuoden aikana terveyteni on  
 Huonontunut voimakkaasti
 Huonontunut hieman
 Pysynyt ennallaan
 Parantunut hieman
 Parantunut selvästi
            /           / 19
   päivä         kuukausi          vuosi
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6 PITUUS JA PAINO
Pituuteni on cm Painoni on kg
7 TUPAKOINTI
Tupakoitteko nykyään tai oletteko koskaan tupakoinut säännöllisesti?
Tupakoinnilla tarkoitetaan savukkeiden, sikarien tai piipun polttoa.
 En  
 Kyllä
 Olen lopettanut tupakoinnin
Jos tupakoitte tai olette tupakoineet, vastatkaa vielä seuraaviin kysymyksiin:
Minä vuonna aloititte säännöllisen tupakoinnin? Vuonna
Jos olette lopettanut tupakoinnin, minä vuonna? Vuonna
Kuinka paljon poltatte päivittäin nykyään?
Tai, kuinka paljon poltitte päivittäin ennen lopettamista?
Savukkeita tai pikkusikareja kpl
Piippua pesällistä
Sikareja kpl
8 MUUT NAUTINTOAINEET
Juotteko kahvia tai teetä päivittäin?  
 En
 Kyllä, _____ kuppia kahvia päivässä.
 Kyllä, _____ kuppia teetä päivässä.
Juotteko alkoholipitoisia juomia?
 En lainkaan. Voitte siirtyä kysymysryhmään 9.
 Kyllä, satunnaisesti, mutta en joka viikko.
 Kyllä, viikoittain
Jos käytätte alkoholia viikoittain, arvioikaa 
keskimääräinen viikoittainen kulutuksenne tässä.
Olutta pulloa (1/3 l)
Viiniä pulloa (3/4 l), tai ____(12 cl) lasillista 
Väkeviä pulloa (1/2 l), tai ____ (4 cl) lasillista
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9 SAIRAUDET JA VAMMAT
Sairastatteko tai oletteko joskus sairastanut jotain seuraavista
sairauksista? (Rastittakaa Teillä olevat tai joskus olleet sairaudet.) 
 
 En sairasta, enkä ole sairastanut mitään näistä sairauksista. 
 Sokeritauti  Pikäaikainen selkäkipu
 Kohonnut verenpaine  Selkäytimen vamma
 Sepelvaltimotauti Selkärankareuma
 Muu sydänsairaus Masennus
 Nivelkulumia Nivelreuma
 Ummetus Maha- tai pohjukkaissuolen haava
 Ulosteen pidätyskyvyttömyyttä Korkea veren kolesteroli
	 Keuhkosairaus Uniapnea

 Neurologinen sairaus, Syöpä, mikä _________________
mikä  ______________________
 Aivoverenkierron häiriö tai halvaus
10 TUTKIMUKSET JA LEIKKAUKSET
Onko Teille tehty viimeisen viiden vuoden aikana jokin  
seuraavista tutkimuksista tai leikkauksista? (Merkitkää rastilla.)
 Ei mitään tässä luetelluista.
 Peräsuolen poistoleikkaus
 Lonkka- tai polviproteesileikkaus
 Selkäleikkaus
 Verisuonileikkaus, (koronaariohitus, valtimon pullistuma tai ahtauma tms.)
 Eturauhasen höyläysleikkaus (TURP)
 Eturauhasen liikakasvun avoleikkaus
 Eturauhasen poistoleikkaus syövän vuoksi
	 Virtsarakkoon kohdistunut leikkaus (avoin tai tähystysleikkaus)

 PSA-verikoe (eturauhassyöpätesti)
11 MUU HOITO
Oletteko viimeisen viiden vuoden aikana saanut hoitoa
erektiohäiriön vuoksi?
 En
 Kyllä
Jos olette saanut hoitoa, valitkaa tastä saamanne hoito:
 Tablettihoito Mikä lääke ___________________________
 Pistoshoito
 Muu hoito Mikä ___________________________
Oletteko viimeisen viiden vuoden aikana saanut hoitoa
miehen vaihdevuosivaivojen (andropaussi) vuoksi?
 En
 Kyllä Mitä hoitoa ___________________________





	




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OSA II
VIRTSAAMINEN JA SUKUPUOLITOIMINNAT:
Tämä kysely koostuu kahdenlaisista kysymyksistä:
A-kysymyksissä kysytään virtsaamioireen esiintymistä tai voimakkuutta.
B-kysymyksissä kysytään, kuinka paljon haittaa on oireesta.
Vastatkaa jokaiseen kysymykseen merkitsemällä rasti sopivan vastausvaihtoehdon kohdalle.
1 A Täytyykö virtsaamisen alkamista 1 B Mikäli joudutte odottamaan
odottaa? virtsaamisen alkamista, 
kuinka paljon siitä on Teille haittaa?
Ei koskaan Ei lainkaan
Harvoin Vähän
Usein Kohtalaisesti
Aina Hyvin paljon
2 A Tuleeko virtsa omasta mielestänne: 2 B Mikäli virtsa tulee heikosti, 
kuinka paljon siitä on Teille haittaa?
Normaalisti Ei lainkaan
Heikosti Vähän 
Hyvin heikosti Kohtalaisesti
Tipoittain Hyvin paljon
3 A Tuntuuko, että virtsatessanne 3 B Mikäli tunnette, ettei rakko tyhjene,
rakko tyhjenee täysin? täysin kuinka paljon siitä on Teille
haittaa?
Kyllä, aina Ei lainkaan
Usein Vähän 
Harvoin Kohtalaisesti
Ei koskaan Hyvin paljon
4 A Joudutteko ponnistamaan virtsaamisen 4 B Mikäli joudutte ponnistelemaan,
aloittamiseksi tai virtsaamisen jatkamiseksi? kuinka paljon siitä on Teille haittaa?
En koskaan Ei lainkaan
Harvoin Vähän 
Usein Kohtalaisesti
Aina Hyvin paljon
5 A Tippuuko virtsa vielä, vaikka luulitte 5 B Mikäli jälkitippumista esiintyy
virtsaamisen loppuneen (jälkitippuminen)? kuinka paljon siitä on Teille haittaa?
Ei koskaan Ei lainkaan
Kyllä, WC:ssä Vähän 
Hieman alushousuihin Kohtalaisesti
Runsaasti alushousuihin Hyvin paljon
6 A Kuinka pitkä on pisin kahden 6 B Mikäli joudutte virtsaamaan usein,
virtsaamisen välinen aika päivällä? kuinka paljon siitä on Teille haittaa?
Yli 3 tuntia Ei lainkaan
2-3 tuntia Vähän 
1-2 tuntia Kohtalaisesti
Alle tunti Hyvin paljon
7 A Kuinka monta kertaa joudutte 7 B Mikäli joudutte virtsaamaan yöllä,
virtsaamaan yön aikana? kuinka paljon siitä on Teille haittaa?
0 kertaa Ei lainkaan
1-2 kertaa Vähän 
3-4 kertaa Kohtalaisesti
5 kertaa tai useammin Hyvin paljon
8 A Tuleeko Teille äkillinen 8 B Mikäli Teille tulee äkillinen virtsaamis-
virtsaamistarve? tarve, kuinka paljon siitä on Teille
haittaa?
Ei koskaan Ei lainkaan
Harvoin Vähän 
Usein Kohtalaisesti
Aina Hyvin paljon
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9 A Tuleeko virtsaamisen tarve niin 9 B Mikäli virtsa karkaa ennen kuin
voimakkaana että virtsa karkaa ehditte WC:hen, kuinka paljon siitä
ennen kuin ehditte WC:hen? on Teille haittaa?
Ei koskaan Ei lainkaan
Harvoin Vähän 
Usein Kohtalaisesti
Aina Hyvin paljon
10 A Tunnetteko virtsatessanne kipua 10 B Mikäli virtsatessanne tuntuu kipua tai
tai poltetta? poltetta, kuinka paljon siitä on Teille
haittaa?
En koskaan Ei lainkaan
Harvoin Vähän 
Usein Kohtalaisesti
Aina Hyvin paljon
11 A Karkaako virtsaa fyysisen ponnistuksen 11 B Mikäli virtsaa karkaa fyysisen
aikana (esim. yskiessänne, aivastaessanne ponnistuksen aikana, kuinka paljon
tai nostaessanne)? siitä on Teille haittaa?
Ei koskaan Ei lainkaan
Harvoin Vähän 
Usein Kohtalaisesti
Aina Hyvin paljon
12 A Karkaako virtsaa ilman fyysistä ponnistusta 12 B Mikäli virtsaa karkaa ilman fyysistä 
ja ilman virtsaustarvetta? ponnistusta ja virtsaustarvetta, kuinka
paljon siitä on Teille haittaa?
Ei koskaan Ei lainkaan
Harvoin Vähän 
Usein Kohtalaisesti
Aina Hyvin paljon
13. Kuinka usein viimeksi kuluneen kuukauden En kertaakaan
aikana olette tavallisimmin joutunut nousemaan Kerran yössä
virtsalle  mentyänne illalla nukkumaan ja ennen Kaksi kertaa yössä
kuin nousitte aamulla ylös? Kolme kertaa yössä
Neljä kertaa yössä
Viisi kertaa tai  useammin yössä
14. Onko virtsaamistoiminnoissanne tapahtunut muutos (paraneminen tai huononeminen)
viimeksi kuluneen viiden vuoden aikana?
Ei muutosta
Kyllä, virtsaamiseni on huonontunut Milloin? _____________________
Kyllä, virtsaamiseni on parantunut Milloin? _____________________
15. Kuinka tyytyväinen olette seksielämäänne?  Erittäin tyytyväinen
 Melko tyytyväinen
 En tyytyväinen enkä tyytymätön
 Melko tyytymätön
 Erittäin tyytymätön
16. Kuinka monta kertaa keskimäärin olette  
yhdynnässä kuukauden aikana? ___kertaa
17. Onko Teillä ollut vaikeuksia saada siitin  Ei koskaan
jäykistymään ennen yhdyntää?  Joskus
 Melko usein
 Aina, yhdyntä ei onnistu lainkaan
18. Onko Teillä ollut vaikeuksia saada siitin  Ei koskaan
pysymään jäykkänä yhdynnän aikana?  Joskus
 Melko usein
 Aina, yhdyntä ei onnistu lainkaan
19. Kuinka usein herätessänne siittimenne  Päivittäin
on ollut täysin jäykkä?  2-3 kertaa viikossa
 Kerran viikossa
 Harvemmin kuin kerran viikossa
20. Onko erektiokyvyssänne tapahtunut muutos (paraneminen tai huonontuminen)
viimeksi kuluneen viiden vuoden aikana?
Ei muutosta
Kyllä, erektiokykyni on huonontunut Milloin? _____________________
Kyllä, erektiokykyni on parantunut Milloin? _____________________
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1. Jos Teillä on virtsankarkailua päiväsaikaan,
tarvitseeko Teidän vaihtaa vaatteita tai käyttää vaippaa?
Ei, virtsa ei karkaa
Kyllä, vaihtaa alushousuja
Kyllä, vaihtaa vaatteita
Käytän vaippaa (tai tippasuojaa)
2. Vähennättekö juomistanne virtsaoireiden helpottamiseksi
ja voidaksenne tehdä haluamianne asioita?
En koskaan
Silloin tällöin
Joskus
Useimmiten
Jatkuvasti
3. Kuinka paljon kaiken kaikkiaan virtsaoireet vaikuttavat elämäänne?
Ei lainkaan
Hieman
Jonkin verran
Paljon
4. Kuinka kauan Teillä on ollut haittaavia virtsaoireita?
Alle vuoden, ____ kk
Vuodesta kahteen
Kahdesta kolmeen vuotta
Yli kolme vuotta
5. Aiheuttavatko virtsavaivat Teille huolia?
Pyydämme listaamaan mahdolliset huolenne alle
6. Jos virtsaoireenne jatkuisivat nykyisellään koko loppuelämänne, miltä se Teistä tuntuisi?
Täysin onnelliselta
Hyvältä
Enimmäkseen tyytyväiseltä
Ei hyvältä eikä pahalta
Enimmäkseen tyytymättömältä
Hyvin onnettomalta
Epätoivoiselta
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OSA III
YLEISET ELÄMÄNLAATUKYSYMYKSET:
Seuraavissa kysymyksissä esitetään vaihtoehtoja, jotka kuvaavat mahdollisen sairautenne Teille 
aiheuttamaa haittaa ja toimintahäiriön astetta. Lukekaa ensin kunkin kysymyksen kaikki 
vastausvaihtoehdot huolellisesti läpi. Merkitkää sen jälkeen rastilla se vaihtoehto, joka parhaiten
kuvaa terveydentilaanne tänään. Jokaisesta kysymyksestä valitaan vain yksi vaihtoehto.
1. Liikuntakyky
Pystyn kävelemään ja liikkumaan normaalisti (vaikeuksitta) sisällä, ulkona ja portaissa.
Pystyn kävelemään vaikeuksitta sisällä, mutta ulkona tai portaissa on pieniä vaikeuksia.
Pystyn kävelemään ilman apua sisällä (välinein tai ilman), mutta ulkona tai portaissa 
melkoisin vaikeuksin tai toisen avustamana.
Pystyn kävelemään sisälläkin vain toisen avustamana.
Olen täysin liikuntakyvytön ja vuoteen omana.
2. Näkö
Näen normaalisti, eli näen lukea lehteä ja TV:n tekstejä vaikeuksitta silmälaseilla tai ilman.
Näen lukea lehteä tai TV:n tekstejä pienin vaikeuksin silmälaseilla tai ilman.
Näen lukea lehteä tai TV:n tekstejä huomattavin vaikeuksin silmälaseilla tai ilman.
En näe lukea lehteä enkä TV:n tekstejä ilman silmälaseja tai niiden kanssa, 
mutta näen kulkea ilman opasta.
En näe kulkea ilman opasta eli olen lähes tai täysin sokea.
3. Kuulo
Kuulen normaalisti eli kuulen hyvin normaalia puheääntä kuulokojeen kanssa tai ilman sitä.
Kuulen normaalia puheääntä pienin vaikeuksin.
Kuulen normaalia puheääntä melkoisin vaikeuksin, keskustelussa on käytettävä normaalia
kovempaa puheääntä.
Kuulen kovaakin puheääntä heikosti, olen melkein kuuro.
Olen täysin kuuro.
4. Hengitys
Pystyn hengittämään normaalisti, eli minulla ei ole hengenahdistusta eikä
muita hengitysvaikeuksia.
Minulla on hengenahdistusta raskaassa työssä tai urheillessa, reippaassa kävelyssä
tasamaalla tai lievässä ylämäessä.
Minulla on hengenahdistusta kävellessä muitten samanikäisten vauhtia tasamaalla.
Minulla on hengenahdistusta pienenkin rasituksen jälkeen, esimerkiksi pukeutuessa, 
peseytyessä tai levossa.
Minulla on hengenahdistusta lähes koko ajan, myös levossa.
5. Nukkuminen
Nukun normaalisti, eikä minulla ole ongelmia unen suhteen.
Minulla on lieviä uniongelmia, esimerkiksi nukahtamisvaikeuksia tai heräilen satunnaisesti yöllä
Minulla on melkoisia uniongelmia, esimerkiksi nukun levottomasti, uni ei tunnu riittävän.
Minulla on suuria uniongelmia, esimerkiksi joudun käyttämään usein tai säännöllisesti
unilääkettä. Herään säännöllisesti yöllä tai aamuisin liian varhain.
Kärsin vaikeasta unettomuudesta, esimerkiksi unilääkkeiden runsaasta käytöstä
huolimatta nukkuminen on lähes mahdotonta. Valvon suurimman osan yöstä.
6. Syöminen
Pystyn syömään normaalisti eli itse ilman mitään vaikeuksia.
Pystyn syömään pienin vaikeuksin, esimerkiksi hitaasti, kömpelösti,
vapisten tai erityisapuneuvoin.
Tarvitsen hieman toisten apua syömisessä.
En pysty syömään itse lainkaan, vaan minua pitää syöttää.
En pysty syömään itse lainkaan, vaan minua pitää syöttää joko letkulla tai 
suonensisäisellä ravintoliuoksella.
7. Puhuminen
Pystyn puhumaan normaalisti, eli selvästi, kuuluvasti ja sujuvasti.
Puhuminen tuottaa minulle pieniä vaikeuksia, esimerkiksi sanoja on etsittävä tai ääni
ei ole riittävän kuuluva tai se vaihtaa korkeutta.
Pystyn puhumaan ymmärrettävästi, mutta katkonaisesti, ääni vavisten,
sammaltaen tai änkyttäen.
Muilla on vaikeuksia ymmärtää puhettani.
Pystyn ilmaisemaan itseäni vain elein.
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8. Eritystoiminta
Virtsarakkoni ja suolistoni toimivat normaalisti ja ongelmitta
Virtsarakkoni tai suolistoni toiminnassa on lieviä ongelmia, esimerkiksi
minulla on virtsaamisvaikeuksia tai kova tai löysä vatsa.
Virtsarakkoni tai suolistoni toiminnassa on melkoisia ongelmia, esimerkiksi minulla on
satunnaisia virtsanpidätysvaikeuksia tai vaikea ummetus tai ripuli.
Virtsarakkoni tai suolistoni toiminnassa on suuria ongelmia, esimerkiksi minulla on
säännöllisesti "vahinkoja" tai peräruiskeiden tai katetroinnin tarvetta.
En hallitse lainkaan virtsaamistani tai ulostamistani.
9. Tavanomaiset toiminnot
Pystyn suoriutumaan normaalisti tavanomaisista toiminnoista, esimerkiksi 
ansiotyöstä, opiskelusta, kotityöstä ja vapaa-ajan toiminnoista.
Pystyn suoriutumaan tavanomaisista toiminnoista hieman alentuneella teholla tai
pienin vaikeuksin.
Pystyn suoriutumaan tavanomaisista toiminnoista huomattavasti alentuneella teholla tai
huomattavin vaikeuksin tai vain osittain.
Pystyn suoriutumaan tavanomaisista toiminnoista vain pieneltä osin.
En pysty suoriutumaan lainkaan tavanomaisista toiminnoista.
10. Henkinen toiminta
Pystyn ajattelemaan selkeästi ja johdonmukaisesti, muistini toimii täysin moitteettomasti.
Minulla on lieviä vaikeuksia ajatella selkeästi ja johdonmukaisesti, muistini ei
toimi täysin moitteettomasti.
Minulla on melkoisia vaikeuksia ajatella selkeästi ja johdonmukaisesti, minulla on 
jonkin verran muistinmenetystä.
Minulla on suuria vaikeuksia ajatella selkeästi ja johdonmukaisesti, minulla on 
huomattavaa muistinmenetystä.
Olen koko ajan sekaisin ja vailla ajan ja paikan tajua.
11. Vaivat ja oireet
Minulla ei ole mitään vaivoja tai oireita, esim. kipua, särkyä, pahoinvointia, kutinaa jne.
Minulla on lieviä vaivoja tai oireita, esimerkiksi kipua, särkyä, pahoinvointia, kutinaa jne.
Minulla on melkoisia vaivoja tai oireita, esim. kipua, särkyä, pahoinvointia, kutinaa jne.
Minulla on voimakkaita vaivoja tai oireita, esim. kipua, särkyä, pahoinvointia, kutinaa jne.
Minulla on sietämättömiä vaivoja tai oireita, esim. kipua, särkyä, pahoinvointi, kutinaa jne.
12. Masentuneisuus
En tunne itseäni lainkaan surulliseksi, alakuloiseksi tai masentuneeksi.
Tunnen itseni hieman surulliseksi, alakuloiseksi tai masentuneeksi.
Tunnen itseni melko surulliseksi, alakuloiseksi tai masentuneeksi.
Tunnen itseni erittäin surulliseksi, alakuloiseksi tai masentuneeksi.
Tunnen itseni äärimmäisen surulliseksi, alakuloiseksi tai masentuneeksi.
13. Ahdistuneisuus
En tunne itseäni lainkaan ahdistuneeksi, jännittyneeksi tai hermostuneeksi.
Tunnen itseni hieman ahdistuneeksi, jännittyneeksi tai hermostuneeksi.
Tunnen itseni melko ahdistuneeksi, jännittyneeksi tai hermostuneeksi.
Tunnen itseni erittäin ahdistuneeksi, jännittyneeksi tai hermostuneeksi.
Tunnen itseni äärimmäisen ahdistuneeksi, jännittyneeksi tai hermostuneeksi.
14. Energisyys
Tunnen itseni terveeksi ja elinvoimaiseksi.
Tunnen itseni hieman uupuneeksi, väsyneeksi tai voimattomaksi.
Tunnen itseni melko uupuneeksi, väsyneeksi tai voimattomaksi.
Tunnen itseni hyvin uupuneeksi, väsyneeksi tai voimattomaksi, lähes "loppuun palaneeksi".
Tunnen itseni äärimmäisen uupuneeksi, väsyneeksi tai voimattomaksi,
täysin "loppuun palaneeksi".
15. Sukupuolielämä
Terveydentilani ei mitenkään vaikeuta sukupuolielämääni.
Terveydentilani vaikeuttaa hieman sukupuolielämääni.
Terveydentilani vaikeuttaa huomattavasti sukupuolielämääni.
Terveydentilani tekee sukupuolielämäni lähes mahdottomaksi.
Terveydentilani tekee sukupuolielämän mahdottomaksi.
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OSA IV
A. SUKUPUOLIELÄMÄN HÄIRIÖT:
Seuraavaa kysymyssarjaa arvioimme kahdesta eri näkökulmasta, riippuen mahdollisesta
erektiolääkityksestänne. Pyydämme Teitä vastaamaan kahdesti, mikäli käytätte tai olette joskus
käyttäneet erektiolääkettä. Jos käytössänne ei ole lainkaan erektiolääkitystä, riittää että vastaatte
ainoastaan kohtaan A.
Valitkaa ja merkitkää rastilla kunkin kysymyksen vastausvaihtoehdoista se, joka parhaiten kuvaa
tilannettanne viimeisen kuuden kuukauden aikana. Valitkaa jokaiseen kysymykseen
ainoastaan yksi vastaus!
A. Siinä tapauksessa, että ette käytä tai ette ole ottaneet lääkettä,
1. Millaiseksi arvioitte luottamuksenne siihen,  Hyvin vähäiseksi
että voitte saavuttaa erektion  Vähäiseksi
ja säilyttää sen yhdynnän ajan?  Kohtalaiseksi
 Suureksi
 Hyvin suureksi
2. Kun Teillä oli seksuaalisen kiihottumisen  Ei seksuaalista toimintaa.
aikana erektioita, kuinka usein ne olivat  Ei koskaan tai ei juuri koskaan.
tarpeeksi kovia yhdyntään?  Muutaman kerran (harvemmin kuin joka toisella
kerralla).
 Joskus (noin joka toisella kerralla).
 Useimmiten (useammin kuin joka toisella
kerralla).
 Melkein aina tai aina.
3. Kuinka usein pystyitte yhdynnässä  Ei seksuaalista toimintaa.
ylläpitämään erektion sisään  Ei koskaan tai ei juuri koskaan.
työntymisen jälkeen?  Muutaman kerran (harvemmin kuin joka toisella
kerralla).
 Joskus (noin joka toisella kerralla).
 Useimmiten (useammin kuin joka toisella
kerralla).
 Melkein aina tai aina.
4. Kuinka vaikeaa Teidän oli säilyttää  En yrittänyt yhdyntää.
erektionne yhdynnän loppuun saakka?  Äärimmäisen vaikeaa.
 Hyvin vaikeaa.
 Vaikeaa
 Hieman vaikeaa.
 Ei lainkaan vaikeaa.
5. Kun yrititte sukupuoliyhdyntää,  En yrittänyt yhdyntää.
kuinka usein saitte siitä tyydytystä?  En koskaan tai en juuri koskaan.
 Muutaman kerran (harvemmin kuin joka toisella
kerralla).
 Joskus (noin joka toisella kerralla).
 Useimmiten (useammin kuin joka toisella
kerralla).
 Melkein aina tai aina.
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B. Siinä tapauksessa, että olette ottaneet lääkkeen,
1. Millaiseksi arvioitte luottamuksenne siihen,  Hyvin vähäiseksi
että voitte saavuttaa erektion  Vähäiseksi
ja säilyttää sen yhdynnän ajan?  Kohtalaiseksi
 Suureksi
 Hyvin suureksi
2. Kun Teillä oli seksuaalisen kiihottumisen  Ei seksuaalista toimintaa.
aikana erektioita, kuinka usein ne olivat  Ei koskaan tai ei juuri koskaan.
tarpeeksi kovia yhdyntään?  Muutaman kerran (harvemmin kuin joka toisella
kerralla).
 Joskus (noin joka toisella kerralla).
 Useimmiten (useammin kuin joka toisella
kerralla).
 Melkein aina tai aina.
3. Kuinka usein pystyitte yhdynnässä  Ei seksuaalista toimintaa.
ylläpitämään erektion sisään  Ei koskaan tai ei juuri koskaan.
työntymisen jälkeen?  Muutaman kerran (harvemmin kuin joka toisella
kerralla).
 Joskus (noin joka toisella kerralla).
 Useimmiten (useammin kuin joka toisella
kerralla).
 Melkein aina tai aina.
4. Kuinka vaikeaa Teidän oli säilyttää  En yrittänyt yhdyntää.
erektionne yhdynnän loppuun saakka?  Äärimmäisen vaikeaa.
 Hyvin vaikeaa.
 Vaikeaa
 Hieman vaikeaa.
 Ei lainkaan vaikeaa.
5. Kun yrititte sukupuoliyhdyntää,  En yrittänyt yhdyntää.
kuinka usein saitte siitä tyydytystä?  En koskaan tai en juuri koskaan.
 Muutaman kerran (harvemmin kuin joka toisella
kerralla).
 Joskus (noin joka toisella kerralla).
 Useimmiten (useammin kuin joka toisella
kerralla).
 Melkein aina tai aina.
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B. ELÄMÄNLAATUKYSELY MIESTEN SEKSUAALISUUDESTA:
Tämä kysely koostuu väittämistä, joissa kysytään ajatuksistasi ja tuntemuksistasi, joita sinulla saattaa
olla sukupuolielämästäsi. Väittämä voi olla myönteinen tai kielteinen. Pyydämme sinua arvioimaan jokaista
väittämää ja kertomaan, kuinka vahvasti olet samaa tai eri mieltä. Rastita yksi vastausvaihtoehto kuudesta.
Väittämiin vastattaessa käytetään seuraavia määritelmiä:
Sukupuolielämä: Tarkoittaa sekä fyysistä seksuaalista toimintaa että sinun ja kumppanisi välisen
sukupuolisuhteen tunnepuolta.
Seksuaalinen toiminta/seksi: Kattaa kaiken toiminnan, mikä saattaa johtaa seksuaaliseen kiihottumiseen 
tai seksuaaliseen nautintoon, esim. yhdyntä, hyväily, esileikki, masturbaatio (itsetyydytys tai kumppanin
suorittama) ja suuseksi (ts. kumppanin sinulle suorittama suuseksi).
Täysin Osittain Hieman Hieman Osittain Täysin
samaa samaa samaa eri eri eri
mieltä mieltä mieltä mieltä mieltä mieltä
1. Kun ajattelen sukupuoli-
elämääni, tunnen itseni
turhautuneeksi.
2. Kun ajattelen sukupuoli-
elämääni, tunnen oloni
masentuneeksi.
3. Kun ajattelen sukupuoli-
elämääni, tunnen miehuuteni
vajavaiseksi.
4. Olen menettänyt luotta-
muksen itseeni seksi-
kumppanina.
5. Kun ajattelen sukupuoli-
elämääni, tunnen ahdistusta.
6. Kun ajattelen sukupuoli-
elämääni, tunnen suuttumusta.
7. Olen huolissani sukupuoli-
elämäni tulevaisuudesta.
8. Kun ajattelen sukupuoli-
elämääni, tunnen itseni
vaivautuneeksi.
9. Kun ajattelen sukupuoli-
elämääni, tunnen syyllisyyttä.
10. Kun ajattelen sukupuoli-
elämääni, olen huolissani siitä,
että kumppanini tuntee itsensä
loukatuksi tai torjutuksi.
11. Kun ajattelen sukupuoli-
elämääni, minusta tuntuu
ikään kuin olisin menettänyt
jotain.
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OSA V
TOIMINTAKYKY JA AKTIIVISUUS:
A. YLEINEN TOIMINTAKYKY
Valitkaa kunkin kysymyksen jäljestä teille sopiva vastausvaihtoehto.
1. Oletteko viime aikoina pystynyt keskittymään töihinne?
Paremmin kuin tavallisesti
Yhtä hyvin kuin tavallisesti
Huonommin kuin tavallisesti
Paljon huonommin kuin tavallisesti
2. Oletteko viime aikoina valvonut paljon huolien vuoksi?
En ollenkaan
En enempää kuin tavallisesti
Jonkin verran enemmän kuin tavallisesti
Paljon enemmän kuin tavallisesti
3. Onko Teistä viime aikoina tuntunut siltä, että mukana olonne asioiden hoidossa on…
Tavallista hyödyllisempää
Yhtä hyödyllistä kuin tavallisesti
Vähemmän hyödyllistä kuin tavallisesti
Paljon vähemmän hyödyllistä kuin tavallisesti
4. Oletteko viime aikoina tuntenut kykenevänne päättämään asioista?
Paremmin kuin tavallisesti
Yhtä hyvin kuin tavallisesti
Huonommin kuin tavallisesti
Paljon huonommin kuin tavallisesti
5. Oletteko viime aikoina tuntenut olevanne jatkuvasti rasituksen alaisena?
En ollenkaan
En enempää kuin tavallisesti
Jonkin verran enemmän kuin tavallisesti
Paljon enemmän kuin tavallisesti
6. Onko Teistä viime aikoina tuntunut siltä, ettette voisi selviytyä vaikeuksistanne?
Ei ollenkaan
Ei enempää kuin tavallisesti
Jonkin verran enemmän kuin tavallisesti
Paljon enemmän kuin tavallisesti
7. Oletteko viime aikoina kyennyt nauttimaan tavallisista päivittäisistä toimistanne?
Enemmän kuin tavallisesti
Yhtä paljon kuin tavallisesti
Vähemmän kuin tavallisesti
Paljon vähemmän kuin tavallisesti
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8. Oletteko viime aikoina kyennyt kohtaamaan vaikeutenne?
Paremmin kuin tavallisesti
Yhtä hyvin kuin tavallisesti
Huonommin kuin tavallisesti
Paljon huonommin kuin tavallisesti
9. Oletteko viime aikoina tuntenut itsenne onnettomaksi ja masentuneeksi?
En ollenkaan
En enempää kuin tavallisesti
Jonkin verran enemmän kuin tavallisesti
Paljon enemmän kuin tavallisesti
10. Oletteko viime aikoina kadottanut itseluottamuksenne?
En ollenkaan
En enempää kuin tavallisesti
Jonkin verran enemmän kuin tavallisesti
Paljon enemmän kuin tavallisesti
11. Oletteko viime aikoina tuntenut itsenne ihmisenä arvottomaksi?
En ollenkaan
En enempää kuin tavallisesti
Jonkin verran enemmän kuin tavallisesti
Paljon enemmän kuin tavallisesti
12. Oletteko viime aikoina tuntenut itsenne kaiken kaikkiaan kohtalaisen onnelliseksi?
Enemmän kuin tavallisesti
Yhtä paljon kuin tavallisesti
Vähemmän kuin tavallisesti
Paljon vähemmän kuin tavallisesti
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B. LIIKUNTA-AKTIIVISUUS
Seuraavissa kysymyksissä kysytään aikaa, jonka käytätte fyysiseen aktiivisuuteen tavallisen
viikon aikana. Niissä tiedustellaan toiminnoista, joita teette työpaikallanne, siirtyessänne
paikasta toiseen, osana koti- ja pihatöitä sekä vapaa-aikananne virkistyksen, kuntoilun
tai urheilun vuoksi.
1.A Kuinka monena päivänä tavallisen viikon aikana fyysinen aktiivisuutenne on ruumiillisesti
rasittavaa (vaatii kovaa ponnistelua ja saa selvästi hengästymään), esimerkiksi painavien
taakkojen nostamista, aerobicia tai reipasta pyöräilyä?
Vastaus:_____________ päivänä.
1.B Kuinka paljon aikaa tavallisesti käytätte kaikkiaan tuollaisena päivänä rasittavaan fyysiseen 
aktiivisuuteen?
Vastaus:_____________ tuntia ____________ minuuttia.
2.A Kuinka monena päivänä tavallisen viikon aikana fyysinen aktiivisuutenne on ruumiillisesti
kohtuukuormitteista (vaatii kohtuullista ponnistelua ja saa hengästymään lievästi),
esimerkiksi kevyiden taakkojen kantamista tai pyöräilyä tasaista vauhtia. Älkää laskeko mukaan
kävelyä.
Vastaus:_____________ päivänä.
2.B Kuinka paljon aikaa tavallisesti käytätte kaikkiaan tuollaisena päivänä kohtuukuormitteiseen
fyysiseen aktiivisuuteen?
Vastaus:_____________ tuntia ____________ minuuttia.
3.A Kuinka monena päivänä tavallisen viikon aikana kävelette vähintään 10 minuuttia kerrallaan?
Tähän sisältyy kävely töissä ja kotona, kävely paikasta toiseen siirtyessänne ja kaikki
muu kävely, jota ehkä harrastatte virkistyksen, urheilun ja kuntoilun vuoksi tai vapaa-aikananne.
Vastaus:_____________ päivänä viikossa.
3.B Kuinka kauan aikaa tavallisesti käytätte kaiken kaikkiaan kävelyyn tuollaisena päivänä?
Vastaus:_____________ tuntia ____________ minuuttia.
3.C Millaista vauhtia yleensä kävelette?
Kävelettekö
1  ripeästi, niin että hengästytte selvästi?
2  kohtalaisen nopeasti, niin että hengästytte lievästi?
3  rauhallisesti, niin että ette hengästy?
Viimeiset kysymykset koskevat aikaa, jonka käytätte päivittäin istumiseen työssä, kotona,
tehdessänne opiskelutehtäviä tai vapaa-aikananne. Tähän sisältyy aika, jonka käytätte
pöydän ääressä istumiseen, ystävien luona olemiseen, lukemiseen tai television katselemiseen
tai loikoiluun.
4.A Kuinka paljon aikaa käytätte yleensä istumiseen arkipäivänä?
Vastaus:_____________ tuntia ____________ minuuttia päivässä.
Kuinka paljon aikaa käytätte yleensä istumiseen lauantaina ja sunnuntaina?
4.B Vastaus:_____________ tuntia ____________ minuuttia päivässä.
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OSA VI
TERVEYDEN LISÄKYSYMYKSET:
Valitkaa kuhunkin kysymykseen yksi Teille sopiva vaihtoehto.
Kysymykset koskevat viimeksi kulunutta kuukautta.
Koko Melkein Enim- Melko Harvoin Ei
ajan aina mäkseen harvoin koskaan
1. Yleinen terveydentila
1. Onko Teillä kipuja tai särkyjä tai 
oletteko sairas?
2. Tunnetteko itsenne niin terveeksi että
voitte tehdä mitä haluatte tai mitä Teidän
täytyy tehdä?
3. Oletteko huolissanne tai peloissanne
terveytenne vuoksi?
2. Yleinen mieliala
1. Tunnetteko itsenne alakuloiseksi?
2. Tunnetteko itsenne hermostuneeksi?
3. Oletteko onnellinen ja tyytyväinen
elämäänne?
4. Tunnetteko itsenne tasapainoiseksi ja
rauhalliseksi?
5. Oletteko niin masentunut, että mikään
ei tunnu minkään arvoiselta?
3. Huoli virtsaamisvaivoista ja potenssista
1. Oletteko huolissanne potenssinne vuoksi?
2. Oletteko huolissanne virtsaamisenne
vuoksi?
3. Oletteko tuntenut itsenne noloksi 
virtsaamisenne vuoksi?
4. Aktiivisuus
1. Jaksatteko tehdä kotonanne kaikki 
välttämättömät ja haluamanne askareet?
2. Oletteko niin terve, että voitte käydä
missä haluatte?
3. Oletteko niin hyvässä kunnossa, että 
voitte harrastaa haluamianne asioita?
5. Virtsavaivojen vaikutus aktiviteettiin?
Kuinka usein mahdolliset virtsavaivanne vaikuttavat seuraaviin asioihin?
Ei Joskus Melko Taval- Aina
koskaan usein usein lisesti
1. Juominen ennen matkaa
2. Juominen ennen nukkumaan menoa
3. Autolla ajo 2 tuntia pysähtymättä
4. Riittävä unen saaminen
5. Käyminen paikoissa, joissa ei ole vessaa
6. Urheilun harrastaminen
7. Kirkossa, teatterissa, elokuvissa ym. käyminen
Pyydämme Teitä vielä ystävällisesti tarkastamaan että olette vastannut kaikkiin kysymyksiin.
Palauttakaa kysely oheisessa vastauskuoressa, postimaksu on maksettu puolestanne.
KIITÄMME TEITÄ SYDÄMELLISESTI OSALLISTUMISESTANNE! 
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Age 
group 
Nocturia case 
definition Gender 
Incidence rate/ 
1000 person-years 
Remission rate/ 
1000 person-years 
No. of 
subgro
ups 
Rate 95% CI 
No. of 
subgr
oups 
Rate 95% CI 
18-39 
years 
≥ 1 voids/ night 
Male 1 3.8 0.0-9.0 1 166.7 0.0-397.7 
Female 1 2.0 0.0-4.6 1 125.0 0.0-266.5 
Both 2 2.3 0.0-4.7 2 136.4 15.7-257.0 
≥ 2 voids/ night 
Male 1 0.9 0.0-3.5    
Female 2 4.2 0.0-11.9 1 95.2 1.9-188.6 
Both 3 2.6 0.0-6.1 1 95.2 1.9-188.6 
40-59 
years 
≥ 1 voids/ night 
Male 2 34.4 0.0-69.5 2 117.6 0.0-291.3 
Female 2 34.5 0.0-86.1 2 80.4 0.0-211.2 
Both 5 33.7 16.4-51.1 5 70.5 34.8-106.3 
≥ 2 voids/ night 
Male 2 48.7 0.0-134.2 2 235.5 168.6-302.4 
Female 3 14.4 0.0-30.2 3 56.2 15.2-97.1 
Both 6 24.9 10.6-39.1 5 115.2 57.0-173.5 
≥ 3 voids/ night 
Male 2 8.8 0.0-22.3 1 100.0 12.4-187.7 
Female 1 17.0 11.5-22.5 1 367.0 209.9-524.1 
Both 3 11.7 0.3-23.0 2 225.2 0.0-486.4 
60+  
years 
≥ 1 voids/ night 
Male 3  120.6 63.9-177.4 3 54.9 13.5-96.3 
Female 3 298.5 1.9-595.1 4 68.9 14.1-123.7 
Both 6 87.6 64.9-110.3 7 62.0 31.1-93.0 
≥ 2 voids/ night 
Male 3 135.9 0.0-282.4 3 120.4 102.8-138.0 
Female 3 91.0 0.0-210.3 3 189.3 121.1-257.6 
Both 7 114.2 92.2-136.1 7 180.4 130.6-230.1 
≥ 3 voids/ night 
Male 3 54.8 0.1-109.4 2 170.9 35.7-306.0 
Female 2 65.9 53.7-78.1 2 318.7 236.7-400.7 
Both 5 61.2 21.7-100.6 4 228.3 116.6-340.1 
All 
≥ 1 voids/ night 
Male 6 48.9 29.0-68.8 6 65.7 35.4-96.0 
Female 6 34.9 20.7-49.0 7 74.6 35.0-114.2 
Both 13 40.8 30.1-51.5 14 66.9 45.4-88.5 
≥ 2 voids/ night 
Male 6 63.3 46.2-80.3 5 141.6 109.9-173.3 
Female 7 20.5 12.6-28.3 7 122.6 54.9-190.3 
Both 16 43.5 35.5-51.5 13 154.8 103.7-205.8 
≥ 3 voids/ night 
Male 5 34.0 18.5-49.5 3 149.9 49.3-250.5 
Female 3 49.4 6.3-92.5 3 329.0 256.3-401.7 
Both 8 37.3 23.7-51.0 6 222.9 132.4-313.4 
Appendix 10. Incidence and remission of nocturia: subgroup analyses by 
nocturia case definition, age and gender – Study I. 
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Nocturia case 
definition Study-level variable 
Effect on 
incidence 
rate 
p-value 95% CI 
 
 
≥1 voids/night 
Age 4.7 0.12 -1.4 to 10.8 
Follow-up time -49.7 0.06 -100.9 to 1.5 
Gender distribution -25.3 0.75 -203.8 to 153.3 
Risk of bias -55.9 0.62 -304.7 to 192.9 
 
 
≥2 voids/night 
Age 2.5 0.04 0.1 to 4.9 
Follow-up time -11.2 0.06 -22.8 to 0.4 
Gender distribution 30.8 0.38 -42.8 to 104.3 
Risk of bias -89.2 0.07 -186.2 to 7.7 
 
 
≥3 voids/night 
Age 2.6 0.06 -0.2 to 5.4 
Follow-up time -16.6 0.14 -43.2 to 10.0 
Gender distribution 28.0 0.33 -48.1 to 104.0 
Risk of bias -18.7 0.54 -105.8 to 68.4 
Appendix 11. Multivariable meta-regression for incidence of nocturia per 1000 
person-years of follow-up by three different nocturia case definitions – Study I. 
 147 
 
 
  
Nocturia case 
definition Study-level variable 
Effect on 
remission rate p-value 95% CI 
 
 
 
 
≥1 voids/night 
Age -0.2 0.92 -4.1 to 3.8 
Follow-up time 11.7 0.35 -15.0 to 38.4 
Gender distribution -11.5 0.80 -108.6 to 85.7 
Risk of bias 85.7 0.19 -51.6 to 223.1 
 
 
 
 
≥2 voids/night 
Age 0.7 0.69 -3.4 to 4.9 
Follow-up time -20.0 0.006 -32.6 to -7.5 
Gender distribution 10.9 0.79 -80.3 to 102.1 
Risk of bias -121.3 0.04 -235.1 to -7.5 
 
 
 
 
≥3 voids/night 
Age -0.1 0.99 -42.9 to 42.8 
Follow-up time -46.6 0.33 -389.5 to 296.3 
Gender distribution 76.5 0.36 -547.3 to 700.3 
Risk of bias -47.6 0.76 -1586.0 to 1490.8 
Appendix 12. Multivariable meta-regression for remission of nocturia per 1000 
person-years of follow-up by three different nocturia case definitions – Study I. 
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Study Gender Age strata Nocturia case 
definition 
(voids/night) a 
Hazard ratio, 95% 
confidence 
interval 
Adjusted variables 
(besides age) 
Nakagawa  
2010 b 
Both sex 70-97 yr, mean 76 yr 2 vs. 0-1 1.59, 0.80-3.17 E.g. gender, BMI, 
CHD, diabetes, 
diuretic medication  3 vs. 0-1  2.34, 1.09-5.00 
≥4 vs. 0-1 3.60, 1.38-9.35 
Kupelian  
2011  
Men 20-49 yr, mean 33 yr 2 vs. 0 2.55, 1.12-5.83 E.g. BMI, CVD, 
diabetes, diuretic 
medication, smoking ≥3 vs. 0 3.94, 1.80-8.64 
50-64 yr, mean 58 yr 2 vs. 0 1.16, 0.66-2.05 
≥3 vs. 0 1.85, 0.97-3.53 
65-90 yr, mean 75 yr 2 vs. 0 1.38, 1.04-1.84 
≥3 vs. 0 1.45, 1.06-1.98 
Women 20-49 yr, mean 33 yr 2 vs. 0 1.19, 0.53-2.69 
≥3 vs. 0 1.38, 0.66-2.89 
50-64 yr, mean 57 yr 2 vs. 0 2.25, 1.46-3.46 
≥3 vs. 0 1.87, 0.89-3.90 
65-90 yr, mean 76 yr 2 vs. 0 1.04, 0.85-1.28 
≥3 vs. 0 1.12, 0.85-1.48 
Endeshaw  
2016 
Men 70-79 yr, mean 74 yr 2 vs. 0-1 1.04, 0.87-1.26 E.g. BMI, CVD, 
diabetes, diuretic 
medication, smoking ≥3 vs. 0-1 1.18, 0.97-1.44 
Appendix 14. Relative measures of association of nocturia with mortality – 
additional estimates included in the subgroup meta-analyses of Study II. 
a Nocturia treated as a three-value categorical (discrete) variable. 
b Supplementary data extracted from a conference abstract (Nakagawa H, Niu K, Kaiho Y, Ikeda Y, Arai Y. 
Mortality in the elderly correlates with frequency of nighttime voiding: results of a 5-year prospective cohort 
study in Japan. AUA annual meeting 2010, abstract 3).  
BMI = body mass index, CHD = coronary heart disease, CVD = cardiovascular disease, HR = hazard ratio 
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Variable No. of studies 
No. of 
subgroups a 
Relative 
risk b 95% CI I
2 (%) c 
Mean age 
18-49 yr 2 3 1.49 0.92-2.42 50.7 
50-69 yr 6 7 1.40 1.18-1.67 26.8 
≥70 yr 8 9 1.19 1.07-1.33 49.8 
Gender 
Male 6 11 1.30 1.16-1.45 23.0 
Female 1 3 1.34 0.98-1.83 58.7 
Mixed 5 5 1.23 0.97-1.56 62.6 
Follow-up time 
<10 yr 6 13 1.30 1.16-1.45 36.6 
≥10 yr 5 6 1.22 1.00-1.48 58.6 
 
Nocturia case 
definition 
(voids/night) 
 
≥2 vs. 0-1 d 6 12 1.30 1.13-1.49 62.0 
≥3 vs. 0-2 d 5 7 1.24 1.10-1.39 0.0 
2 vs. 0-1 e 3 8 1.32 1.07-1.64 59.0 
≥3 vs. 0-1 e 3 8 1.50 1.19-1.88 51.7 
≥4 vs. 0-1 e 1 1 3.60 1.38-9.35  
Risk of bias 
Low 4 11 1.34 1.17-1.54 61.7 
High 7 8 1.18 1.04-1.35 18.2 
Region 
West Asia 1 1 0.89 0.55-1.43  
East Asia 2 2 1.94 1.26-2.97 0.0 
Europe 4 5 1.16 0.99-1.36 47.3 
North America 4 11 1.31 1.17-1.46 33.0 
Appendix 15. Relative measures of association of nocturia with mortality – 
subgroup meta-analyses stratified by age, gender, follow-up time, nocturia case 
definition, risk of bias and study region (Study II). 
a Stratified by mean age (18-49 yr, 50-69 yr, ≥70 yr) and gender when data available. 
b Pooled estimate for subgroups of studies. 
c Variation due to heterogeneity (random-effects meta-analyses). 
d Estimates from studies treating nocturia as a two-value categorical variable. 
e Estimates from studies treating nocturia as a three-value categorical (discrete) variable to test exposure-
response relationship. 
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Study-level 
variable 
 
Univariable model Multivariable model 
Unadjusted 
coefficient a 95% CI p-value 
Adjusted 
coefficient b 95% CI p-value 
Mean age <70 yr 1.17 0.96-1.43 0.12 1.23 0.98-1.54 0.07 
Male gender 1.04 0.85-1.29 0.67 1.01 0.83-1.25 0.85 
Follow-up time 
<10 yr 1.11 0.89-1.38 0.34 1.19 0.96-1.46 0.10 
Nocturia 3+ 0.97 0.78-1.21 0.99 1.09 0.84-1.43 0.48 
High risk of bias 0.89 0.72-1.09 0.25 0.84 0.65-1.08 0.15 
Appendix 16. Unadjusted and adjusted meta-regression analyses for relative 
measures of association of nocturia with mortality – Study II. 
a Meta-regression coefficient, representing interaction between nocturia-associated death risk (relative 
risk) and each categorical variable: mean age <70 vs. ≥70 yr, male vs. female or mixed gender, follow-
up time <10 vs. ≥10 yr, nocturia ≥3 vs. ≥2 voids/night, high vs. low risk of bias. 
b Adjusted for all covariables. Proportion of between-study variance explained (adjusted R2) = 66.4%, 
residual variation due to heterogeneity (I2 res.) = 24.7%. 
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Appendix 17. Flow chart of data used in calculations of baseline risks. – Study II. 
References: 
1. Centers for Disease Control and Prevention. Available from: 
https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm 
2. Bosch JL, Weiss JP. Prevalence and causes of nocturia. J Urol 2010;184:440-6. 
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Appendix 18. Flow chart of the assessments of nocturia, mortality, falls and 
fractures in the PREHCO study – Studies II and III. 
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Variable  No. of studies Relative risk 95% CI I
2 (%) a 
Mean age b 
≤74 yr 3 1.21 0.99-1.49 70.8 
>74 yr 2 1.24 1.04-1.48 0.0 
Gender 
Male 3 1.11 0.99-1.25 27.3 
Mixed 2 1.36 1.13-1.64 0.0 
Follow-up time b 
<3 yr 2 1.06 0.97-1.16 0.0 
≥3 yr 3 1.31 1.14-1.49 0.0 
Nocturia case 
definition 
(voids/night) 
≥3 vs. 0-2 c 3 1.31 1.14-1.49 0.0 
2-3 vs. 0-1 d 2 1.06 0.97-1.16 0.0 
≥4 vs. 0-1 d 2 1.24 1.09-1.40 0.0 
Risk of bias 
Low 2 1.13 0.94-1.36 61.4 
High 3 1.28 1.11-1.49 0.0 
Appendix 20. Relative risk of falling at least least once in the follow-up in people 
with nocturia – subgroup meta-analyses stratified by age, gender, follow-up time, 
nocturia case definition and risk of bias (Study III). 
a Variation due to heterogeneity (random-effects meta-analyses). 
b Median split. 
c Estimates from studies treating nocturia as a two-value categorical variable. 
d Estimates from studies treating nocturia as a three-value categorical (discrete) variable to test 
exposure-response relationship. 
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Variable No. of studies 
Relative 
risk 95% CI I
2 (%) a 
Mean age b 
<74 yr 1 1.66 1.29-2.11  
≥74 yr 2 1.23 1.09-1.40 0.0 
Gender 
Male 3 1.38 1.11-1.71 54.7 
Female 0    
Follow-up time b 
1 yr 2 1.23 1.09-1.40 0.0 
>1 yr 1 1.66 1.29-2.11  
Nocturia case 
definition 
(voids/night) 
≥3 vs. 0-2 c 1 1.66 1.29-2.11  
2-3 vs. 0-1 d 2 1.23 1.09-1.40 0.0 
≥4 vs. 0-1 d 2 1.42 1.17-1.72 0.0 
Risk of bias 
Low 1 1.23 1.08-1.41  
High 2 1.58 1.27-1.96 0.0 
Appendix 21.Relative risk of recurrent falls in the follow-up in people with nocturia 
– subgroup meta-analyses stratified by age, gender, follow-up time, nocturia case 
definition and risk of bias (Study III). 
a Variation due to heterogeneity (random-effects meta-analyses). 
b Median split. 
c Estimates from a study treating nocturia as a two-value categorical variable. 
d Estimates from studies treating nocturia as a three-value categorical (discrete) variable to test 
exposure-response relationship. 
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Variable No. of studies  Relative risk  95% CI I
2 (%) a 
Mean age b 
≤70 yr 3 1.41 1.09-1.82 0.0 
>70 yr 2 1.31 0.67-2.56 75.8 
Gender 
Male 5 1.27 0.95-1.69 50.5 
Female 1 2.07 0.95-4.51  
Follow-up time b 
≤5 yr 4 1.47 1.16-1.87 0.0 
>5 yr 1 1.00 0.90-1.20  
Nocturia case 
definition 
(voids/night) 
≥1 vs. 0 or  
≥2 vs. 0-1 4 1.33 0.96-1.85 67.3 
≥3 vs. 0-2 1 1.38 0.57-3.32  
Risk of bias 
Low 1 1.00 0.90-1.20  
High 4 1.47 1.16-1.87 0.0 
Appendix 22.Relative risk of fractures in people with nocturia – subgroup meta-
analyses stratified by age, gender, follow-up time, nocturia case definition and risk 
of bias (Study III). 
a Variation due to heterogeneity (random-effects meta-analyses). 
b Median split. 
 160 
 
 
 
  
Appendix 23.Flow chart of data used in calculations of baseline risks of falls and 
fall-related fractures – Study III. 
References: 
1. Morrison A, Fan T, Sen SS et al. Epidemiology of falls and osteoporotic fractures: a 
systematic review. Clinicoecon Outcomes Res 2013;5:9-18. 
2. Deandrea S, Lucenteforte E, Bravi F et al. Risk factors for falls in community-dwelling older 
people: a  systematic review and meta-analysis. Epidemiology 2010;21:658-68. 
3.  Bosch JL, Weiss JP. Prevalence and causes of nocturia. J Urol 2010;184:440-6. 
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 1994 1999 2004 2009 
 n % n % n % n % 
Number of men 1 332  1 193  1 067  955  
Urgency a 24 1.8 173 14.5 190 17.8 182 19.1 
Daytime frequency 144 10.8 87 7.3 82 7.7 70 7.3 
Nocturia 51 3.8 69 5.8 100 9.4 85 8.9 
Year of birth         
1944 544 40.8 513 43.0 498 46.7 476 49.8 
1934 477 35.8 452 37.9 412 38.6 367 38.4 
1924 311 23.3 228 19.1 157 14.7 112 11.7 
Marital status         
Married/cohabiting 1 086 81.5 981 82.2 865 81.1 754 79.0 
Single/divorced 198 14.9 158 13.2 144 13.5 119 12.5 
Widowed 48 3.6 54 4.5 58 5.4 82 8.6 
BMI         
≤25 465 34.9 374 31.3 349 32.7 329 34.5 
25-30 654 49.1 625 52.4 520 48.7 459 48.1 
>30 213 16.0 194 16.3 198 18.6 167 17.5 
Current smoking 258 19.4 193 16.2 149 14.0 116 12.1 
Alcohol intake >150 g/week 270 20.3 195 16.3 172 16.1 67 7.0 
Medical conditions         
Diabetes 98 7.4 100 8.4 128 12.0 157 16.4 
Hypertension 398 29.9 325 34.0 492 46.1 470 49.2 
Cardiac disease 238 17.9 227 19.0 248 23.2 268 28.1 
Pulmonary disease 127 9.5 152 12.7 126 11.8 103 10.8 
Cerebrovascular disease 60 4.5 50 4.2 64 6.0 59 6.2 
Cancer 43 3.2 70 5.9 101 9.5 146 15.3 
Neurological disease 29 2.2 44 3.7 40 3.7 59 6.2 
Appendix 24.Characteristics of men at various stages of follow-up – Study IV. 
a Assessed with a modified question in 1994. 
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 Unadjusted Adjusted 
   Urgency Frequency Nocturia 
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Urgency 1.71 1.36-2.14 1.19 0.94-1.50 - - - - 
Frequency 1.95 1.52-2.49 - - 1.42 1.11-1.83 - - 
Nocturia 2.31 1.79-2.98 - - - - 1.38 1.07-1.79 
Age in 1994 (vs. 50 yrs)         
60 yrs 1.93 1.52-2.47 1.80 1.40-2.32 1.82 1.41-2.34 1.79 1.38-2.30 
70 yrs 7.14 5.67-8.99 6.81 5.23-8.88 6.83 5.25-8.90 6.69 5.13-8.73 
Marital status (vs. 
married) 
        
Single/divorced 1.98 1.60-2.46 2.39 1.91-2.98 2.38 1.90-2.98 2.35 1.88-2.94 
Widowed 2.31 1.72-2.46 1.20 0.89-1.63 1.21 0.90-1.64 1.21 0.90-1.64 
BMI (vs. ≤25)         
25-30 0.70 0.58-0.85 0.77 0.64-0.94 0.76 0.63-0.93 0.77 0.63-0.94 
>30 0.85 0.67-1.09 0.97 0.74-1.26 0.94 0.72-1.23 0.96 0.74-1.25 
Current smoking 1.51 1.22-1.86 1.98 1.58-2.49 1.95 1.56-2.45 2.01 1.60-2.52 
Alcohol intake >150 
g/week  
0.85 0.65-1.09 1.16 0.89-1.52 1.17 0.90-1.54 1.16 0.89-1.53 
Medical conditions         
Diabetes 1.90 1.51-2.38 1.66 1.31-2.11 1.66 1.31-2.10 1.68 1.33-2.13 
Hypertension 1.20 1.01-1.43 1.12 0.93-1.34 1.11 0.92-1.34 1.11 0.93-1.34 
Cardiac disease 2.58 2.16-3.08 1.54 1.27-1.86 1.52 1.26-1.84 1.54 1.27-1.86 
Pulmonary disease 1.78 1.42-2.24 1.35 1.07-1.70 1.33 1.06-1.68 1.34 1.06-1.68 
Cerebrovascular disease 1.96 1.45-2.64 1.43 1.05-1.93 1.42 1.04-1.92 1.43 1.06-1.94 
Cancer 2.37 1.87-3.02 1.77 1.38-2.27 1.76 1.37-2.25 1.73 1.35-2.22 
Neurological disease 2.00 1.43-2.80 1.65 1.17-2.33 1.70 1.21-2.39 1.67 1.18-2.35 
Appendix 25.Unadjusted and adjusted associations of LUTS and covariables with 
all-cause mortality in the follow-up of 21 years - Cox regression analyses with 
variable values updated every five years (time-dependent analysis) – Study IV. 
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 Unadjusted Adjusted 
   Urgency Frequency Nocturia 
 HR 95% CI HR 95% CI HR 95% CI HR 95% CI 
Urgency 1.52 0.86-2.69 0.94 0.52-1.68 - -   
Frequency 1.43 1.11-1.84 - - 1.09 0.84-1.42   
Nocturia 2.56 1.81-3.63 - - - - 1.41 0.99-2.02 
Age in 1994 (vs. 50 yrs)         
60 yrs 1.93 1.52-2.47 1.92 1.49-2.48 1.91 1.49-2.46 1.91 1.48-2.46 
70 yrs 7.14 5.67-8.99 8.18 6.31-10.62 8.12 6.26-10.53 8.00 6.17-10.38 
Marital status (vs. 
married)         
Single/divorced 1.78 1.44-2.22 2.09 1.67-2.63 2.09 1.67-2.63 2.06 1.64-2.59 
Widowed 3.02 2.10-4.34 1.87 1.30-2.71 1.89 1.31-2.72 1.88 1.31-2.72 
BMI (vs. ≤25)         
25-30 0.88 0.72-1.06 0.92 0.75-1.12 0.92 0.75-1.12 0.92 0.76-1.12 
>30 1.00 0.77-1.28 1.03 0.79-1.35 1.03 0.79-1.34 1.02 0.78-1.33 
Current smoking 1.66 1.37-2.03 2.44 1.96-3.03 2.41 1.94-3.00 2.46 1.98-3.05 
Alcohol intake >150 
g/week  1.20 0.98-1.48 1.42 1.14-1.77 1.42 1.14-1.76 1.40 1.12-1.74 
Medical conditions         
Diabetes 2.12 1.62-2.77 1.78 1.35-2.34 1.77 1.34-2.34 1.74 1.32-2.30 
Hypertension 1.42 1.19-1.71 1.21 1.00-1.47 1.21 1.00-1.47 1.21 1.00-1.47 
Cardiac disease 2.64 2.18-3.19 1.49 1.22-1.83 1.49 1.22-1.83 1.49 1.22-1.83 
Pulmonary disease 1.91 1.49-2.45 1.39 1.08-1.80 1.39 1.07-1.79 1.38 1.07-1.78 
Cerebrovascular disease 2.00 1.42-2.80 1.42 1.00-2.02 1.41 0.99-2.00 1.42 1.00-2.02 
Cancer 2.57 1.76-3.74 2.21 1.50-3.26 2.24 1.52-3.30 2.26 1.53-3.32 
Neurological disease 1.67 1.01-2.74 2.00 1.21-3.32 2.00 1.21-3.31 1.99 1.20-3.29 
Appendix 26.Unadjusted and adjusted associations of LUTS and covariables with 
all-cause mortality in the follow-up of 21 years - Cox regression analyses with variable 
values fixed to the baseline assessment of 1994 (fixed analysis) – Study IV. 
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Urgency Daytime frequency Nocturia  
p-value p-value p-value 
Year of birth 0.882 0.050 0.704 
Marital status 0.474 0.335 0.594 
BMI 0.370 0.398 0.992 
Current smoking 0.017 0.778 0.920 
Alcohol intake 0.227 0.374 0.264 
Diabetes 0.121 0.499 0.644 
Hypertension 0.599 0.261 0.561 
Cardiac disease 0.041 0.823 0.701 
Pulmonary disease 0.505 0.605 0.472 
Cerebrovascular disease 0.172 0.295 0.499 
Cancer 0.631 0.900 0.643 
Neurological disease 0.943 0.185 0.696 
Appendix 27.P-values of interaction terms in regression analyses of  
the association of LUTS with all-cause mortality – Study IV. 
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Abstract
Context: Although vital for decision-making about management, the natural history of
nocturia remains uncertain. A systematic review would clarify the issue, but because
natural history reviews are uncommon it would require methodological innovations.
Objective: To estimate the incidence and remission of nocturia, and reﬁne methods for
meta-analyses assessing natural history.
Evidence acquisition: We conducted a comprehensive search of PubMed, Scopus, and
Cumulative Index of Nursing and Allied Health Literature databases and abstracts of
major urologic meetings as far as August 31, 2015. Random effects meta-analyses
addressed incidence/remission rates of nocturia; meta-regression explored potential
determinants of heterogeneity. Studieswere categorized as either low or high risk of bias
using a novel instrument speciﬁcally designed for longitudinal symptom studies aimed
at the general population.
Evidence synthesis: Of 4165 potentially relevant reports, 16 proved eligible. Pooled
estimates from 13 studies (114 964 person-years of follow-up) demonstrated that annual
incidence was strongly associated with age: 0.4% (0–0.8%) for adults aged < 40 yr;
2.8% (1.9–3.7%) for adults aged 40–59 yr; and 11.5% (9.1–14.0%) for adults aged
 60 yr. Of those with nocturia, each year 12.1% (9.5–14.7%) experienced remission.
Conclusions: The available evidence suggests that nocturia onset is strongly associated
with age, with much higher rates in those over 60 yr; remission occurs in approximately
12% each year. These estimates can aid with management decisions and counseling
related to nocturia.
* Corresponding author. Departments of Urology and Public Health, University of Helsinki and
Helsinki University Hospital, Haartmaninkatu 4, Helsinki 00029, Finland. Tel. +358-50-5393222.
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1. Introduction
Nocturia (waking from sleep at night to void) [1] is one of
the most common and bothersome urinary symptoms
[2]. Nocturia is associated with impaired quality of life, and
is a significant cause of sleep disruption. Nocturia may
increase fracture and mortality risk [3,4]. Cross-sectional
studies suggest that older age increases the risk of nocturia
[5], and studies have identified additional risk factors,
suggesting a multifactorial etiology [6]. Little is known,
however, about patterns of progression and remission of
nocturia over time, knowledge of which would facilitate
shared decision-making about the initiation and continua-
tion of therapeutic options between patients and healthcare
providers [7].
Conventional systematic reviews that compare one
treatment against another or against a nontreatment
control are common and the methods are well established
[8]. However, systematic reviews and meta-analyses
addressing natural history or prognosis of symptoms are
rare, and require methodological innovation. Although
investigators have conducted longitudinal studies addres-
sing nocturia, summarizing the data is challenging, with
variation between assessment tools, case definitions, and
analytic strategies [6]. The primary aim of this systematic
review was to explore and compare, using different
analytical methods and definitions, the average annual
cumulative incidence and remission of nocturia. We also
aimed to examine progression of nocturia, and further
developmethods for systematic reviews andmeta-analyses
assessing natural history and prognosis of symptoms.
2. Evidence acquisition
We registered the review protocol (PROSPERO:
CRD42012001985), and followed the Preferred Reporting
Items for Systematic reviews and Meta-Analyses guidance
[9]. No ethical approval was required.
2.1. Data sources and searches
An experienced research librarian (M.A.) collaborated in
planning the search strategy, performed up to 31 August,
2015, in PubMed (from 1946 to present), Scopus (1995 to
present), and Cumulative Index of Nursing and Allied Health
Literature (1960 to present) without search limits or
language restrictions. As increasing evidence suggests the
benefits of inclusion of grey literature to the systematic
reviews [10], we also searched abstracts published in the
annual meetings of the American Urological Association,
European Association of Urology, International Continence
Society, and International Urogynecological Association
from the past 10 yr (2005–2015) for ongoing and
unpublished studies. Supplementary Appendix 1 provides
the search strategy.We also hand searched reference lists of
all included articles.
2.2. Eligibility criteria
We included longitudinal studies with a follow-up of at
least 3 mo reporting the incidence, progression, remission,
or change in prevalence in a primarily [11_TD$DIFF]non-care seeking
adult population.We excluded studies inwhich the aimwas
to assess the effect of any intervention, including thosewith
untreated control arms. We also excluded studies assessing
lower urinary tract symptoms (LUTS) in patients with any
specific health disorder. Finally, we excluded studies
assessing the impact of pregnancy or delivery on LUTS if
the baseline LUTS assessment was carried out either during
pregnancy or in the 1st postpartum year.
2.3. Study selection and data extraction
We developed standardized, pilot-tested forms together
with detailed instructions for screening of abstracts and
full texts, risk of bias assessments, and data extraction. The
reviewers conducted pilot screening and data extraction
exercises to achieve a high level of agreement. Pairs of
reviewers, independently and in duplicate, screened study
reports for eligibility, assessed risk of bias, and collected
data from each eligible study. Reviewers resolved dis-
agreements through discussions; one of two adjudicators
resolved remaining disagreements.
Whenmore than one report provided data from the same
study, we used the most complete report, and additionally
combined data from less complete reports where possible.
We recorded the country/source of study sample, age and
sex distribution, exclusion criteria used in individual
studies, assessment tools used for nocturia, follow-up time,
sample size including response rate, as well as incidence
and remission rates of nocturia.
2.4. Assessment of risk of bias
One challenge for a systematic review of symptom
prognosis is that risk of bias criteria, as well as criteria
for overall certainty in estimates, although well established
for reviews of therapeutic trials, are controversial in
observational studies [11]. Through iterative discussion
and consensus building, and informed by prior literature
Patient summary: We reviewed all previous studies of progression of night-time urination
(nocturia). We found that in any given year 0.4% of adults aged < 40 yr, 3% of adults aged
40–59 yr, and 12% of adults aged  60 yr will develop nocturia, while overall 12% of those
with nocturia will improve. These ﬁndingsmay be helpful inmaking decisions about coping
with or treating nocturia.
# 2016 Published by Elsevier B.V. on behalf of European Association of Urology.
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[12,13], we developed a novel instrument to categorize
studies as either low or high risk of bias, evaluating the
representativeness of the source populations, accuracy of
the outcome assessment, and the proportion ofmissing data
(Supplementary Appendix 2) [14].
2.5. Data analysis, including statistical analysis
We used three different analytic definitions to assess the
incidence of nocturia: (1) any new nocturia case (1 voids/
night) at follow-up for individuals without nocturia at
baseline, (2) any new case of 2 voids/night for individuals
with no or one void per night at baseline, and (3) any new
case of3 voids/night for individuals with two or less voids
per night at baseline. Similarly, we used three analytic
definitions for nocturia remission: (1) one ormore voids per
night resolving to no nocturia, (2) two or more nocturia
episodes resolving to no or one void per night, and (3) three
or more nocturia episodes resolving to two or less voids per
night. Epidemiological studies have suggested that[3_TD$DIFF] differ-
ence of at least one void per night [4_TD$DIFF] is [12_TD$DIFF]patient-important
[15,16].
For cumulative incidence and remission rates, person-
years were calculated by multiplying the number of
individuals without/with nocturia (for incidence and remis-
sion, respectively) at the follow-upby follow-up time (simple
cumulative incidence methodology). Standard errors and
95% confidence intervals were calculated for natural
logarithms of incidence/remission rates per 1000 person-
years of follow-up. In the case of zero events, a correction of
0.5was added to observed events and person-years to enable
calculation of confidence intervals. Finally, we also used
actuarial cumulative incidence methodology for sensitivity
analyses (Supplementary Appendix 3).
We calculated pooled rates of incidence and remission of
nocturia using the DerSimonian–Laird random effects
inverse variance method. Rates were expressed as observed
events per 1000 person-years of follow-up. If a study
provided more than one definition for incidence/remission
of nocturia, when pooling data, we preferred nocturia
estimates using a definition of two or more voids/night.
Analyseswerealso carriedout for three agegroups (18–39yr,
40–59 yr, and 60 yr and over) as earlier research suggest
substantial differences between individuals in young adult-
hood, middle age, and in older age [5]. Finally, we measured
estimates stratified by sex and across the three nocturia
case definitions (defined as 1, 2, or 3 voids/night).
We employed prespecified hypotheses to examine
heterogeneity using meta-regression analysis weighted by
the inverse of the variance in a random effects model.
Separately for each nocturia case definition (1, 2, or
3 voids/night), we examined the following variables as
potential sources of heterogeneity: (1) mean age, (2) sex
distribution, (3) length of follow-up, and (4) risk of bias. For
incidence, we had prespecified hypotheses that effect
estimates would be higher for: (1) older age, (2) higher
proportion of male population, (3) shorter follow-up
time, and (4) lower risk of bias. For remission, we had
prespecified hypotheses that effect estimates would be
higher for: (1) younger age, (2) higher proportion of female
population, (3) shorter follow-up time, and (4) lower risk
of bias.
To illustrate the relation of nocturia incidence and
remission with nocturia prevalence, we estimated the
(baseline) prevalence of nocturia 1, 2 and 3 episodes/
night using a previous comprehensive systematic review
addressing the prevalence of nocturia [5].
We narratively summarized the studies on progression
of nocturia but did not pool estimates because too few
studies on progression were included in our meta-analysis.
Statistical analyzes were performed using metan and
metareg in Stata 12.1 (StataCorp, College Station, TX,
USA) [17].
3. Evidence synthesis
3.1. Literature search and study characteristics
We screened 4165 abstracts and retrieved 74 full texts and
two eligible conference abstracts (Fig. 1). Sixteen studies
provided usable data from 15 142 men and 18 726 women
(Table 1). From these 16 studies, two provided propor-
tional measures of progression and remission of nocturia
among all persons in follow-up but did not report actual
number of incident or remitting cases [18,19]. Similarly,
one study provided only periodic prevalences of nocturia
but not data of incident or remitting cases [20]. We were
therefore able to include 13 studies (114 964 person-
years) in meta-analyses of incidence and remission rates
of nocturia [21–33].
Table 1 provides a description of the 16 studies. Ten
(62%) were conducted in Europe, three (19%) in North
America, and three (19%) in Asia. The studies varied widely,
including sex and age distributions, as well as in follow-up
times (median 4.5 yr; range, 6 mo to 16 yr). Fifteen studies
(94%) used symptom questionnaires and one [5_TD$DIFF] (6%)[13_TD$DIFF] used
frequency-volume charts.
3.2. Risk of bias
Of the 16 included studies, 10 (62%)were at high risk and six
(38%) at low risk of bias (Fig. 2). Of these 16 studies, 14 (88%)
accurately assessed nocturia both at baseline and at follow-
up, nine (56%) had little missing data in the follow-up, and
eight (50%) used representative source populations.
3.3. Incidence
In meta-analyses of the incidence rates of nocturia
(12 studies, five low and seven high risk of bias), the
pooled average annual cumulative incidence was 4.9% (95%
confidence interval 4.1–5.8, I2 = 98.6%; no difference
between simple and actuarial cumulative incidence meth-
odology; Fig. 3; Supplementary Fig. 1). With age stratifica-
tion, annual incidence increased with increasing age: 0.4%
(0–0.8%, I2 = 65.1%) for adults aged < 40 yr, 2.8% (1.9–3.7%,
I2 = 98.1%) for adults aged 40–59 yr, and 11.5% (9.1–14.0%,
I2 = 98.8%) for adults aged  60 yr (Fig. 3). Pooled incidence
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rates did not significantly differ by nocturia case definition
(4.1% (3.0–5.2%) for 1 episode per night, 4.4% (3.6–5.2%)
for 2 episodes per night, and 3.7% (2.4–5.1%) for
3 episodes per night; Supplementary Table 1).
In multivariable meta-regression, (borderline) signifi-
cant predictor for higher incidence was older age (4.7%
increase/decade for 1 voids/night, –1.4 to 10.8, p = 0.12,
2.5% increase/decade for 2 voids/night, 0.1–4.9, p = 0.04;
and 2.6% increase/decade for 3 voids/night, –0.2 to 5.4,
p = 0.06). Follow-up time, sex distribution, or risk of bias
were not strongly suggestive of higher or lower incidence of
nocturia (Supplementary Table 2).
3.4. Remission
In meta-analyses of remission rates of nocturia (12 studies,
five low and seven high risk of bias), the pooled average
annual cumulative remission was 12.1% (9.5–14.7%,
I2 = 97.8%; no difference between simple and actuarial
cumulative remission methodology; Fig. 4; Supplementary
Fig. 2). With age stratification, annual remission rates did
not differ by age: 11.1% (3.7–18.5%, I2 = 0.0%) for adults aged
< 40 yr, 9.4% (6.2–12.6%, I2 = 94.1%) for adults aged 40–59
yr, and 13.9% (9.0–18.8%, I2 = 98.8%) for adults aged  60 yr
(Fig. 4). Pooled remission rates for nocturia increased with
higher nocturia case definition: 6.7% (4.5–8.9%) for1 voids/
night, 15.5% (10.4–20.6%) for 2 voids/night, and 22.3%
(13.2–31.3%) for 3 voids/night (Supplementary Table 1).
In multivariable meta-regression, age, sex distribution,
follow-up time, or risk of bias were not consistently
suggestive of higher or lower remission of nocturia
(Supplementary Table 3).
3.5. Relation between incidence and remission rates with
baseline prevalence of nocturia
Figure 5 illustrates the relation of baseline prevalence
(of having or not having nocturia) with (average annual)
cumulative incidence and remission. For instance, baseline
prevalence is 5% for 3 nocturia episodes. Therefore, 5% of
population are ‘‘at risk’’ of nocturia remission and 95% are
‘‘at risk’’ of nocturia incidence. According to our meta-
analyses (Supplementary Table 1), cumulative incidence
is 3.7% (2.4–5.1%) and cumulative remission is 22.3%
(13.2–31.3%) for 3 nocturia episodes. However, due to
the baseline prevalence, indeed more incident than
remittent nocturia cases emerge annually and the preva-
lence therefore grows with age (Fig. 5).
[(Fig._1)TD$FIG]
Fig. 1 – Study flow chart.
[7_TD$DIFF]CINAHL = Cumulative Index to Nursing and Allied Health Literature.
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[(Fig._2)TD$FIG]
Fig. 2 – Risk of bias of the included studies.
[(Fig._3)TD$FIG]
Fig. 3 – Forest plot of incidence rates of nocturia per 1000 person-years of follow-up.
CI = confidence interval.
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[(Fig._4)TD$FIG]
Fig. 4 – Forest plot of remission rates per 1000 person-years of follow-up.
CI = confidence interval.
[(Fig._5)TD$FIG]
Fig. 5 – Relation of annual incidence and remission rates of nocturia to baseline prevalence of at least one void per night (30%), at least two voids per
night (12%), and at least three voids per night (5%).
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3.6. Progression of nocturia
Three studies provided proportional measures for progres-
sion/remission of nocturia [18,19,28]. In a Scottish study
conducted among middle-aged and elderly men [18],
progression of nocturia occurred in 40% and remission in
10%, whereas in 50% of men nocturia remained unchanged
after 5-yr follow-up. In an Austrian study also conducted
among middle-aged and elderly men [19], progression
occurred in 28%, remission in 27%, while in 45% of men
nocturia symptoms were unchanged. An Austrian study
conducted among women of all adult ages [28], reported
after [14_TD$DIFF]6.5-yr follow-up, progression from one void to at least
two voids per night occurred in 21% ofwomenwith one void
per night at the baseline, and remission to one void per
night in 23% of women with at least two voids per night at
the baseline.
3.7. Strengths
To our knowledge, this is the first systematic review
assessing the natural history of nocturia. The strengths of
this review include a contemporary and comprehensive
search of both published and unpublished studies without
language restrictions, the duplicate assessment of eligibility
and data extraction, and the appraisal of risk of bias.
Although randomized trials provide estimates of treatment
effect with the lowest risk of bias, populations enrolled are
likely to differ from general populations in a variety of ways,
making their application to general populations limited
[34]. Hence, we chose to provide estimates from observa-
tional studies of unselected patients; such studies are likely
to be the best source of estimates of prognosis. We used
appropriate statistical methods to generate pooled esti-
mates, followed a prespecified data analysis plan, and
employed a limited number of important and plausible
hypotheses to explore potential determinants of heteroge-
neity, and applied novel approaches to risk of bias
assessment [14]. Finally, sensitivity analyses did not change
results appreciably.
3.8. Limitations
The limitations of our review are largely the weaknesses of
the eligible studies. Firstly, included studies use several
different instruments for assessment with different defini-
tions of nocturia. Secondly, variation in follow-up times
makes comparison of estimates for incidence and remission
rates of nocturia challenging because of the fluctuating
nature of this symptom [35]. Pooling the rates from studies
with follow-up times varying from 6 mo to 16 yr (Table 1)
necessarily involves some approximation when trying to
estimate average annual incidence and remission. These
studies have included some people with interventions and
are therefore somewhat limited as not entirely representing
the ‘‘natural’’ history. Another important limitation is the
very wide differences between rates of both incidence and
remission across studies, differences that could be partially
explained by age. Differences in age distributions and
follow-up times between male and female studies limited
the comparability of the estimates between sexes. Finally,
although identified studies include bothmen andwomen of
all adult ages, there is paucity of studies including younger
adults.
3.9. Implications for clinical practice and future research
Besides being useful in counseling patients with nocturia,
these results highlight the burden of nocturia among older
men and women compared with younger adults. Those
aged over 60 yr were nearly four times more likely to
develop nocturia comparedwith adults aged 40–59 yr. Also,
while one out of every eight persons with nocturia reported
remission annually, for clinicians and patients, nocturia
remains a challenging condition to treat [6,36]. With the
aging of populations worldwide and the well-recognized
negative health impact of frequent nocturia [15,37],
development of novel treatment strategies that are well-
tolerated should remain a research priority.
4. Conclusions
Our study summarizes the incidence and remission of
nocturia in a general population using data from five low
and eight high risk of bias studies. Across all available
studies, the incidence of nocturia is 0.4% per year among
adults aged < 40 yr, 2.8% among those aged 40–59 yr, and
11.5% among those aged  60 yr, while overall remission is
12.1% per year; estimates, however, varied considerably
among studies. These estimates can aid with management
decisions and counseling related to nocturia.
Author contributions: Kari A.O. Tikkinen had full access to all the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design: Pesonen, Cartwright, Tikkinen.
Acquisition of data: Pesonen, Cartwright, Mangera, Santti, Griebling,
Pryalukhin, Riikonen, Ta¨htinen, Agarwal, Tsui, Vaughan, Markland,
Johnson, Fonsell-Annala, Khoo, Aoki, Tikkinen.
Analysis and interpretation of data: Pesonen, Cartwright, Auvinen, Heels-
Ansdell, Guyatt, Tikkinen.
Drafting of the manuscript: Pesonen, Cartwright, Tikkinen.
Critical revision of the manuscript for important intellectual content:
Pesonen, Cartwright, Mangera, Santti, Griebling, Pryalukhin, Riikonen,
Ta¨htinen, Agarwal, Tsui, Vaughan, Markland, Johnson, Fonsell-Annala,
Khoo, Tammela, Aoki, Auvinen, Heels-Ansdell, Guyatt, Tikkinen.
Statistical analysis: Pesonen, Cartwright, Heels-Ansdell, Guyatt, Tikkinen.
Obtaining funding: Tikkinen.
Administrative, technical, or material support: Tammela.
Supervision: Cartwright, Guyatt, Tikkinen.
Other: None.
Financial disclosures: Kari A.O. Tikkinen certiﬁes that all conﬂicts of
interest, including speciﬁc ﬁnancial interests and relationships and
afﬁliations relevant to the subject matter or materials discussed in the
manuscript (eg, employment/afﬁliation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents ﬁled, received, or pending), are the following: Pesonen
declares research grants from Pﬁzer and Ferring, reimbursements for
attending scientiﬁc meetings from Astellas and Novartis, and honoraria
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 3 7 2 – 3 8 1 379
from Astellas and Merck. Pryalukhin declares a reimbursement for
attending a scientiﬁc meeting and an honorarium from Zentiva Pharma,
and travel grants from Astellas Pharma Europe and Gedeon Richter.
Riikonen declares reimbursements for attending scientiﬁc meetings
from Astellas and Ferring, and an honorarium from Abbvie. Ta¨htinen
declares a reimbursement for attending a scientiﬁc meeting from
Johnson & Johnson. Santti declares a reimbursement for attending a
scientiﬁc meeting and an honorarium from Astellas. Vaughan was a
subinvestigator on an investigator-initiated trial supported by Astellas.
Johnson declares consultancy, travel reimbursements, research grants,
and honoraria from Vantia and Astellas. Tammela declares consultancy
for GlaxoSmithKline, Astellas, and Ferring, and an honorarium for Sanoﬁ,
and has participated in trials by Medivation, Orion Pharma, Takeda,
Jansen Cilag, Lidds AB, Camurus AB, and Bayer.
Funding/Support and role of the sponsor: This study was conducted by
the Clinical Urology and Epidemiology Working Group supported by the
Academy of Finland (#276046), Competitive Research Funding of the
Helsinki, UusimaaHospital District, Jane andAatos Erkko Foundation, and
Sigrid Juse´lius Foundation. [15_TD$DIFF]Pesonen was[6_TD$DIFF] supported also[16_TD$DIFF] by the Competi-
tiveResearch Fundingof theKanta-Ha¨meCentralHospital, andCartwright
by the UK Medical Research Council. Vaughan [17_TD$DIFF]was supported by a US
Department of Veterans Affairs Career Development Award (1 IK2
RX000747-01). The sponsors hadno role in the analysis and interpretation
of the data or the manuscript preparation, review, or approval.
Acknowledgments: The authors would like to thank information
specialist Mervi Ahola for advice regarding literature search strategies.
We would also like to thank the following researchers for checking
extracted data for accuracy and/or providing additional information
regarding the original studies: Yoshitaka Aoki, Akihide Hirayama,
Kathleen Hunter, and Jukka Ha¨kkinen.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.
eururo.2016.02.014.
References
[1] Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardixation
of terminology in nocturia: report from the Standardixation Sub-
committee of the International Continence Society. Neurourol
Urodyn 2002;21:179–83.
[2] Agarwal A, Eryuzlu LN, Cartwright R, et al. What is the most
bothersome lower urinary tract symptom? Individual- and popu-
lation-level perspectives for both men and women. Eur Urol
2014;65:1211–7.
[3] Temml C, Ponholzer A, Gutjahr G, Berger I, Marszalek M, Maders-
bacher S. Nocturia is an age-independent risk factor for hip-frac-
tures in men. Neurourol Urodyn 2009;28:949–52.
[4] Nakagawa H, Niu K, Hozawa A, et al. Impact of nocturia on bone
fracture and mortality in older individuals: A Japanese longitudinal
cohort study. J Urol 2010;184:1413–8.
[5] Bosch JL, Weiss JP. Prevalence and causes of nocturia. J Urol
2010;184:440–6.
[6] Marshall SD, Raskolnikov D, Blanker MH, et al. Nocturia: Current
levels of evidence and recommendations from the international
consultation on male lower urinary tract symptoms. Urology
2015;85:1291–9.
[7] Blanker MH, Van Deventer KR, Bijl D. Measuring symptomatic relief
in men with lower urinary tract symptoms. BMJ 2014;349:g6664.
[8] Cochrane Handbook for Systematic Reviews of Interventions, Ver-
sion 5.1.0. http://handbook.cochrane.org/.
[9] Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: The
PRISMA statement. BMJ 2009;21:339.
[10] Montori V, Ioannidis J, Guyatt G. Reporting bias. In: Guyatt G,
Rennie D, Meade MO, Cook DJ, editors. Users’ Guides to the Medical
Literature: AManual for Evidence-based Clinical Practice. ed 2. New
York, NY: McGraw-Hill; 2008.
[11] Guyatt GH, Oxmanb AD, Vistb G, et al. GRADE guidelines: 4. Rating
the quality of evidence-study limitations (risk of bias). J Clin
Epidemiol 2011;64:407–15.
[12] Hayden JA, van der Windt DA, Cartwright JL, Coˆte´ P, Bombardier C.
Assessing bias in studies of prognostic factors. Ann Intern Med
2013;158:280–6.
[13] Kim SY, Park JE, Lee YJ, Seo H-J, Sheen SS, Hahng S, Janga BH, Son HJ.
Testing a tool for assessing the risk of bias for nonrandomized
studies showed moderate reliability and promising validity. J Clin
Epidemiol 2013;66:408–14.
[14] Tikkinen KAO, Busse JW, Guyatt GH. Tool to assess risk of bias in
observational studies of natural history of medical symptoms/
conditions in general populations. https://distillercer.com/
resources/methodological-resources/.
[15] Tikkinen KA, Johnson IInd TM, Tammela TL, et al. Nocturia frequen-
cy, bother, and quality of life: how often is too often? A population-
based study in Finland. Eur Urol 2010;57:488–98.
[16] Kupelian V,Wei JT, O’LearyMP, Norgaard JP, Rosen RC, McKinlay JB.
Nocturia and quality of life: results from the Boston Area Commu-
nity Health Survey. Eur Urol 2012;61:78–84.
[17] Harris R, BradburnM, Deeks J, Altman D, Harbord R, Sterne J Metan.
Fixed- and random-effects meta-analysis. Stata J 2008;8:3–28.
[18] Lee AJ, Garraway WM, Simpson RJ, Fisher W, King D. The natural
history of untreated lower urinary tract symptoms in middle-
aged and elderly men over a period of ﬁve years. Eur Urol 1998;
34:325–32.
[19] Temml C, Bro¨ssner C, Schatzl G, Ponholzer A, Knoepp L,
Madersbacher S. The natural history of lower urinary tract symp-
toms over ﬁve years. Eur Urol 2003;43:374–80.
[20] Malmsten UG, Molander U, Peeker R, Irwin DE, Milsom I. Urinary
incontinence, overactive bladder, and other lower urinary tract
symptoms: a longitudinal population-based survey in men aged
45–103 years. Eur Urol 2010;58:149–56.
[21] Bulpitt CJ, Dollery CT, Carne S. Change in symptoms of hypertensive
patients after referral to hospital clicic. Br Heart J 1976;38:121–8.
[22] Møller L, Lose G, Jorgensen T. Incidence and remission rates of lower
urinary tract symptoms at one year in women aged 40–60: longi-
tudinal study. BMJ 2000;320:1429–32.
[23] Johnson 2nd TM, Sattin RW, Parmelee P, Fultz NH, Ouslander JG.
Evaluating potentially modiﬁable risk factors for prevalent and
incident nocturia in older adults. J Am Ger Soc 2005;53:1011.
[24] Ha¨kkinen JT, HakamaM, Shiri R, Auvinen A, Tammela TL, Koskima¨ki
J. Incidence of nocturia in 50- to 80-year-old Finnish men. J Urol
2006;176:2541.
[25] Chen FY, Dai YT, Liu CK, Yu HJ, Liu CY, Chen TH. Perception of
nocturia and medical consulting behavior among community-
dwelling women. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:
431–6.
[26] Viktrup L, Lose G. Incidence and remission of lower urinary tract
symptoms during 12 years after the ﬁrst delivery: a cohort study.
J Urol 2008;180:992–7.
[27] Wennberg A-L, Molander U, Fall M, Edlund C, Peeker R, Milsom I. A
longitudinal population-based survey of urinary incontinence,
overactive bladder, and other lower urinary tract symptoms in
women. Eur Urol 2009;55:783–91.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 3 7 2 – 3 8 1380
[28] Heidler S, Mert C, Temml C, Madersbacher S. The natural history
of the overactive bladder syndrome in females: a long-term
analysis of a health screening project. Neurourol Urodyn 2011;
30:1437–41.
[29] Van Doorn B, Blanker MH, Kok ET, Westers P, Bosch JL. Once
nocturia, always nocturia? Natural history of nocturia in older
men based on frequency-volume charts: the Krimpen study. J Urol
2011;186:1956–61.
[30] Aoki Y, Matsuta Y, Tsuchiyama K, Matsumoto C, Kusaka Y,
Yokoyama O. The association between nocturia and hypertension:
a longitudinal study in Japanese men and women. AUA Annual
Meeting 2012, abstract 290.
[31] Hunter KF, Moore KN, Voaklander D, Hsu ZY. A prospective study of
lower urinary tract symptoms and quality of life older women
receiving home support. ICS Annual Meeting 2012, abstract 192.
[32] Hirayama A, Torimoto K, Mastusita C, et al. Evaluation of factors
inﬂuencing the natural history of nocturia in elderly subjects:
results of the Fujiwara-kyo Study. J Urol 2013;189:980–6.
[33] Araujo AB, Yaggi HK, Yang M, McVary KT, Fang SC, Bliwise D. Sleep
related problems and urological symptoms: testing the hypothesis
of bidirectionality in a longitudinal, population based study. J Urol
2014;191:100–6.
[34] Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of
randomized controlled trials published in high-impact general
medical journals: a systematic sampling review. JAMA 2007;297:
1233–40.
[35] Vaughan CP, Johnson 2nd TM, Haukka J, et al. The ﬂuctuation of
nocturia in men with lower urinary tract symptoms allocated to
placebo during a 12-month randomized, controlled trial. J Urol
2013;191:1040–4.
[36] Drake MJ. Should nocturia not be called a lower urinary tract
symptom? Eur Urol 2015;67:289–90.
[37] Zhang L, Zhu L, Xu T, et al. A population-based survey of the
prevalence, potential risk factors, and symptom-speciﬁc bother
of lower urinary tract symptoms in adult Chinese women. Eur Urol
2015;68:97–112.
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 3 7 2 – 3 8 1 381
 PUBLICATION 
II 
The impact of nocturia on mortality: a systematic review and meta-analysis 
Pesonen JS, Cartwright R, Vernooij RWM, Aoki Y, Agarwal A, Mangera A, 
Markland AD, Tsui JF, Santti H, Griebling TL, Pryalukhin AE, Riikonen J, 
Tähtinen RM, Vaughan CP, Johnson TM 2nd, Auvinen A, Heels-Ansdell D, Guyatt 
GH, Tikkinen KAO 
J Urol 2019 (https://doi.org/10.1097/JU.0000000000000463) [Epub ahead of print]. 
Publication reprinted with the permission of the copyright holders. 
 
  
  
 
 
 
 
 
The Journal of Urology Publish Ahead of Print
DOI: 10.1097/JU.0000000000000463 
 
The Impact of Nocturia on Mortality: A Systematic Review and Meta-Analysis 
 
Jori S. Pesonena,b, Rufus Cartwrightc,d, Robin W.M. Vernooije, Yoshitaka Aokif, Arnav 
Agarwalg, Altaf Mangerah, Alayne D. Marklandi,j, Johnson F. Tsuik, Henrikki Santtil, 
Tomas L. Grieblingm, Alexey E. Pryalukhinn,o, Jarno Riikonenb, Riikka M. Tähtinenp, 
Camille P. Vaughanj,q, Theodore M. Johnson 2nd j,q, Anssi Auvinenr, Diane Heels-
Ansdells, Gordon H. Guyatts,t, Kari A.O. Tikkinenl,u* 
 
For affiliations see end of article. 
 
* Corresponding author: Departments of Urology and Public Health, University of 
Helsinki and Helsinki University Hospital, Haartmaninkatu 4, Helsinki 00029, Finland. 
Tel. +358-50-5250971. E-mail address: kari.tikkinen@gmail.com (Kari A.O. Tikkinen). 
 
 
Running head: Nocturia and mortality 
 
 
No. of figures and tables: 4 figures, 2 tables and a supplementary document 
Word count: 3439 words (including abstract of 243 words)  
 
 
 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 2 
ABSTRACT  
Purpose: Nocturia (waking from sleep at night to void) is a common cause of sleep 
disruption and associated with increased comorbidity and impaired quality of life. 
However, its impact on mortality remains unclear. We performed a systematic review 
and meta-analysis to evaluate the association of nocturia with mortality, both as a 
prognostic and causal risk factor. 
Materials and Methods: We searched PubMed, Scopus, CINAHL and major 
conference abstracts up to December 31, 2018. Random effects meta-analyses addressed 
adjusted relative risks (RR) of mortality for people with nocturia and a meta-regression 
explored potential determinants of heterogeneity, including risk of bias. We applied the 
GRADE framework to rate the quality of evidence for nocturia as a prognostic risk 
factor for mortality and, separately, as a cause of mortality. 
Results: Of 5230 identified reports, 11 observational studies proved eligible. For the 
assessment of nocturia, ten studies used symptom questionnaires and one frequency-
volume charts. Nocturia was defined as 2 episodes/night in six (55%), and as 3 
episodes/night in five (45%) studies. Pooled estimates demonstrated a risk ratio of 1.27 
(95% confidence interval 1.16-1.40; I2=48%; absolute 5-year mortality difference 1.6% 
and 4.0% in people aged 60 and 75 years, respectively). The pooled estimates of relative 
risk did not differ significantly across varying age, gender, follow-up time, nocturia case 
definition, risk of bias, or study region. We rated the quality of evidence for nocturia as 
a prognostic factor as moderate and as a cause of mortality as very low. 
Conclusions: Nocturia is probably associated with an approximately 1.3-fold increased 
risk of death.  
 
Keywords: epidemiology; meta-analysis; mortality; nocturia; systematic review 
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INTRODUCTION 
Nocturia (waking from sleep at night to void) is one of the most common and 
bothersome lower urinary tract symptoms (LUTS) [1,2]. The incidence of nocturia 
increases markedly with age in both women and men [3]. Besides being a common 
cause of sleep disruption and impaired quality of life, nocturia is associated with 
comorbidities such as diabetes, cardiovascular diseases, chronic respiratory diseases, 
neurological diseases and malignancies [4-6]. An accompanying meta-analysis 
demonstrates that nocturia is associated with a 1.2-fold risk of falls and 1.3-fold risk of 
fractures [7]. Suggesting a number of possible causal pathways, some authors have 
postulated that nocturia may increase the risk of death [8]. 
 
As people with nocturia tend to be older and are more likely to have comorbid 
conditions, the relevance of using nocturia as a mortality risk factor must consider the 
effect of various confounders of the association between nocturia and mortality (i.e. we 
would not want to attribute to nocturia an association with death that can be completely 
explained by older age). To optimally assess the impact of nocturia on mortality, one 
must also take into account fluctuation of nocturia, as well as follow-up time (time 
interval after initial assessment) [3]. Furthermore, investigators should use a validated 
nocturia assessment method, and to further minimize the risk of bias, reliably register all 
deaths during follow-up.  
 
The primary aim of our systematic review and meta-analysis is to clarify the association 
with, and the possible impact of nocturia on mortality, addressing possible effect 
modification by age, gender, follow-up time, varying nocturia definitions, and different 
sources of bias on the relative measures of association (i.e. possible variation in the 
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extent of association by age, gender, and other factors). We therefore tested the relation 
of nocturia with mortality, both as a prognostic risk factor and causal agent. 
 
MATERIALS AND METHODS 
We registered the review protocol (PROSPERO: CRD42016051132), and followed the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidance [9].  
 
Data sources and searches 
We searched the databases of PubMed (from 1946), Scopus (from 1995), and 
Cumulative Index of Nursing and Allied Health Literature (CINAHL) (from 1960) up to 
December 31, 2018. Additionally, we searched the conference proceedings of the 
American Urological Association (AUA), European Association of Urology (EAU), 
International Continence Society (ICS), and International Urogynecological Association 
(IUGA) annual conferences from 2005 to 2018 for any ongoing or unpublished studies. 
We did not apply any restrictions to language or publication status. Finally, we hand-
searched the reference lists of the included articles. Supplementary Appendix 1 provides 
the search strategy. 
 
Eligibility criteria 
We included longitudinal studies with a follow-up (study duration) of at least three 
months with at least 95% of the participants being adults (aged 18 years), assessing 
nocturia at baseline and reporting death during follow-up (after an initial assessment). 
We excluded studies that evaluated the effect of any intervention, including cohorts of 
untreated control arms.  
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Study selection and data extraction 
We employed standardized, pilot-tested forms with detailed instructions for screening of 
abstracts and full texts, risk of bias assessments, and data extraction. Pairs of two 
reviewers independently screened study reports for eligibility, assessed risk of bias of 
eligible studies, and abstracted data. The reviewers resolved disagreements through 
discussion and, if necessary, consulted clinician-methodologist adjudicators. When more 
than one report provided data of the same study, we extracted relevant data from all 
reports after excluding overlap. We recorded the country/source of the study sample, age 
and sex distribution, exclusion criteria, assessment tools used for nocturia, follow-up 
time, sample size, exclusion criteria and response rate, and adjustment variables (for the 
mortality effect estimates). We contacted the authors of primary studies for confirmation 
and clarification of our data extraction. 
 
Assessment of the quality of evidence and risk of bias 
According to the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) framework, for assessments of prognosis, a body of observational 
studies begins as high-quality evidence. Several categories of limitations may, however, 
reduce evidence quality, including risk of bias, imprecision, inconsistency and 
indirectness [10]. In contrast, in the GRADE approach for studies of interventions, a 
body of observational studies begins as ‘low-quality’ evidence, and may be rated down 
to ‘very low’ by the same limitations as in intervention studies, but may also be rated up 
by factors such as a large effect size or a dose-response gradient [11]. Therefore, in this 
review, which includes only observational studies, the evidence can provide trustworthy 
inferences about prognosis (i.e. is nocturia associated with mortality) but not causation 
(i.e. does nocturia cause an increase in deaths). To formally compare the certainty of the 
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pooled estimates for nocturia both as a prognostic factor (synonymous with risk factor) 
and as a cause of mortality, we assessed the quality of evidence with the GRADE 
framework for both prognostic and intervention research [10,11].  
 
The methods for risk of bias evaluation for longitudinal cohort studies are less 
developed than the methods for randomised controlled trials [12]. Through discussion 
and consensus building, and taking previous literature into account [3, 13-15], we 
developed an instrument to categorise studies as either low or high risk of bias 
(Supplementary Appendix 2). This includes the features of the included studies that 
could potentially bias the estimates: representativeness of the sample to the general 
population, confidence in the assessments of nocturia and mortality, proportion of 
missing data and adjustments for important potential confounders/risk factors of 
mortality.  
 
Data analysis, including statistical analysis 
To calculate the pooled estimates for relative measures of association of nocturia with 
mortality, we extracted hazard ratios (HR), or alternatively relative risks (RR) to be used 
interchangeably with HRs. To minimize confounding, from the reported regression 
models we selected those with maximum adjustments. If a study reported only an odds 
ratio (OR) instead of HR or RR we, acknowledging the high prevalence of nocturia, 
converted the OR into RR using the following formula:  
 RR = OR / (1 – p + (p x OR)) 
in which p represents the baseline risk i.e. the risk of death in people without nocturia at 
the baseline [16]. We calculated the pooled RRs using the DerSimonian–Laird random 
effects inverse variance method. When raw data were available, to take account of the 
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effect of potential confounders including age and comorbidities, we derived adjusted 
RRs from multivariable logistic regression models.  
 
To address the effect of age and the natural history of nocturia on the relative measures 
of association, we stratified the analyses by three age groups (18-49 yr, 50-69 yr and 70 
yr).  We adjusted for gender, follow-up time (<10 vs. 10 yr), risk of bias and study 
region and examined these variables as possible effect modifiers using chi-square tests. 
We stratified estimates by nocturia status in terms of a binary variable (case definitions 
of 2 vs. 0-1; and 3 vs. 0-2 voids/night) and a three-value categorical variable (2 vs. 0-
1 and 3 vs. 0-1 voids/night), using the latter to explore exposure-response relationship 
of nocturia with mortality. 
 
We complemented our subgroup analyses using chi-square tests with meta-regression 
analysis weighted by the inverse of the variance in a random effects model employing 
pre-specified hypotheses. We examined the following variables as potential sources of 
heterogeneity: (1) gender, (2) age, (3) length of follow-up, (4) nocturia case definition, 
and (5) risk of bias.  We pre-specified hypotheses that the effect of nocturia on mortality 
would be higher for: (1) male vs. female or mixed gender, (2) younger age (<70 vs. 70 
yr), (3) shorter follow-up time (<10 vs. 10 yr), (4) higher nocturia case definition (3 
vs. 2 voids/night), and (5) high vs. low risk of bias. We set a threshold of p value less 
than 0.05 as a minimum criterion for a credible subgroup effect. 
 
We report the association of nocturia with mortality in terms of both relative and 
absolute estimates, presenting five-year absolute risks of death among men and women 
aged 60 years and older — an age group commonly affected by nocturia [3]. When 
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calculating the baseline risks, we first estimated the average five-year death rates from 
the reported annual death rates for people aged 55-64 and 75-84 yr in the USA for 2016 
[17]. Then, for the average estimates on the prevalence of nocturia of two or more voids 
per night [18] in desired age groups, we extracted the reported prevalences from studies 
included in a previous comprehensive systematic review [19] (Supplementary Appendix 
3), calculated the 95% confidence intervals (CI) for natural logarithms of prevalences 
per 100 people and pooled the estimates in random-effects meta-analysis 
(Supplementary Fig. 1). Finally, to derive the baseline risks in the absence and presence 
of nocturia, we divided the average death rates in proportions based on the prevalence of 
nocturia and pooled relative risks for the desired age groups. Statistical analyses were 
performed using metan and metareg in Stata 12.1 (StataCorp, College Station, TX, 
USA) [20]. 
 
 
RESULTS 
Literature search and study characteristics 
We screened 5 230 abstracts and retrieved 132 potentially eligible full text reports and 
22 conference abstracts (Fig. 1). Ten original full text articles and one conference 
abstract provided data on nocturia-associated death, including 19 590 men and 14 241 
women with a total follow-up of 297 379 person-years (Table 1) [21-32]. Five (45%) of 
the 11 authors confirmed the accuracy of our data extraction [22,25,27,29,31]; two 
(18%) corrected some errors or provided additional information [26,32] and four (36%) 
were unable respond to our requests for data checks and clarifications [21,23,28,30]. 
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Studies were conducted on three continents, in male and mixed gender populations that 
varied widely in their age distributions and follow-up times (Table 1). Nocturia was 
defined as 2 episodes per night in six (55%), and as 3 episodes per night in five (45%) 
studies. Reflecting the differences in study populations, as well as variations in symptom 
assessment methods, the baseline prevalence of nocturia in the study populations varied 
widely, with ranges of 8-34% based on a case definition of 2 (vs. 0-1 voids/night) and 
2.5-35% with a case definition of 3 (vs. 0-2 voids/night) in adults aged <70 yr; in 
adults aged 70 yr, the range was 35-49% in the broader case definition and 8-38% in 
the more restrictive (Supplementary Table 1). 
 
Risk of bias 
To identify eligible individuals, two studies used electoral rolls [22,27], two household 
registries [23,26] and three civil registries [25,29,32]. One study used a combination of 
hospital and primary care registries [28], one recruited patients from a hospital’s 
diabetes clinic [30] and one used primary care registries for White and zip code lists for 
Black participants [31]. We considered the cohorts of seven studies to adequately 
represent general populations with a satisfactory participation rate [21-23,26-28,32] 
(Fig. 2, Table 1). For assessment of nocturia at baseline, ten studies used symptom 
questionnaires and one used frequency-volume charts. We considered eight studies 
(73%) to have assessed nocturia accurately [25-32] (Fig. 2, Table 1). Five studies (45%) 
collected mortality data from a national death registry, and five (45%) used linkage to 
registries of different health care institutions. We considered that ten studies (91%) 
assessed mortality accurately through registry data [21-23,25-30,32]. Eight studies 
(73%) had little missing data [22,25-29,31,32]. Six studies (55%) adequately performed 
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
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adjustments for their estimates [22,25,26,29,31,32] (Fig. 2, Table 1, Supplementary 
Table 1).   
 
Impact of nocturia on mortality 
The pooled relative risk of death in 11 studies (2 low and 9 high risk of bias) proved 
higher in people with nocturia compared to those without nocturia (RR 1.27; 95% CI 
1.16-1.40; heterogeneity: I2=48.3%; moderate quality evidence for prognosis and very 
low quality evidence for causality) (Fig. 3, Table 2).  
 
In subgroup meta-analyses, the pooled estimates for association between nocturia and 
mortality did not differ significantly for samples stratified by age, gender, follow-up 
time, nocturia case definition, risk of bias, or study region (Supplementary Tables 1-3). 
This was also true for the multivariable-adjusted meta-regression analyses 
(Supplementary Table 4).   
 
Based on the mean death rates in the USA among people aged 60 and 75 yr with 
respective age-specific prevalences of nocturia (2 episodes per night) of approximately 
20% and 40% (Supplementary Fig. 1), the nocturia-associated increase in the overall 
five-year absolute death risk were 1.6% and 4.0% among people aged 60 and 75 yr, 
respectively (Fig. 4, Supplementary Fig. 2). 
 
The quality of evidence 
We identified 11 studies: 2 low and 9 high risk of bias (Figure 2). We rated down the 
quality due to the high risk of bias (to which the majority of the included studies were 
susceptible). We therefore rated the quality of evidence (certainty in estimates) as 
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moderate for nocturia as a prognostic risk factor for mortality, and as very low quality 
for nocturia as a causal factor for mortality (Table 2). 
 
DISCUSSION 
This meta-analysis showed a 27% increase in relative risk of death in people with 
nocturia (defined as either 2 or 3 episodes/night) compared to those without nocturia 
after adjustment for age, gender and various comorbidities. This correspondents with 
nocturia-associated increase in the overall five-year absolute death risk by 1.6% among 
aged 60 yr and 4.0% among aged 75 yr. The magnitude of the association did not differ 
across a number of predictor variables. Our finding is of moderate-quality evidence for 
nocturia as prognostic factor of increased risk of death but only very low-quality 
evidence for nocturia as a cause of mortality.  
 
Strengths and limitations 
The strengths of this review include a comprehensive search of both published and 
unpublished studies without language restrictions; duplicate assessment of eligibility, 
risk of bias, and data extraction; checking of data accuracy with the authors of the 
original studies; and appraisal of the quality of evidence using the GRADE approach for 
inferences regarding nocturia both as a prognostic factor and as a causal factor for 
mortality. Besides the novel approaches in establishing the best available evidence on 
the topic, to our knowledge, our study is the first to provide absolute effects in addition 
to relative estimates on the association between nocturia and mortality (for this purpose, 
we also meta-analyzed the prevalence of nocturia; this information is likely of interest 
itself, see Supplementary Figure 3). 
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The limitations of our review are largely those of the eligible studies. No study was free 
of risk of bias and limitations related to non-representativeness of source populations, 
inaccuracy in assessments of nocturia or mortality, missing data or inadequately adjusted 
analyses were common (Figure 2). Second, although the analyses showed no effect for 
nocturia case definition, only three studies provided estimates for nocturia as a discrete 
variable with multiple values (number of voids). Third, only one study [26], provided 
data on the association between nocturia and mortality specifically for women. Fourth, 
none of the studies addressed causes of death; and we were therefore unable to assess 
mortality from specific causes. Fifth, no detailed data from bladder diaries were 
available, and we were therefore unable to differentiate the effects of nocturia on 
mortality when appearing as an isolated symptom or accompanied by other LUTS, or if 
nocturia was due to global/nocturnal polyuria, reduced bladder capacity or mixed 
etiology [1]. Sixth, there was paucity of studies assessing sleep disorders as potential 
comorbid conditions with nocturia, and thus, we were unable to differentiate between 
the roles of insomnia symptoms as potential confounders vs. mediators for mortality 
(nocturia caused by primary insomnia vs. insomnia secondary to nocturia) [33]. Given 
that, especially among the older people, nocturia is one of the leading causes of sleep 
disruption, which has further been shown to prognosticate mortality, analyses to test 
effect modification by sleep disorders would be highly relevant [34-36]. Accordingly, in 
the two available studies exploring the role of sleep disruption as one of the potential 
mediators between nocturia and mortality, both conducted in Western male populations 
and the other excluded from our review for being an interventional study (a randomized 
trial of dutasteride for prostate cancer chemoprevention), the association between 
nocturia and mortality turned non-significant after controlling the estimates for sleep 
disorders and other comorbidities [31,36]. Seventh, none of the studies utilized more 
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sophisticated analytical techniques, such as structural equation modeling, to identify 
potential causal pathways between nocturia and mortality [37]. Eighth, although the 
meta-regression analysis failed to show an influence of duration of follow-up, lack of 
repeated assessments during the follow-up and, therefore, failure to take into account the 
effect of incident and remittent nocturia on the estimates limits that analysis. Finally, 
results provide only very low-quality evidence regarding nocturia as a cause of the 
increased death rate associated with the exposure. 
 
Relation to prior work  
Only one earlier systematic review with meta-analysis has been published examining the 
impact of nocturia on mortality [38]. This systematic review published in 2015, reported 
a pooled HR of 1.23 (1.07-1.42), comparable to our best estimate. The review included 
seven studies, all included in our review [18,19,22,23,24-26], but failed to include four 
studies that proved eligible in our systematic review: one full text article [30] and one 
conference abstract [23] that were reported before the publication of their review and 
apparently met their eligibility criteria, and two studies that were published after their 
review appeared [31,32]. In their subgroup analyses (no adjustments used or meta-
regression performed), shorter follow-up time (<10 yr vs. >10 yr), larger sample size 
(>5000 vs. <5000 people) and more restrictive nocturia case definition (3 vs. 2 voids 
per night) predicted mortality. With comprehensive adjustments and inclusion of four 
additional studies [23,30,31,32], none of these subgroup effects remained significant in 
our meta-analysis. To rate the risk of bias, the authors reported that they used or planned 
to use an instrument designed for observational studies [39]; they did not, however, 
present the results. The review also lacked any assessment of nocturia-associated 
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absolute effects on mortality and included no assessment of quality of evidence for 
prognosis or causation.  
 
Implications of findings 
Clinicians and patients should be aware that nocturia occurring at least twice per night 
may be a marker of ill health. Although urological treatments have potential to improve 
quality of life of patients with nocturia, clinicians should focus not only on treating the 
symptom, but also exploring patients’ general health taking into account the relevant 
risk factors for each individual [40,41]. The association between nocturia and mortality 
likely reflects chronic illness as a cause of both nocturia and mortality. For instance, it is 
not difficult to imagine how diabetes could cause both nocturia and premature death.  It 
is less likely, but still possible, that nocturia is in the causal pathway leading to 
premature death. For instance, impaired sleep as a result of nocturia could impair 
physiological night-time blood pressure dipping, increase sympathetic activity [42], and 
thus increase cardiovascular deaths. In addition, fractures and other injuries may result 
from falls or other accidents related to frequent night-time toileting and daytime fatigue 
[7], and complications of these events could result in premature death. Indeed, the 
companion review to this article documents an association between nocturia and falls 
and fractures. These causal pathways are, however, speculative, and we have concluded 
that there is only very low-quality evidence supporting nocturia as a causal factor in 
premature death [7].   
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CONCLUSIONS 
Moderate-quality evidence suggests that nocturia (defined as either 2 or 3 
episodes/night) is associated with a 1.3-fold increased risk of death. Future 
investigations should address the impact of treatment for nocturia on mortality. 
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Figure (and supplementary material) legends 
Table 1. Characteristics of the original studies included in analyses. 
Table 2. Evidence profile: nocturia as a prognostic factor for mortality versus as a cause 
of mortality. 
Figure 1. Study flow chart. 
Figure 2. Risk of bias of the included studies. 
Figure 3. A forest plot of the relative risks of death in people with nocturia. 
Figure 4. Relative and absolute risk of death in five years between people with and 
without nocturia. 
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 22 
ABSTRACT  23 
Purpose: Although nocturia is associated with various comorbidities, its impact on 24 
falls and fractures remains unclear. We performed a systematic review and meta-25 
analysis to evaluate the association between nocturia with falls and fractures, both as a 26 
prognostic and causal risk factor. 27 
Materials and Methods: We searched PubMed, Scopus and CINAHL and abstracts 28 
of major urologic meetings up to December 31, 2018. We conducted random effects 29 
meta-analyses of adjusted relative risks (RR) of falls and fractures. We applied the 30 
GRADE approach to rate the quality of evidence for nocturia as a prognostic and 31 
causal factor of falls and fractures. 32 
Results: Of 5230 potential reports, nine observational longitudinal studies provided 33 
data on the association between nocturia and falls or fractures (1 for both, 4 for falls, 4 34 
for fractures). Pooled estimates demonstrated a risk ratio of 1.20 (95% confidence 35 
interval 1.05-1.37; I2=51.7%; annual risk difference 7.5% among the elderly) for 36 
association between nocturia and falls and 1.32 (95% confidence interval 0.99-1.76; 37 
I2=57.5%; annual risk difference 1.2%) for association between nocturia and 38 
fractures. Subgroup analyses showed no significant effect modification by age, 39 
gender, follow-up time, nocturia case definition or risk of bias. We rated the quality of 40 
evidence for nocturia as a prognostic factor as moderate for falls and low for fractures, 41 
and as very low as a cause of falls/fractures.  42 
Conclusions: Nocturia is probably associated with an approximately 1.2-fold 43 
increased risk of falls and possibly with an approximately 1.3-fold increased risk of 44 
fractures.  45 
 46 
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INTRODUCTION 47 
Falls and fractures are common, associated with substantial healthcare costs, and are a 48 
major reason for long-term functional impairment [1,2]. Older adults are at an 49 
increased risk of falling due to the age-related deterioration in balance and gait, which 50 
is worsened by illness and medications [3]. Over 30% of people aged over 65 years 51 
and living at home fall at least once per year [3,4]. Although only a minority of falls 52 
lead to fractures [4], injuries due to falls are common and, among older adults, are 53 
associated with a high risk of institutionalisation [2]. Developing multifactorial fall 54 
prevention programs therefore represents a major focus in geriatric research [5].  55 
 56 
Nocturia is one of the most common and bothersome lower urinary tract symptoms 57 
(LUTS) [6,7], and according to an accompanying meta-analysis [8] (parallel 58 
submission to The Journal of Urology), associated with an approximately 30% 59 
increase in the risk of death. Nocturia is strongly associated with advanced age [9,10]. 60 
Approximately one in four adults in their sixties and half of adults in their eighties 61 
void two times per night [9] – a level that typically causes bother and is associated 62 
with impaired quality of life [11]. The etiology of nocturia is multifactorial, including 63 
age-related changes in the lower urinary tract, as well as alterations in renal function 64 
and sleep quality due to various medical conditions and lifestyle factors [12,13].  65 
 66 
The relationship between nocturia and falls and fractures is complex as they are each 67 
associated with multiple comorbidities that could confound or mediate associations. 68 
Common factors associated with both nocturia and falls include older age, diabetes, 69 
cardiovascular diseases, depression and physical inactivity [12-14]. Some risk factors, 70 
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such as obesity, may however, increase nocturia but decrease fractures (e.g. obesity) 71 
[15,16]. 72 
 73 
Cross-sectional studies have consistently found an association of nocturia with falls 74 
[17,18] but less consistently an association with fractures [17,19]. However, in cross-75 
sectional studies one can never be sure of the temporal relation between exposure and 76 
outcome. We therefore undertook a systematic review of longitudinal studies to 77 
explore the impact of nocturia on the risk of falls and fractures in a general 78 
population. 79 
 80 
MATERIALS AND METHODS 81 
We registered the review protocol (PROSPERO CRD42016051525), and followed the 82 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 83 
guidance [20].  84 
 85 
Data sources and searches 86 
We searched the databases of PubMed (from 1946 to present), Scopus (from 1995 to 87 
present), and Cumulative Index of Nursing and Allied Health Literature (CINAHL) 88 
(from 1960 to present) up to December 31, 2018 (Supplementary Appendix 1), and 89 
annual conference abstracts of the American Urological Association (AUA), the 90 
European Association of Urology (EAU), the International Continence Society (ICS), 91 
and the International Urogynecological Association (IUGA) from 2005 to 2018 for 92 
any ongoing or unpublished studies. We did not apply restrictions to language or 93 
publication status. We hand-searched the reference lists of the included articles.  94 
 95 
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Eligibility criteria 96 
We included longitudinal studies with a follow-up of at least three months, with at 97 
least 95% of the participants aged 18 years. We included studies assessing nocturia 98 
at baseline and reporting falls or fractures at a later follow-up time. We excluded 99 
studies that evaluated the effect of any intervention, including cohorts of untreated 100 
control arms.  101 
 102 
Study selection and data extraction 103 
Pairs of reviewers, independently and in duplicate, screened the references for 104 
eligibility, assessed risk of bias using a pilot-tested standardized form, and extracted 105 
data from eligible studies. Reviewers resolved disagreements through discussion and, 106 
if necessary, consulted a clinician-methodologist adjudicator. When more than one 107 
report provided data from the same study, we extracted data from all reports after 108 
excluding overlap. We recorded the country/source of the study sample, age and sex 109 
distribution, exclusion criteria of the cohorts, assessment tools used for nocturia, 110 
follow-up time, sample size including response rate, and variables used to adjust for 111 
falls/fractures in the presence/absence of nocturia. We contacted the authors of 112 
primary studies for confirmation and clarification of our data extraction. 113 
 114 
Risk of bias and quality of evidence assessment 115 
The methods for risk of bias evaluation for longitudinal cohort studies are less well 116 
developed than the methods for randomised controlled trials [21]. Taking the previous 117 
literature into account [22-24], through discussion and consensus building, we 118 
developed an instrument to categorise studies as either low or high risk of bias. This 119 
includes the features of the included studies that could potentially bias the estimates: 120 
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the comparability of source populations, confidence in the assessment of nocturia and 121 
falls/fractures, proportion of missing data, and adjustments for important potential 122 
confounders/risk factors for falls and fractures. The overall risk of bias was 123 
categorised low if the study met criteria for low risk of bias in each of the five 124 
domains of the assessment (Supplementary Appendix 2).  125 
 126 
The Grading of Recommendations, Assessment, Development and Evaluation 127 
(GRADE) approach includes separate criteria for rating the quality of evidence 128 
regarding a prognostic issue (is there a true association) versus a causal issue (is an 129 
exposure causally related to an outcome). With respect to prognosis, GRADE 130 
stipulates that observational studies can often provide trustworthy inferences (i.e. is 131 
nocturia associated with falls/fractures) and thus in GRADE rating begin as high-132 
quality evidence. Observational studies, according to GRADE, seldom provide 133 
trustworthy evidence regarding causation (i.e. does nocturia cause falls/fractures) and 134 
therefore, for causation, observational studies begin as low-quality evidence. To 135 
highlight this key distinction, we evaluated the quality of evidence for nocturia both 136 
as a prognostic factor (synonymous with risk factor) and as a cause of falls/fractures 137 
[21,25,26]. More information on the rationale is available in the accompanying 138 
systematic review [8].  139 
 140 
Data analysis, including statistical analysis 141 
To calculate the pooled estimates for relative measures of association of nocturia with 142 
falls and fractures, we extracted relative risks (RR), or alternatively hazard ratios 143 
(HR) to use interchangeably with RRs. From the reported regression models, we 144 
selected the estimates with the highest level of adjustments to minimize the effect of 145 
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confounding. If a study reported only an odds ratio (OR) instead of HR or RR we 146 
converted the OR into RR using the following formula:  147 
 RR = OR / (1 – p + (p x OR)) 148 
in which p represents the baseline risk i.e. the fall/fracture risk in individuals without 149 
nocturia at the baseline [27]. We calculated the pooled RRs by using the 150 
DerSimonian–Laird random effects inverse variance method. For studies providing 151 
access to the raw data, we derived new adjusted RRs from multivariable logistic 152 
regression models to take account of the effect of potential confounders.  153 
 154 
To explore the association of nocturia with falls and fractures in subgroups, we 155 
stratified the estimates by age, gender, follow-up time and risk of bias. The estimates 156 
were stratified by nocturia status as a binary variable (case definitions of 2 vs. 0-1 157 
and 3 vs. 0-2 voids/night) and a three-value categorical variable (2-3 vs. 0-1 and 4 158 
vs. 0-1 voids/night), using the latter to explore exposure-response relationship of 159 
nocturia with falls and fractures. Additional subgroup-analyses with similar 160 
stratifications were conducted for studies reporting recurrent falls as an outcome. 161 
 162 
As optimal decision-making requires estimates of both relative and absolute effects, 163 
we illustrated the difference in the absolute annual risk of falls and fall-related 164 
fractures between individuals with and without nocturia. To assess the average risks 165 
of falls and fractures in the general elderly population, the annual number people with 166 
1 falls/year and the proportion of those who fell and sustained a fracture were 167 
extracted from prospective Western population-based studies included in a previous 168 
systematic review [4] (Supplementary Appendix 3). After calculating the 95% 169 
confidence intervals for natural logarithms of incidence rates of fallers per 100 170 
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person-years and proportions of individuals with a fall-related fracture per 100 fallers, 171 
the estimates were pooled in random-effects meta-analyses (Supplementary Figs. 1 172 
and 2). To stratify the pooled estimates of average annual fall and fall-related fracture 173 
rates by age, coefficients from another systematic review, assessing various risk 174 
factors for falls, were utilized [3]. For estimating the prevalence of patient-important 175 
nocturia (defined as two or more voids per night) [11] in relevant age groups, we i) 176 
extracted the reported prevalences from studies included in a previous systematic 177 
review [9] (Supplementary Appendix 4), ii) calculated the 95% confidence intervals 178 
(CI) for natural logarithms of prevalence per 100 people, and iii) pooled the estimates 179 
in random-effects meta-analysis (Supplementary Fig. 3). Finally, to derive the 180 
baseline risks in the absence and presence of nocturia, we divided the average annual 181 
fall and fracture rates in proportions based on the prevalence of nocturia and pooled 182 
relative risks for the desired age groups. Statistical analyses were performed using 183 
metan and metareg in Stata 12.1 (StataCorp, College Station, TX, USA) [28]. 184 
 185 
RESULTS 186 
Literature search and study characteristics 187 
We screened 5 230 abstracts and retrieved 132 potentially eligible full text articles and 188 
22 conference abstracts (Fig. 1). Five studies provided data on the association 189 
between nocturia and falls [29-35] and five on nocturia and fractures [29,30,36-39] 190 
(Table 1). Of the five studies assessing falls, three of the five authors confirmed the 191 
accuracy of our consensus data extraction [32-34], one provided additional 192 
information [31] and one was unable to assist with our requests [29]. Of the five 193 
studies assessing fractures, three of the five authors confirmed the accuracy of our 194 
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consensus data extraction [36-38], one provided additional information [39] and one 195 
was unable to assist with our requests [29]. 196 
 197 
Of the five studies assessing falls, three were conducted in North America, one in 198 
Europe and one in Australia. Of the five studies assessing fractures, two were 199 
conducted in North America, two in Europe and one in Eastern Asia. Studies included 200 
mainly older people in their seventies and predominantly men, with follow-up times 201 
varying from one to six years for studies of falls and four to nine years for studies of 202 
fractures (Table 1). Two studies were conducted in the same base population of older 203 
men with separate reports on falls and non-spine fractures with varying follow-up 204 
times [31,39]. We identified one conference abstract [29], which reported only death 205 
as an endpoint (was included in the accompanying meta-analysis [8]) but access to the 206 
study raw data provided assessments also for both falls and fractures [30] 207 
(Supplementary Fig. 4). We were therefore able to include five studies in the meta-208 
analysis of falls with a total follow-up of 23 678 person-years and five studies in the 209 
meta-analysis of fractures with a total follow-up of 87 973 person-years. 210 
 211 
Risk of bias 212 
Of the five studies assessing falls, three used representative source populations [32-213 
34], three conducted the baseline assessments of nocturia and follow-up assessments 214 
of falls accurately, three had little missing data at the follow-up [32,33,35], and three 215 
adequately adjusted their estimates for important prognostic risk factors for falls [31-216 
33]. We judged three studies (assessing impact on falls) to be at overall high risk of 217 
bias (Fig. 2, Table 1, Supplementary Table 1).  218 
 219 
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Of the five studies assessing fractures, three used representative source populations 220 
[31,37,39], three assessed nocturia accurately [36,38,39], four assessed fractures 221 
accurately [36-39], three had little missing data at the follow-up [37-39], and two 222 
adequately adjusted their estimates for important prognostic risk factors for fractures 223 
[31,39]. We therefore considered four studies (assessing impact on factures) to be at 224 
overall high risk of bias (Fig. 2, Table 1, Supplementary Table 1). 225 
 226 
Impact of nocturia on falls 227 
In the meta-analysis of estimates adjusted at least for age and gender (5 studies: 2 low 228 
and 3 high risk of bias), the pooled relative risk of falling at least once in the follow-229 
up was higher in people with nocturia compared to those without nocturia at baseline 230 
(RR 1.20; 95% CI 1.05-1.37; heterogeneity: I2=52%; moderate quality evidence for 231 
prognosis and very low quality for causality) (Fig. 3, Table 2). In the subgroup 232 
analyses, the estimates did not differ by age, gender, follow-up time, nocturia case 233 
definition, or risk of bias (Supplementary Tables 1 and 2).  234 
 235 
In the additional analysis of studies reporting recurrent falls as an outcome (3 studies: 236 
1 low and 2 high risk of bias), the pooled, adjusted relative risk was 38% higher in 237 
people with nocturia at the baseline (RR 1.38; 95% CI 1.11-1.71; I2=54.7%). The 238 
estimates were available only for men and did not differ by age, follow-up time, 239 
nocturia case definition, or risk of bias (Supplementary Tables 1 and 3). 240 
 241 
The absolute risk of falling at least once a year was 5.5% higher among people aged 242 
65 yr with nocturia (defined as 2 voids/night) compared to people without (defined 243 
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as 0-1 voids/night), and 7.5% higher in people aged 80 yr with nocturia compared to 244 
people without (Fig. 5, Supplementary Fig. 5).  245 
 246 
Impact of nocturia on fractures 247 
In the meta-analysis of estimates adjusted for at least age and gender (5 studies: 1 low 248 
and 4 high risk of bias), the pooled relative risk of having a fracture at follow-up was 249 
32% higher in people with nocturia compared to those without nocturia at baseline 250 
(RR 1.32; 95% CI 0.99-1.76; heterogeneity: I2=57.5%; low quality evidence for 251 
prognosis and very low quality for causality) (Fig. 4, Table 2). In subgroup analyses, 252 
the estimates did not differ significantly by age, gender, follow-up time, nocturia case 253 
definition or risk of bias (Supplementary Tables 1 and 4).  254 
 255 
Regarding assessments on the association between nocturia and different types of 256 
fractures, only one estimate was available for each specific association with RRs of 257 
1.36 (95% CI 1.03-1.79) for hip fractures in men [36], 1.00 (95% CI 0.90-1.20) for 258 
non-spine fractures in men [39], 1.37 (95% CI 0.19-9.86) for osteoporotic fractures in 259 
men [37] and 2.20 (95% CI 1.04-4.68) for specifically fall-related fractures in a mixed 260 
gender population [38], respectively (Supplementary Table 1). 261 
 262 
The absolute annual risk of fractures was 0.9% higher in people with nocturia 263 
compared to people without among people aged 65 yr (Fig. 5). The absolute 264 
difference in annual fracture risk among people aged 80 yr was 1.2% between people 265 
with and without nocturia. (Fig. 5, Supplementary Fig. 5). 266 
 267 
 268 
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The quality of evidence 269 
Of the five studies assessing falls, three were high and two low risk of bias (Fig. 2). 270 
We rated down due to high risk of bias (to which the majority of the included studies 271 
were susceptible). We therefore rated the quality of evidence as moderate for nocturia 272 
as a prognostic risk factor and as very low quality for nocturia as a causal factor for 273 
falls (Table 2). Of the five studies assessing fractures, four were high and one low risk 274 
of bias. We therefore rated down for risk of bias. We also rated down for imprecision 275 
(confidence interval crossed no effect). We therefore rated the quality of evidence as 276 
low for nocturia as a prognostic risk factor for fractures, and as very low quality for 277 
nocturia as a causal factor of fractures (Table 2). 278 
 279 
 280 
DISCUSSION 281 
This meta-analysis, based on best available evidence conducted predominantly among 282 
older adults, showed a probable excess relative risk of 20% for falling at least once, 283 
and an excess relative risk of 38% for falling recurrently during follow-up among 284 
people with nocturia compared to those without nocturia at baseline. The 20% relative 285 
risk increase corresponds with nocturia-associated increase in the absolute annual risk 286 
of falling by 5.5% among people aged 65 and by 7.5% among people aged 80. This 287 
meta-analysis also showed a possible increased relative risk of fracture of 32% in 288 
people with nocturia compared to people without nocturia after adjustment for age, 289 
gender and various comorbidities. The absolute risk of fractures was 0.9% higher in 290 
people with nocturia compared to people without among aged 65 yr, and 1.2% higher 291 
among aged 80 yr. Our findings are of moderate quality evidence for nocturia as a 292 
prognostic factor of increased risk of falls, low quality for nocturia as a prognostic 293 
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factor of increased risk of fractures, and very low quality for nocturia as a cause of 294 
falls or fractures.  295 
 296 
Strengths and limitations 297 
The strengths of this review include a contemporary and comprehensive search of 298 
both published and unpublished studies without language restrictions; the duplicate 299 
assessment of eligibility and data extraction and risk of bias; the communication with 300 
the authors of the original studies; and the appraisal of the quality of evidence, using 301 
the GRADE framework for both prognosis and causation. This is the first systematic 302 
review with meta-analysis to estimate the effect of nocturia on the risk of falls and 303 
fractures. By including only population-based studies and excluding the effects of any 304 
systematic intervention, our results provide the best available evidence on the 305 
association between nocturia and falls and fractures. Finally, we also provided 306 
estimates of both relative and absolute estimates of the risks of falls and fractures by 307 
nocturia status (to get absolute estimates, we also meta-analyzed the prevalence of 308 
nocturia; Supplementary Fig. 3). 309 
 310 
The limitations of our review are largely those of the included studies. Firstly, because 311 
of the small numbers of events, the confidence intervals around the estimates of the 312 
association between nocturia and fractures are wide. Second, although the analyses 313 
showed no significant effect for nocturia case definition, the evaluation of exposure-314 
response relationship was limited as only two studies of falls [31,34] and one study of 315 
fractures [39] provided estimates for nocturia as a discrete variable with multiple 316 
values. Third, there was a paucity of studies included women. Estimates of the 317 
association between nocturia and falls were available only from cohorts of male or 318 
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mixed gender, while none of these studies and only one study of fractures, provided 319 
estimates separately for women. Fourth, although subgroup analyses split by median 320 
of mean age (75 yr for falls and 70 for fractures), showed no significant differences 321 
between the estimates, because of limited age-specific data, our pooled estimates can 322 
be used only to roughly estimate the differences in fall and fracture risks in different 323 
age groups. Fifth, as majority of the studies were conducted in Western countries, 324 
estimates may differ in non-Western countries.  Finally, because the majority of 325 
studies were at high risk of bias, quality ratings were low for prognosis of fractures 326 
and very low for causation for both falls and fractures (indeed no data are available on 327 
whether successful treatment of nocturia prevents falls or fractures, evidence that 328 
would be required to be confident of a causal relationship). 329 
 330 
Relation to prior work 331 
One earlier systematic review examined the association of lower urinary tract 332 
symptoms in men with falls, injuries and fractures, and found that nocturia was 333 
consistently associated with increased risk of any fall [40]. This review published in 334 
2016 included six retrospective and three prospective studies; all the prospective 335 
studies – but not the retrospective – studies were also included in our review 336 
[31,37,38]. The prior review did not include six studies that proved eligible in our 337 
systematic review: two studies conducted among men (one full text article [36] and 338 
one conference abstract [29]) and two studies [32,33] conducted among both genders 339 
that were reported before the publication of their review; and two studies [34,39] 340 
(both conducted among men) that were published after their review appeared. The 341 
prior review did not conduct a meta-analysis, nor did the authors provide estimates of 342 
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the impact of nocturia on the absolute risks of falls or fractures, or assess the quality 343 
of evidence.  344 
 345 
Implications of findings 346 
Clinicians and patients should be aware that nocturia is a marker of increased risk of 347 
falls, which may perhaps lead to fractures. The decision whether to treat or not to treat 348 
nocturia, primarily depends on the level of bother it causes. Especially when 349 
managing older adults reporting nocturia, the treatment requires understanding of the 350 
multifactorial etiology of nocturia [41,42]. At its worst, medical treatment of nocturia 351 
by manipulating diuresis, sleep or lower urinary tract function, can cause more harm 352 
than benefit [43,44]. Future research priorities include development of safer and more 353 
effective treatments for nocturia, establishment of how and when to offer the nocturia 354 
patient further evaluation, including when to refer to other specialties, such as 355 
geriatrics or sleep medicine, and including falls as an outcome in randomized trials of 356 
nocturia management.  357 
 358 
CONCLUSIONS 359 
Moderate quality evidence suggests that nocturia is associated with an excess relative 360 
risk of 20% for falls and low quality evidence suggests that nocturia is associated with 361 
an excess relative risk of 32% for fractures indicating an increase of more than 7% in 362 
the absolute annual fall risk and approximately 1% in fall-related fracture risk among 363 
the older adults. Future investigations should address the impact of treatment for 364 
nocturia on falls and fractures. 365 
 366 
 367 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 16 
Authors’s affiliations 368 
a Department of Urology, Päijät-Häme Central Hospital, Lahti, Finland.  369 
b Department of Urology, Tampere University Hospital, and Faculty of Medicine and 370 
Life Science, University of Tampere, Tampere, Finland  371 
c Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), 372 
Utrecht, The Netherlands. 373 
d Department of Epidemiology and Biostatistics, Imperial College, London, UK. 374 
e Department of Urogynaecology, Oxford University Hospitals NHS Trust, Oxford, 375 
UK. 376 
f Department of Urology, University of Fukui, Fukui, Japan. 377 
g Department of Medicine, University of Toronto, Toronto, ON, Canada. 378 
h Department of Urology, Sheffield Teaching Hospitals, Sheffield, UK. 379 
i Department of Medicine, Division of Gerontology, Geriatrics and Palliative Care, 380 
University of Alabama̺Birmingham UAB School of Medicine, Birmingham, AL, 381 
USA 382 
j Department of Veterans Affairs, Birmingham/Atlanta Geriatric Research Education 383 
and Clinical Center, Atlanta, GA, USA. 384 
k Department of Urology, Hackensack University Medical Center, New Jersey, NY, 385 
USA. 386 
l Department of Urology, University of Helsinki and Helsinki University Hospital, 387 
Helsinki, Finland. 388 
m Department of Urology and The Landon Center On Aging, University of Kansas, 389 
Kansas City, KS, USA. 390 
n Department of Urology, North-Western State Medical University named after I.I. 391 
Mechnikov, Saint Petersburg, Russia. 392 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 17 
o Department of Pathology, University Hospital of Bonn, Bonn, Germany. 393 
p Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, 394 
Finland. 395 
q Department of Medicine, Division of General Medicine and Geriatrics, Emory 396 
University School of Medicine, Atlanta, GA, USA 397 
r Department of Clinical Epidemiology and Biostatistics, McMaster University, 398 
Hamilton, ON, Canada. 399 
s Department of Medicine, McMaster University, Hamilton, ON, Canada. 400 
t Department of Public Health, University of Helsinki, Helsinki, Finland. 401 
 402 
 403 
Funding/Support and role of the sponsor 404 
This study was conducted by the Clinical Urology and Epidemiology (CLUE) 405 
Working Group supported by the Academy of Finland (grants 276046 and 309387), 406 
Competitive Research Funding of the Helsinki, Uusimaa Hospital District (grants 407 
TYH2016135, TYH2017114, TYH2018120, and TYH2019321), Jane and Aatos 408 
Erkko Foundation, and Sigrid Jusélius Foundation. Pesonen was supported also by the 409 
Finnish Urological Association, Cartwright by the UK Medical Research Council, 410 
Markland by US Department of Veterans Affairs and National Institute of Health, and 411 
Vaughan by a US Department of Veterans Affairs Merit Award (I01 RX002293-412 
01A2). The sponsors had no role in the analysis and interpretation of the data or the 413 
manuscript preparation, review, or approval. 414 
 415 
 416 
 417 
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 18 
 418 
Acknowledgments 419 
The authors would like to thank information specialist Mervi Ahola for advice 420 
regarding literature search strategies, and Professor Pekka Kannus for advice 421 
regarding research methodology on falls and fractures. The authors would also like to 422 
thank the following researchers for checking extracted data for accuracy and/or 423 
providing additional information regarding the original studies: Sölve Elmståhl, 424 
Morten Frost, Theodore M. Johnson 2nd, Stephan Madersbacher, Lynn M. Marshall, 425 
Haruo Nakagawa, Naomi Noguchi. 426 
 427 
References 428 
1. Burns ER, Stevens JA and Lee R: The direct costs of fatal and non-fatal falls 429 
among older adults—United States. J Safety Res 2016; 58: 99. 430 
2. Tinetti ME and Williams CS: Falls, injuries due to falls, and the risk of 431 
admission to a nursing home. N Engl J Med 1997; 337: 1279. 432 
3. Deandrea S, Lucenteforte E, Bravi F et al: Risk factors for falls in community-433 
dwelling older people: a systematic review and meta-analysis. Epidemiology 434 
2010; 21: 658. 435 
4.  Morrison A, Fan T, Sen SS et al: Epidemiology of falls and osteoporotic 436 
fractures: a systematic review. Clinicoecon Outcomes Res 2013; 5: 9. 437 
5. Gillespie LD, Robertson MC, Gillespie WJ et al: Interventions for preventing 438 
falls in older people living in the community. Cochrane Database Syst Rev 439 
2012; CD007146.  440 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 19 
6.  Hashim H, Blanker MH, Drake MJ et al: International Continence Society 441 
(ICS) report on the terminology for nocturia and nocturnal lower urinary tract 442 
function. Neurourol Urodyn 2019; 38: 499. 443 
7. Agarwal A, Eryuzlu LN, Cartwright R et al: What is the most bothersome 444 
lower urinary tract symptom? Individual- and population-level perspectives 445 
for both men and women. Eur Urol 2014; 65: 1211. 446 
8.  Pesonen JS, Vernooij RWM, Cartwright R et al: The impact of nocturia on 447 
mortality: a systematic review and meta-analysis. Unpublished data. 448 
9. Bosch JL and Weiss JP: Prevalence and causes of nocturia. J Urol 2010; 184: 449 
440. 450 
10. Pesonen JS, Cartwright R, Mangera A et al: Incidence and remission of 451 
nocturia: a systematic review and meta-analysis. Eur Urol 2016; 70: 372. 452 
11. Tikkinen KA, Johnson TM 2nd, Tammela TL et al: Nocturia frequency, 453 
bother, and quality of life: how often is too often? A population-based study in 454 
Finland. Eur Urol 2010; 57: 488. 455 
12.  Fitzgerald MP, Litman HJ, Link CL et al: The association of nocturia with 456 
cardiac disease, diabetes, body mass index, age and diuretic use: results from 457 
the BACH survey. J Urol 2007; 177: 1385. 458 
13.  Tikkinen KA, Auvinen A, Johnson TM 2nd et al: A systematic evaluation of 459 
factors associated with nocturia—the population-based FINNO study. Am J 460 
Epidemiol 2009; 170: 361. 461 
14. Gibson W, Hunter KF, Camicioli R et al: The association between lower 462 
urinary tract symptoms and falls: forming a theoretical model for a research 463 
agenda. Neurourol Urodyn 2018; 37: 501. 464 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 20 
15.  Tikkinen KA, Auvinen A, Huhtala H et al: Nocturia and obesity: a population-465 
based study in Finland. Am J Epidemiol 2006; 163: 1003. 466 
16. De Laet C, Kanis JA, Odén A et al: Body mass index as a predictor of fracture 467 
risk: a meta-analysis. Osteoporos Int 2005; 16: 1330. 468 
17. Stewart RB, Moore MT, May FE et al: Nocturia: a risk factor for falls in the 469 
elderly. J Am Geriatr Soc 1992; 40: 1217. 470 
18. Kim SY, Bang W, Kim MS et al: Nocturia is associated with slipping and 471 
falling. PLoS One 2017; 12: e0169690. 472 
19. Asplund R: Hip fractures, nocturia, and nocturnal polyuria in the elderly. Arch 473 
Gerontol Geriatr 2006; 43: 319. 474 
20. Moher D, Liberati A, Tetzlaff J et al: Preferred reporting items for systematic 475 
reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535. 476 
21. Guyatt GH, Oxman AD, Vist G et al: GRADE guidelines: 4. Rating the 477 
quality of evidence—study limitations (risk of bias). J Clin Epidemiol 2011; 478 
64: 407.  479 
22.  Tähtinen RM, Cartwright R, Tsui JF et al: Long-term impact of mode of 480 
delivery on stress urinary incontinence and urgency urinary incontinence: a 481 
systematic review and meta-analysis. Eur Urol 2016; 70: 148. 482 
23. Hayden JA, van der Windt DA, Cartwright JL et al: Assessing bias in studies 483 
of prognostic factors. Ann Intern Med 2013; 158: 280.  484 
24. Kim SY, Park JE, Lee YJ et al: Testing a tool for assessing the risk of bias for 485 
nonrandomized studies showed moderate reliability and promising validity. J 486 
Clin Epidemiol 2013; 66: 408.  487 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 21 
25. Iorio A, Spencer FA, Falavigna M et al: Use of GRADE for assessment of 488 
evidence about prognosis: rating confidence in estimates of event rates in 489 
broad categories of patients. BMJ 2015; 350: h870. 490 
26. Guyatt GH, Oxman AD, Kunz R et al: What is “quality of evidence” and why 491 
is it important to clinicians? BMJ 2008; 336: 995. 492 
27.  Sinclair JC and Bracken MB: Clinically useful measures of effect in binary 493 
analyses of randomized trials. J Clin Epidemiol 1994; 47: 881. 494 
28.  Harris RJ, Bradburn MJ, Deeks JJ et al: Metan: fixed- and random-effects 495 
meta-analysis. Stata J 2008; 8: 3. 496 
29. Fitzgerald MP, Dávila-Roman AL, Garcia A et al: Nocturia prevalence and 497 
association with chronic medical illness, 2-year mortality in older Puerto 498 
Rican men (abstract 277). Presented at annual meeting of International 499 
Continence Society, San Francisco, California, October 3, 2009. 500 
30. Palloni A, Dávila-Roman AL and Sanchez-Ayendez M: Puerto Rican Elderly: 501 
Health Conditions (PREHCO) Project, 2002-2003, 2006-2007 (ICPSR34596-502 
v1). Ann Arbor, Michigan: Inter-University Consortium for Political and 503 
Social Research 2013. 504 
31. Parsons JK, Mougey J, Lambert L et al: Lower urinary tract symptoms 505 
increase the risk of falls in older men. BJU Int 2009; 104: 63. 506 
32. Vaughan CP, Brown CJ, Goode PS et al: The association of nocturia with 507 
incident falls in an elderly community-dwelling cohort. Int J Clin Pract 2010; 508 
64: 577. 509 
33. Stenhagen M, Ekström H, Nordell E et al: Falls in the general elderly 510 
population: a 3- and 6-year prospective study of risk factors using data from 511 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 22 
the longitudinal population study ‘Good ageing in Skane’. BMC Geriatr 2013; 512 
13: 81. 513 
34. Noguchi N, Chan L, Cumming RG et al: Lower urinary tract symptoms and 514 
incident falls in community-dwelling older men: the Concord Health and 515 
Ageing in Men Project. J Urol 2016; 196: 1694. 516 
35. Noguchi N, Chan L, Cumming R et al: Lower urinary tract symptoms and risk 517 
of falls in community-dwelling older men (abstract 47). Presented at annual 518 
meeting of International Continence Society, Montreal, Quebec, Canada, 519 
October 7, 2015. 520 
36. Temml C, Ponholzer A, Gutjahr G et al: Nocturia is an age-independent risk 521 
factor for hip-fractures in men. Neurourol Urodyn 2009; 28: 949. 522 
37. Frost M, Abrahamsen B, Masud T et al: Risk factors for fracture in elderly 523 
men: a population-based prospective study. Osteoporos Int 2012; 23: 521. 524 
38. Nakagawa H, Niu K, Hozawa A et al: Impact of nocturia on bone fracture and 525 
mortality in older individuals: a Japanese longitudinal cohort study. J Urol 526 
2010; 184: 1413. 527 
39. Marshall LM, Lapidus JA, Wiedrick J et al: Lower urinary tract symptoms and 528 
risk of nonspine fractures among older community dwelling U.S. men. J Urol 529 
2016; 196: 166. 530 
40.  Noguchi N, Chan L, Cumming RG et al: A systematic review of the 531 
association between lower urinary tract symptoms and falls, injuries, and 532 
fractures in community-dwelling older men. Aging Male 2016; 19: 168. 533 
41.  Oelke M, Anderson P, Wood R et al: Nocturia is often inadequately assessed, 534 
diagnosed and treated by physicians: results of an observational, real-life 535 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 23 
practice database containing 8659 European and US-American patients. Int J 536 
Clin Pract 2016; 70: 940.  537 
42.  Sakalis VI, Karavitakis M, Bedretdinova D et al: Medical 538 
treatment of nocturia in men with lower urinary tract symptoms: systematic 539 
review by the European Association of Urology Guidelines Panel for Male 540 
Lower Urinary Tract Symptoms. Eur Urol 2017; 72: 757. 541 
43. Vaughan CP, Fung CH, Huang AJ et al: Differences in the association of 542 
nocturia and functional outcomes of sleep by age and gender: a cross-543 
sectional, population-based study. Clin Ther 2016; 38: 2386. 544 
44. Chrischilles E, Rubenstein L, Chao J et al: Initiation of nonselective alpha1-545 
antagonist therapy and occurrence of hypotension-related adverse events 546 
among men with benign prostatic hyperplasia: a retrospective cohort study. 547 
Clin Ther 2001; 23: 727. 548 
 549 
Figure legends 550 
Table 1. Characteristics of the original studies included in analyses. 551 
Table 2. Evidence profile: nocturia as a prognostic factor for falls and fractures versus 552 
as a cause of falls and fractures. 553 
Figure 1. Study flow chart. 554 
Figure 2. Risk of bias of the included studies. 555 
Figure 3. A forest plot of the relative risks of falls in people with nocturia. 556 
Figure 4. A forest plot of the relative risks of fractures in people with nocturia. 557 
Figure 5. Absolute risk of falls and fall-related fractures between older people with 558 
and without nocturia. 559 
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
T
ab
le
 1
. C
ha
ra
ct
er
is
tic
s 
of
 th
e 
or
ig
in
al
 s
tu
di
es
 in
cl
ud
ed
 in
 a
na
ly
se
s.
 
St
ud
y 
C
ou
nt
ry
 
So
ur
ce
 o
f 
sa
m
pl
e 
P
op
ul
at
io
n 
ch
ar
ac
te
ri
st
ic
s 
E
xc
lu
si
on
 c
ri
te
ri
a 
A
ss
es
sm
en
t 
of
 
no
ct
ur
ia
 a
t 
th
e 
ba
se
lin
e 
A
ss
es
sm
en
t 
of
 f
al
ls
/f
ra
ct
ur
es
 
in
 t
he
 f
ol
lo
w
-u
p 
M
ed
ia
n 
fo
llo
w
-
up
 t
im
e 
 
N
o.
 o
f 
co
nt
ac
te
d 
at
 
th
e 
ba
se
lin
e 
N
o.
 o
f 
el
ig
ib
le
 
re
sp
on
de
nt
s 
 
Fi
tz
ge
ra
ld
 
20
09
 [
29
,3
0]
 a  
P
ue
rt
o 
R
ic
o 
V
ar
io
us
 p
ub
lic
 
re
gi
st
ri
es
 
M
en
, m
ea
n 
ag
e 
70
 y
r 
(r
an
ge
 6
0-
99
 y
r)
 
In
st
it
ut
io
na
liz
ed
 
U
nv
al
id
at
ed
 
qu
es
ti
on
na
ir
e 
F
al
ls
 a
nd
 f
ra
ct
ur
es
 v
ia
 a
n 
in
te
rv
ie
w
, r
ec
al
l p
er
io
d 
of
 1
 y
r 
4 
yr
 
17
36
 
B
as
el
in
e:
 
13
32
 (
77
%
) 
Fo
llo
w
-u
p:
 
10
11
 (
58
%
) 
P
ar
so
ns
 
20
09
 [
31
] 
b  
U
S
A
 
V
ar
io
us
 p
ub
lic
 
re
gi
st
ri
es
 
M
en
, m
ea
n 
ag
e 
74
 y
r 
(r
an
ge
 6
5-
10
0 
yr
) 
P
hy
si
ca
l o
r 
co
gn
it
iv
e 
 
di
sa
bi
lit
y,
 te
rm
in
al
 il
ln
es
s,
  
bi
la
te
ra
l h
ip
 r
ep
la
ce
m
en
t 
A
U
A
-S
I 
F
al
ls
 a
ss
es
se
d 
vi
a 
re
pe
at
ed
 
te
le
ph
on
e 
co
nt
ac
ts
 e
ve
ry
 4
 
m
on
th
s 
1 
yr
 
U
nc
le
ar
 
58
72
 
T
em
m
l  
20
09
 [
36
] 
A
us
tr
ia
 
H
ea
lth
 s
cr
ee
ni
ng
 M
en
, m
ea
n 
ag
e 
52
 y
r 
(r
an
ge
 4
1-
80
 y
r)
 
N
on
e 
IP
SS
 
H
ip
 f
ra
ct
ur
es
 v
ia
 h
os
pi
ta
l 
re
gi
st
ri
es
 
5 
yr
 
U
nc
le
ar
 
18
20
 
Fr
os
t  
20
10
 [
37
] 
D
en
m
ar
k 
C
iv
il 
re
gi
st
ry
 
M
en
, m
ea
n 
ag
e 
65
 y
r 
(r
an
ge
 6
0-
75
 y
r)
 
N
on
e 
U
nv
al
id
at
ed
 
qu
es
ti
on
na
ir
e 
c  
A
ll 
fr
ac
tu
re
s 
vi
a 
ho
sp
ita
l 
re
gi
st
ri
es
 
5 
yr
 
93
14
 
46
96
 (
50
%
) 
N
ak
ag
aw
a 
20
10
 [
38
] 
Ja
pa
n 
C
iv
il 
re
gi
st
ry
 
B
ot
h 
se
x,
 4
6%
 m
en
, 
m
ea
n 
ag
e 
76
 y
r 
(r
an
ge
 
70
-9
7 
yr
) 
N
on
-m
em
be
rs
 o
f 
N
H
I 
sy
st
em
 
A
 q
ue
st
io
nn
ai
re
 in
 
ac
co
rd
an
ce
 w
it
h 
de
fi
ni
tio
ns
 b
y 
IC
S 
A
ll
 f
ra
ct
ur
es
 v
ia
 N
H
I 
re
gi
st
ry
 
5 
yr
 
29
25
 
78
4 
(2
7%
) 
V
au
gh
an
 
20
10
 [
32
] 
U
S
A
 
N
at
io
na
l s
oc
ia
l 
in
su
ra
nc
e 
pr
og
ra
m
 r
eg
is
tr
y 
(M
ed
ic
ar
e)
 
B
ot
h 
se
x,
 5
2%
 m
en
, 
m
ea
n 
ag
e 
75
 y
r 
(r
an
ge
 
65
-1
06
 y
r)
 
P
oo
r 
co
-o
pe
ra
tio
n,
 
in
st
itu
tio
na
liz
ed
, h
is
to
ry
 o
f 
fa
ll
s 
(1
 y
r 
pr
io
r 
to
 th
e 
ba
se
lin
e 
as
se
ss
m
en
t)
 
A
 q
ue
st
io
nn
ai
re
 in
 
ac
co
rd
an
ce
 w
it
h 
de
fi
ni
tio
ns
 b
y 
IC
S 
F
al
ls
 a
ss
es
se
d 
vi
a 
re
pe
at
ed
 
te
le
ph
on
e 
co
nt
ac
ts
 e
ve
ry
 6
 
m
on
th
s 
3 
yr
 
21
88
 
B
as
el
in
e:
 
10
00
 (
46
%
) 
Fo
llo
w
-u
p:
 
69
2 
(6
9%
) 
St
en
ha
ge
n 
20
13
 [
33
] 
S
w
ed
en
 
C
iv
il 
re
gi
st
ry
 
B
ot
h 
se
x,
 4
6%
 m
en
, 
m
ea
n 
ag
e 
71
 y
r 
(r
an
ge
 
60
-9
3 
yr
) 
In
ab
ili
ty
 to
 s
pe
ak
 S
w
ed
is
h,
 
hi
st
or
y 
of
 f
al
ls
 (
6 
m
o 
pr
io
r 
th
e 
ba
se
li
ne
 a
ss
es
sm
en
t)
 
U
nc
le
ar
 
Fa
ll
s 
vi
a 
an
 in
te
rv
ie
w
, r
ec
al
l 
pe
ri
od
 o
f 
6 
m
on
th
s 
6 
yr
 
53
70
 
B
as
el
in
e:
 
25
35
 (
47
%
) 
Fo
llo
w
-u
p:
 
17
20
 (
32
%
) 
M
ar
sh
al
l 
20
16
 [
39
] 
b  
U
S
A
 
V
ar
io
us
 p
ub
lic
 
re
gi
st
ri
es
 
M
en
, m
ea
n 
ag
e 
74
 y
r 
(r
an
ge
 6
5-
10
0 
yr
) 
P
hy
si
ca
l o
r 
co
gn
iti
ve
 
di
sa
bi
lit
y,
 te
rm
in
al
 il
ln
es
s,
 
bi
la
te
ra
l h
ip
 r
ep
la
ce
m
en
t 
A
U
A
-S
I 
(a
ss
es
se
d 
ev
er
y 
2 
yr
s)
 
N
on
sp
in
e 
fr
ac
tu
re
s 
vi
a 
po
st
/t
el
ep
ho
ne
 a
nd
 m
ed
ic
al
 
re
co
rd
 a
ss
es
sm
en
ts
, r
ep
ea
te
d 
ev
er
y 
4 
m
on
th
s 
8.
6 
yr
 
U
nc
le
ar
 
59
89
 
N
og
uc
hi
  
20
16
 [
34
,3
5]
 
A
us
tr
al
ia
 
E
le
ct
or
al
 r
ol
l 
M
en
, m
ea
n 
ag
e 
76
 y
r 
(r
an
ge
 7
0-
99
 y
r)
 
In
st
it
ut
io
na
li
ze
d,
 d
em
en
ti
a,
 
ne
ur
ol
og
ic
al
 d
is
ea
se
, p
oo
r 
m
ob
il
it
y 
 
IP
SS
 
F
al
ls
 a
ss
es
se
d 
vi
a 
re
pe
at
ed
 
te
le
ph
on
e 
co
nt
ac
ts
 e
ve
ry
 4
 
m
on
th
s 
1 
yr
 
38
21
 
13
66
 (
36
%
) 
A
U
A
-S
I 
=
 A
m
er
ic
an
 U
ro
lo
gi
ca
l A
ss
oc
ia
ti
on
 S
ym
pt
om
 I
nd
ex
, G
P
 =
 g
en
er
al
 p
ra
ct
ic
e,
 I
C
S 
=
 I
nt
er
na
ti
on
al
 C
on
ti
ne
nc
e 
So
ci
et
y,
 I
P
SS
 =
 I
nt
er
na
ti
on
al
 P
ro
st
at
e 
S
ym
pt
om
 S
co
re
, N
H
I 
=
 N
at
io
na
l H
ea
lt
h 
In
su
ra
nc
e,
 N
H
S 
=
 N
at
io
na
l H
ea
lt
h 
Se
rv
ic
e,
 O
A
B
SS
 =
 O
ve
ra
ct
iv
e 
B
la
dd
er
 S
ym
pt
om
 S
co
re
 
a  P
re
vi
ou
sl
y 
un
pu
bl
is
he
d 
an
al
ys
es
 b
as
ed
 o
n 
th
e 
st
ud
y 
ra
w
 d
at
a 
[3
0]
.  
b  
O
st
eo
po
ro
ti
c 
Fr
ac
tu
re
s 
in
 M
en
 S
tu
dy
 (
M
rO
S)
 c
oh
or
t. 
c  N
oc
tu
ri
a 
re
gi
st
er
ed
 o
nl
y 
fo
r 
m
en
 s
pe
ci
fy
in
g 
th
e 
sy
m
pt
om
 in
 th
e 
as
se
ss
m
en
t o
f 
sy
m
pt
om
s/
di
se
as
es
 r
el
at
ed
 to
 u
ri
na
ry
 tr
ac
t. 
EP
T
PT
SC
RI
ls
 a
ss
es
le
ph
on
e
m
on
th
NU
H
MAdate
d 
ti
on
na
ir
e
TE
Dques
tio
ac
co
rd  
de
fi
NE
DI
hi
st
or
y 
o
to
 th
e 
ss
m
en
t)
 
A
ED
 Uo spe
ak
 S
f 
fa
ll
s
el
in
e 
a
P
hy
si
ca
l
di
sa
bi
bi
l
AC
C
ge
 7
6 
yr
 
9 
yr
C
op
yr
ig
ht
 ©
 2
01
 A
m
er
ic
an
 U
ro
lo
gi
ca
l A
ss
oc
ia
tio
n 
E
du
ca
tio
n 
an
d 
R
es
ea
rc
h,
 I
nc
. U
na
ut
ho
ri
ze
d 
re
pr
od
uc
tio
n 
of
 th
is
 a
rt
ic
le
 is
 p
ro
hi
bi
te
d.
9
  
 
Su
m
m
ar
y 
of
 f
in
di
ng
s 
Q
ua
lit
y 
as
se
ss
m
en
t 
N
o.
 o
f 
pa
rt
ic
ip
an
ts
  
N
o.
 o
f 
st
ud
ie
s 
(d
es
ig
n)
 
N
o 
no
ct
ur
ia
 
N
oc
tu
ri
aa
 
R
el
at
iv
e 
ri
sk
 
(9
5%
 C
I)
 
A
bs
ol
ut
e 
ri
sk
 
di
ff
er
en
ce
 p
er
 
ye
ar
 
P
ro
gn
os
is
 v
s.
 
ca
us
at
io
nb
 
St
ar
ti
ng
 
qu
al
it
y 
R
is
k 
of
 
bi
as
c  
In
co
ns
is
-
te
nc
y 
In
di
re
ct
ne
ss
 
Im
pr
ec
is
io
n 
C
er
ta
in
ty
 in
 
es
ti
m
at
es
 
E
vi
de
nc
e 
pr
of
ile
 –
 F
al
ls
 
P
ro
gn
os
is
 
H
ig
h 
Se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
M
od
er
at
e 
5 
(o
bs
er
va
tio
n
al
 c
oh
or
t)
 
59
31
 
47
30
 
1.
20
 (
1.
05
-
1.
37
) 
A
ge
 6
5 
yr
: 5
.5
%
  
A
ge
 8
0 
yr
: 7
.5
%
 
C
au
sa
tio
n 
L
ow
 
Se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
V
er
y 
lo
w
 
E
vi
de
nc
e 
pr
of
ile
 –
 F
ra
ct
ur
es
 
P
ro
gn
os
is
 
H
ig
h 
Se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
Se
ri
ou
s 
li
m
ita
tio
ns
 
L
ow
 
5 
(o
bs
er
va
tio
n
al
 c
oh
or
t)
 
97
67
 
45
33
 
1.
32
 (
0.
99
-
1.
76
) 
A
ge
 6
5 
yr
: 0
.9
%
  
A
ge
 8
0 
yr
: 1
.2
%
 
C
au
sa
tio
n 
L
ow
 
Se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
N
o 
se
ri
ou
s 
li
m
ita
tio
ns
 
Se
ri
ou
s 
li
m
ita
tio
ns
 
V
er
y 
lo
w
 
G
R
A
D
E
 =
 G
ra
de
s 
of
 R
ec
om
m
en
da
ti
on
, A
ss
es
sm
en
t, 
D
ev
el
op
m
en
t, 
an
d 
E
va
lu
at
io
n 
a  N
oc
tu
ri
a 
ca
se
 d
ef
in
iti
on
s 
va
ri
ed
 a
cr
os
s 
th
e 
st
ud
ie
s.
 
b  
A
ss
es
sm
en
t b
as
ed
 o
n 
th
e 
pr
in
ci
pl
es
 o
f 
th
e 
G
R
A
D
E
 f
ra
m
ew
or
k 
w
he
re
 th
e 
bo
dy
 o
f 
ob
se
rv
at
io
na
l e
vi
de
nc
e 
be
gi
ns
 a
s 
hi
gh
 q
ua
li
ty
 w
he
n 
us
ed
 f
or
 p
ro
gn
os
is
 r
es
ea
rc
h 
an
d 
as
 lo
w
 
qu
al
it
y 
w
he
n 
us
ed
 f
or
 in
te
rv
en
ti
on
 r
es
ea
rc
h.
 
c 
A
ss
es
sm
en
t d
es
cr
ib
ed
 in
 S
up
pl
. A
pp
en
di
x 
2 
an
d 
Fi
g.
 2
. 
T
ab
le
 2
. E
vi
de
nc
e 
pr
of
il
e:
 n
oc
tu
ri
a 
as
 a
 p
ro
gn
os
tic
 f
ac
to
r 
fo
r 
fa
lls
 a
nd
 f
ra
ct
ur
es
 v
er
su
s 
as
 a
 c
au
se
 o
f 
fa
lls
 a
nd
 f
ra
ct
ur
es
. 
AC
CE
PT
ED
 UN
ED
RIP
T
si
s-
nc
y
C
NU
S
s 
io
ns
 
N
MAS
er
io
us
li
m
ita
ct
ur
es
 
TE
D 
H
ig
h 
I
va
lu
at
io
n
lu
at
io
e 
th
e 
bo
d
e 
th
e 
b
C
op
yr
ig
ht
 ©
 2
01
 A
m
er
ic
an
 U
ro
lo
gi
ca
l A
ss
oc
ia
tio
n 
E
du
ca
tio
n 
an
d 
R
es
ea
rc
h,
 I
nc
. U
na
ut
ho
ri
ze
d 
re
pr
od
uc
tio
n 
of
 th
is
 a
rt
ic
le
 is
 p
ro
hi
bi
te
d.
9
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
AC
CE
PT
ED
 U
NE
DI
TE
D 
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
AC
CE
PT
ED
 U
NE
DI
T
D E
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
AC
CE
PT
ED
 U
NE
DI
TE
D
MA
NU
SC
RI
PT
Copyright © 201  American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.9
 PUBLICATION 
IV 
Impact of lower urinary tract symptoms on mortality: a 21-year follow-up 
among middle-aged and elderly Finnish men 
Åkerla J, Pesonen JS, Pöyhönen A, Häkkinen J, Koskimäki J, Huhtala H, Tammela 
TLJ, Auvinen A 
Prostate Cancer Prostatic Dis 2019;22:317-23.  
 
Publication reprinted with the permission of the copyright holders. 
 
  
  
 
 
 
 
 
Prostate Cancer and Prostatic Diseases
https://doi.org/10.1038/s41391-018-0108-z
ARTICLE
Clinical
Impact of lower urinary tract symptoms on mortality: a 21-year
follow-up among middle-aged and elderly Finnish men
Jonne Åkerla 1,2 ● Jori S Pesonen3,4 ● Antti Pöyhönen1 ● Jukka Häkkinen5 ● Juha Koskimäki4 ● Heini Huhtala6 ●
Teuvo L. J. Tammela2,4 ● Anssi Auvinen6
Received: 28 August 2018 / Accepted: 25 September 2018
© Springer Nature Limited 2018
Abstract
Background The usefulness of lower urinary tract symptoms (LUTS) as mortality risk factors remains unclear. Repeated
assessments are required to take into account symptom ﬂuctuation and de novo symptom appearance. The study objective
was to evaluate mortality in relation to three urinary storage symptoms—urgency, daytime frequency, and nocturia—in
middle-aged and elderly men, considering also other time-varying factors during follow-up.
Methods A mail survey of a population-based cohort of men initially aged 50, 60, and 70 years was conducted in Finland in
1994, 1999, 2004, and 2009. The questionnaire included assessments of LUTS based on the Danish Prostatic Symptom
Score and comorbidities. The men were followed up for mortality through the population registry through 2014. LUTS-
related hazard ratios (HR) were analyzed with time-dependent Cox regression adjusted for the year of birth and comor-
bidities using variable values updated every 5 years. Sensitivity analyses were conducted using values of all variables ﬁxed
to the baseline assessment of 1994.
Results Of the 1332 eligible men with data on LUTS from each preceding survey, 514 (38.6%) died during the 21-year
follow-up. In time-dependent analyses, daytime frequency, and nocturia were signiﬁcantly associated with increased
mortality: the adjusted HR was 1.42 (95% CI 1.11–1.83) for daytime frequency, 1.38 (1.07–1.79) for nocturia and 1.19
(0.94–1.50) for urgency. In sensitivity analyses with ﬁxed baseline characteristics, only nocturia was suggestively associated
with an increased risk of death: the adjusted HR was 1.09 (0.84–1.42) for daytime frequency, 1.41 (0.99–2.02) for nocturia
and 0.94 (0.52–1.68) for urgency.
Conclusions Among aging men, LUTS are more accurate predictors of short-term than longer-term mortality risk. Repeated
assessments are needed to detect clinically relevant and persistent symptoms, often associated with ill health. Accordingly,
men with daytime frequency or nocturia exhibit a 1.4-fold risk of death and therefore, should be evaluated for underlying
comorbidity.
Introduction
The number of patients presenting with lower urinary tract
symptoms (LUTS) is increasing as the population ages. LUTS
are divided into two broad categories: storage symptoms
(daytime urinary frequency, nocturia, urgency, urinary
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incontinence) and voiding symptoms (incomplete emptying,
intermittency, slow stream, and hesitancy). An important
factor for male LUTS is bladder outlet obstruction (BOO),
typically caused by benign prostatic hyperplasia (BPH)—a
condition affecting more than half of men aged over 50 years
[1]. Although various interventions can alleviate bothersome
LUTS, persistent or recurrent symptoms are frequent despite
treatments such as surgery for BOO [2, 3]. This is explained
by the multifactorial etiology of LUTS: age-related physiolo-
gical changes, various lifestyle factors and medical conditions
affect lower urinary tract and renal function. Of the various
LUTS, comorbidities are particularly important for urinary
storage symptoms [4, 5].
As men with LUTS tend to be older and are more likely to
have comorbidities than asymptomatic men, they are poten-
tially at a higher risk of death. To reliably assess the impact of
LUTS on mortality, careful consideration of various con-
founding factors is warranted. Longitudinal studies have
suggested LUTS to predict development of cardiovascular
diseases, albeit with some inconsistency [6, 7]. In previous
longitudinal studies, LUTS have commonly been assessed
either by using pre-deﬁned cutoff values of various symptom
scores or by retrospectively screening medical records for
diagnosis codes without distinguishing individual symptoms.
In the case of nocturia—the only symptom for which an
association with mortality has been addressed in several ear-
lier studies—the heterogeneity among previous results may
reﬂect variation in methods, follow-up times and age dis-
tributions [8], as the natural course of LUTS may vary con-
siderably between populations [9–11]. Hypothetically, the
conﬁdence of the estimates on LUTS-related mortality could
be strengthened by taking into account the incidence and
remission of symptoms and comorbidities in the course of
follow-up. Therefore, the aim of this study is to analyze the
impact of three common storage LUTS—urinary urgency,
daytime frequency, and nocturia—on all-cause mortality
during 21 years of follow-up utilizing repeated assessments in
a population-based cohort of middle-aged and elderly men.
Subjects and methods
Tampere aging male urologic study
A population-based cohort study focusing on urological
symptoms and sexual functioning among middle-aged and
elderly men was launched in Pirkanmaa County, Finland in
1994, with repeat rounds in 1999, 2004, and 2009. Study
details have been published previously [12, 13]. Brieﬂy, a
sample of 3143 men was identiﬁed from the Finnish
Population Register in 1994, comprising all men born in
1924, 1934, or 1944 residing in the study area at the
baseline. Self-administered questionnaires were mailed to
the men in the study population at all rounds. Non-
responders were reminded with a second mailing after
3 months. The questionnaire comprised items on frequency
and bother of LUTS, major health conditions and medica-
tions, as well as sociodemographic, anthropometric, and
lifestyle factors. An exemption from ethical review was
granted by the ethics committee of the Pirkanmaa Hospital
District (tracking number 99050).
Measures
The frequencies of LUTS were assessed using the Danish
Prostatic Symptom Score (DAN-PSS-1) [14], consistent
with the International Continence Society deﬁnitions [15].
An exception was made in 1994 in the assessment of
urgency, where a modiﬁed question translated back from
Finnish to English was as follows: “Is your need to urinate
so urgent that it is difﬁcult to hold it back until you reach
the toilet?”, which was since modiﬁed and used at sub-
sequent the rounds in 1999, 2004, and 2009 as “Do you
experience an imperative (strong) urge to urinate?”. The
response options were never—rarely—often—always.
The question concerning daytime frequency was “What is
the longest interval between each voiding, from when you
wake up until you go to bed?” with response options of
more than 3 h—2–3 h—1–2 h—less than 1 h. The question
concerning nocturia was “How many times do you have to
urinate per night?” with response alternatives of none—1 or
2 times—3 or 4 times—5 times or more. The preceding 4-
week period was used as the reference time frame for the
questions. For the analysis, each symptom was recoded into
a binary variable: no or mild vs. moderate or severe
symptoms (the ﬁrst two versus the two latter options). The
men were followed up for mortality through the population
registry until the end of 2014. Information on the time and
cause of death was obtained by a deterministic linkage with
the unique personal identiﬁcation number as the key.
Statistical analyses
For analyses of mortality, we included men who had
answered questions for LUTS at every survey in 1994–2009
(while alive) and for comorbidities at least in the 1994 sur-
vey. To adjust the analyses for confounders, variables with
well-established prognostic importance were selected for
regression analyses. These variables, of which many are
also known to be associated with LUTS, included age,
marital status (married or cohabiting versus single or
widowed), body mass index (BMI, ≤25 versus >25 kg/m2),
current smoking (yes/no), alcohol consumption (≤150 g/
week vs. >150 g/week), previous diagnosis of diabetes,
hypertension, cardiac disease, pulmonary disease, cere-
brovascular disease, cancer, and neurological disease.
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Univariate Cox regression analysis was performed
for each potential prognostic variable. All variables were
included in the multivariable analyses to assess
their independent effects on each LUTS. All character-
istics were treated as time-dependent categorical vari-
ables in the regression model. “Last observation carried
forward” method [16] was used for comorbidities
with missing values in the following rounds. Parallel
analyses were made for each LUTS to provide time-
varying hazard ratios using variable values updated every
5 years (time-dependent analysis). To further examine
the effect of ﬂuctuation of LUTS and associated comor-
bidities, and for easier comparison to previous studies,
sensitivity analyses were conducted using values of
all variables ﬁxed to the baseline assessment (1994)
and Kaplan–Meier curves were used to graphically
represent these associations. Furthermore, interaction
terms were evaluated in the regression models of the
association of each LUTS with mortality, and subgroup
analyses were conducted for the variables with a sig-
niﬁcant interaction. For all statistical analyses, SPSS
version 23 was used.
Results
A total of 2198 questionnaires (70%) were returned in 1994,
2133 (75%) in 1999, 1905 (76%) in 2004, and 1424 (66%)
in 2009 of whom 1332 were eligible for the study by pro-
viding sufﬁcient data for the analyses, i.e. having answered
questions regarding LUTS at every survey (while alive).
Regarding the age distribution of the included men, the
proportions were 41%, 36 and 23% for men aged 50, 60,
and 70 at the baseline, respectively. Men with LUTS were
generally older than those without LUTS and virtually all
medical conditions were more frequent among men with
LUTS (Table 1, Suppl. Table 1).
The symptoms showed substantial ﬂuctuation with a
decreasing trend for daytime frequency with a prevalence of
10.8% at the baseline and 7.3% at 15 years and an
increasing trend for nocturia, with prevalence 3.8% at the
baseline and 8.9% at 15 years. Reﬂecting the modiﬁed
question in the assessment of urgency in 1994, its pre-
valence was materially lower at the baseline (1.8%) com-
pared to the subsequent rounds (14.5% at 5, 17.8% at 10,
and 19.1% at 15 years) (Fig. 1).
Table 1 Characteristics of men
with and without urgency,
daytime frequency and nocturia
at the follow-up midpoint (2004)
Urgency Daytime frequency Nocturia
Yes No Yes No Yes No
n % n % n % n % n % n %
Number of men 190 877 82 985 100 967
Year of birth
1944 66 34.7 432 49.5 34 41.5 464 47.1 25 25.0 473 48.9
1934 84 44.2 328 37.4 33 40.2 379 38.5 44 44.0 368 38.1
1924 40 21.1 117 13.3 15 18.3 142 14.4 31 31.0 126 13.0
Marital status
Married/cohabiting 148 77.9 717 81.8 63 76.8 802 81.4 81 81.0 784 81.1
Single/divorced 33 17.4 111 12.7 15 18.3 129 13.1 15 15.0 129 13.3
Widowed 9 4.7 49 5.6 4 4.9 54 5.5 4 4.0 54 5.6
BMI
≤25 60 31.6 289 33.0 21 25.6 328 33.3 36 36.0 313 32.4
25–30 89 46.8 431 49.1 39 47.6 481 48.8 51 51.0 469 48.5
>30 41 21.6 157 17.9 22 26.8 176 17.9 13 13.0 185 19.1
Current smoking 28 14.7 121 13.8 9 11.0 140 14.2 12 12.0 137 14.2
Alcohol intake >150 g/week 38 20 134 15.3 8 9.8 164 16.6 8 8.0 164 17.0
Medical conditions
Diabetes 35 18.4 93 10.6 15 18.3 113 11.5 15 15.0 113 11.7
Hypertension 101 53.2 391 44.6 47 57.3 445 45.2 46 46.0 446 46.1
Cardiac disease 60 31.6 188 21.4 26 31.7 222 22.5 32 32.0 216 22.3
Pulmonary disease 27 14.2 99 11.3 8 9.8 118 12.0 19 19.0 107 11.1
Cerebrovascular disease 16 8.4 48 5.5 9 11.0 55 5.6 8 8.0 56 5.8
Cancer 22 11.6 79 9.0 8 9.8 93 9.4 18 18.0 83 8.6
Neurological disease 13 6.8 27 3.1 5 6.1 35 3.6 6 6.0 34 3.5
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Analyses of mortality
During the 21-year follow-up, 514 men died, of whom 139
during the ﬁrst, 126 during the second and 112 during the
third 5-year period and 137 during the last period of 6 years.
The overall mortality was 10.4% at 5 years, 19.9% at
10 years, 28.3% at 15 years, and 38.6% at 21 years. Mor-
tality was higher among men with LUTS at every stage of
follow-up (Fig. 1). In unadjusted time-dependent analyses,
each of the studied storage symptoms was strongly asso-
ciated with an increased risk of death: the HR was 1.71
(95% CI 1.36–2.14) for urgency, 1.95 (1.52–2.49) for
daytime frequency and 2.31 (1.79–2.98) for nocturia
(Table 2). In unadjusted analyses with ﬁxed baseline char-
acteristics, daytime frequency and nocturia were sig-
niﬁcantly associated with an increased risk of death, while
urgency showed no signiﬁcant association: HR 1.43
(1.11–1.84) for daytime frequency, 2.56 (1.81–3.63) for
nocturia and 1.52 (0.86–2.69) for urgency (Fig. 2, Table 2).
In multivariable-adjusted time-dependent analyses, day-
time frequency, and nocturia remained signiﬁcantly asso-
ciated with an increased risk of death, while urgency
showed only a suggestive association: the adjusted HR was
1.42 (1.11–1.83) for daytime frequency, 1.38 (1.07–1.79)
for nocturia and 1.19 (0.94–1.50) for urgency (Table 2,
Suppl. Table 2). In multivariable-adjusted analyses with
ﬁxed baseline characteristics, only nocturia was sugges-
tively associated with an increased risk of death: the
adjusted HR was 0.94 (0.52–1.68) for urgency, 1.09
(0.84–1.42) for daytime frequency and 1.41 (0.99–2.02) for
nocturia (Table 2, Suppl. Table 3).
In the regression analysis, a signiﬁcant interaction was
found between smoking and urgency (p= 0.02), as well as
between previously diagnosed cardiac disease and urgency (p
Fig. 1 Flow chart of mortality rates of men in relation to baseline prevalences and periodic incidence and remission rates of urinary urgency,
frequency and nocturia
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= 0.04). The effect of urgency was suggestively stronger
among non-smokers compared to smokers (HR 1.46,
1.12–1.91 vs. 0.73, 0.45–1.20) and among those without a
diagnosed cardiac disease compared to those with a diagnosis
(HR 1.30, 0.95–1.79 vs. 1.04, 0.73–1.48) (Table 3). The
effects of daytime frequency and nocturia showed no sig-
niﬁcant differences between any subgroups. (Suppl. Table 4).
Discussion
Due to the ﬂuctuating nature of the symptoms and related
comorbidities, the impact of LUTS as predictors of mor-
tality has not been well-established. The inﬂuence of short-
term ﬂuctuating symptoms can mask the effect of clinically
relevant longer-term symptoms, compromising the
reliability of the observed association of baseline LUTS on
subsequent morbidity. To provide more robust estimates,
we explored the impact of LUTS on mortality utilizing
repeated assessments of these symptoms and associated
comorbidities. Our results showed that men with nocturia or
daytime frequency have increased mortality, even after
adjustment for behavioral risk factors and comorbidities.
However, the associations were signiﬁcant only in analyses
where the symptoms and comorbidities were updated every
5 years indicating that the baseline assessments of LUTS are
reliable only in predicting short-term mortality risk while
repeated assessments are needed to predict longer term risk.
The crude death rates were higher in men with LUTS
throughout the follow-up. After adjusting for age and
comorbidities, daytime frequency, and nocturia remained
associated with mortality compared with men free of these
Table 2 Unadjusted and
adjusted association of LUTS
with all-cause mortality in Cox
regression analyses using
variable values updated every
5 years (time-dependent
analysis) and values ﬁxed to the
baseline assessment of 1994
(ﬁxed analysis) during 21-year
follow-up
Urgency Frequency Nocturia
HR 95% CI HR 95% CI HR 95% CI
Time-dependent analysis Unadjusted 1.71 1.36–2.14 1.95 1.52–2.49 2.31 1.79–2.98
Adjusteda 1.19 0.94–1.50 1.42 1.11–1.83 1.38 1.07–1.79
Fixed analysis Unadjusted 1.52 0.86–2.69 1.43 1.11–1.84 2.56 1.81–3.63
Adjustedb 0.94 0.52–1.68 1.09 0.84–1.42 1.41 0.99–2.02
aA regression model including the year of birth and following categorical variables with time-varying values:
LUTS, marital status, BMI, smoking, alcohol consumption, diabetes, hypertension, cardiac disease,
pulmonary disease, cerebrovascular disease, neurological disease and cancer. “Last observation carried
forward” method [14] used for comorbidities with missing values in the follow-up rounds
bAll above-mentioned variables treated as ﬁxed categorical variables in the regression model i.e. the variable
values ﬁxed to the baseline assessment of 1994
Fig. 2 Kaplan–Meier curves for men with and without daytime frequency and nocturia at the baseline (1994)
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symptoms. Although an association with mortality was
more apparent for daytime frequency and nocturia than
urgency, there was indication of an association of urinary
urgency with an elevated death risk conﬁned to non-
smokers. In men with urinary urgency, and lacking the
confounding effect of smoking—a commonly recognized
risk factor for several illnesses, such as cardiovascular dis-
eases—the mortality risk was nearly 1.5-fold. Furthermore,
we found an indication of urgency being related to
increased mortality in men without a history of cardiac
disease, which suggests that urgency might deserve atten-
tion as a potential indicator of latent heart disease.
Our study provides three important improvements to pre-
vious reports of longitudinal associations of LUTS with
mortality. First, we are not aware of any former study utilizing
repeated assessments and thus taking into account the ﬂuc-
tuation and development of symptoms and comorbidities
during follow-up. Second, our follow-up is longer than in any
previous study on the topic, and covers more than 500 deaths
(including >70 deaths among men with each of the LUTS
examined). Third, although some previous studies have
assessed the impact of nocturia and urgency on mortality [8,
17], we are not aware of any earlier study assessing mortality
in relation to daytime frequency. Our effect size for mortality
associated with nocturia is consistent with most previous
studies showing, on average, a 1.3-fold risk [8]. Similarly, the
magnitude of risk associated with urgency is fairly consistent
with a previous Finnish study of elderly men reporting a 1.9-
fold mortality at 10-year follow-up [17].
Regarding the limitations of the study, the nocturia question
in DAN-PSS-1 does not distinguish one void from two voids
per night. Because one nocturnal voiding is often considered
normal, one or two voids/night are unlikely to distinguish
meaningful nocturia and thus, ≥3 voids/night was considered a
more robust indicator of important nocturia. Accordingly, a
previous study suggested a gradient in risk of death with
nocturia severity [18]. Furthermore, although incidence of
nocturia is independent of nocturia case deﬁnition (≥1, ≥2, or
≥3 voids/night), remission frequency increases with more
stringent criteria [9]. Due to a more stringent case deﬁnition in
our analyses, remission over time is more likely and repeated
assessments are therefore crucial.
Due to the relatively small number of deaths related to
speciﬁc symptoms, our study did not have adequate statistical
power to analyse the impact of multiple LUTS in combination.
However, previous ﬁndings suggest that storage symptoms
frequently overlap and various LUTS are often concomitant
[19]. Furthermore, we were unable to assess the effect of
treatments of LUTS on death. However, few men seek treat-
ment for their LUTS [19, 20] and response to treatment can be
unsatisfactory particularly for storage symptoms [2, 3, 21].
Finally, some residual confounding in our results is likely in
spite of extensive adjustments with various medical conditions
and lifestyle factors.
Although urinary symptoms are common in aging men,
they may also be markers of ill health. Investigations for
underlying comorbidity are warranted particularly in cases of
persistent and treatment-resistant symptoms. The multi-
factorial etiology of LUTS includes various medical condi-
tions and behavioral factors, besides age-related changes in the
lower urinary tract such as development of BPH. Although
LUTS share common etiologic factors, distinction between
speciﬁc symptoms is important due to the different patho-
physiologic mechanisms, especially in nocturia, which has
been recently recognized as a separate clinical entity [22]. The
proposed etiologies underlying various LUTS include vascular
insufﬁciency of the pelvic ﬂoor due to atherosclerosis [23, 24],
systemic inﬂammation in metabolic syndrome [25], neuro-
genic dysfunction related to diabetes [26], ﬂuid shifts caused
by hypertension and cardiac failure [27] as well as increased
sympathetic activity caused by hyperinsulinemia or sleep
problems [26, 28]. These complex pathways may explain the
association of LUTS with increased mortality. However, the
evidence on the usefulness of various LUTS as causal risk
factors for mortality is lacking: there is no data available on
whether treatment of LUTS would decrease mortality e.g. by
preventing injuries or cardiovascular events to occur [6, 7, 29].
In conclusion, LUTS are more accurate predictors of short-
term than longer-term mortality risk among aging men.
Repeated assessments are needed to identify clinically relevant
and persistent symptoms, often associated with ill health.
Accordingly, middle-aged and elderly men presenting with
daytime frequrency or nocturia are potentially at a 1.4-fold
increased risk of death. Therefore, the management of men
with LUTS should focus not only on treating the symptoms,
but also assessing their general health, risk factors and major
comorbidities, including pre-clinical conditions.
Table 3 Subgroup analyses for variables with signiﬁcant interaction in
the regression models: association of urinary urgency with mortality
among smoking and non-smoking men and among men with and
without previously diagnosed cardiac disease
Unadjusted Adjusteda
HR 95% CI HR 95% CI
Current smoking
Yes 0.95 0.60–1.51 0.73 0.45–1.20
No 2.09 1.61–2.71 1.46 1.12–1.91
Cardiac disease
Yes 1.20 0.86–1.69 1.04 0.73–1.48
No 2.11 1.55–2.86 1.30 0.95–1.79
aA regression model including the year of birth and following
categorical variables with time-varying values: LUTS, marital status,
BMI, smoking, alcohol consumption, diabetes, hypertension, cardiac
disease, pulmonary disease, cerebrovascular disease, neurological
disease and cancer. “Last observation carried forward” method [14]
used for comorbidities with missing values in the follow-up rounds
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